0001214659-16-011538.txt : 20160513 0001214659-16-011538.hdr.sgml : 20160513 20160513144658 ACCESSION NUMBER: 0001214659-16-011538 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160513 DATE AS OF CHANGE: 20160513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIRTUAL PIGGY, INC. CENTRAL INDEX KEY: 0001437283 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 352327649 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53944 FILM NUMBER: 161647738 BUSINESS ADDRESS: STREET 1: 1221 HERMOSA AVENUE, SUITE 210 CITY: HERMOSA BEACH STATE: CA ZIP: 90254 BUSINESS PHONE: 310-853-1950 MAIL ADDRESS: STREET 1: 1221 HERMOSA AVENUE, SUITE 210 CITY: HERMOSA BEACH STATE: CA ZIP: 90254 FORMER COMPANY: FORMER CONFORMED NAME: Moggle, Inc. DATE OF NAME CHANGE: 20080610 10-Q 1 l51116010q.htm FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2016 l51116010q.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 

 
FORM 10-Q
 
 

 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended March 31, 2016
 
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from                      to                     
 
Commission file number 0-53944
 
 

 
VIRTUAL PIGGY, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
 

 
 
     
Delaware
 
35-2327649
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
   
100 S. Murphy Avenue, Suite 200 Sunnyvale, CA
 
94086
(Address of Principal Executive Offices)
 
(Zip Code)
 
(310)853-1950
(Registrant’s Telephone Number, Including Area Code)

 
(Former Name, Former Address and Former Fiscal year, if Changed Since Last Report)
 
 
 

 
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
             
Large accelerated filer
 
¨
  
Accelerated filer
 
¨
       
Non-accelerated filer
 
¨  (Do not check if a smaller reporting company)
  
Smaller reporting company
 
x
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 117,517,626 shares of common stock outstanding at May 13, 2016.
 


 
 

 
 

 
  
   
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10  
18
 
22
  
22
  
   
PART II - OTHER INFORMATION
 
     
23
  
23
  
23
  
23
  
23
  
23
  
23
  
24
  
 
 
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts included or incorporated by reference in this Quarterly Report on Form 10-Q, including without limitation, statements regarding our future financial position, business strategy, budgets, projected revenues, projected costs and plans and objectives of management for future operations, are forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “plans,” “projects,” “estimates,” “anticipates,” “believes,” “contemplates,” “targets,” “could,” “would” or “should” or the negative thereof or any variation thereon or similar terminology or expressions. Management cautions readers not to place undue reliance on any of the Company’s forward-looking statements, which speak only as of the date made.
 
We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees and are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to: our ability to raise additional capital, the absence of any operating history or revenue, our ability to attract and retain qualified personnel, our ability to develop and introduce a new service and products to the market in a timely manner, market acceptance of our services and products, our limited experience in the industry, the ability to successfully develop licensing programs and generate business, rapid technological change in relevant markets, unexpected network interruptions or security breaches, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments, intense competition with larger companies, general economic conditions, and other risks discussed in this filing, the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission (the “SEC”), and the Company’s other subsequent filings with the SEC.
 
All subsequent written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the foregoing. The Company has no obligation to and does not undertake to update, revise, or correct any of these forward-looking statements after the date of this report.
 
FINANCIAL STATEMENTS
 
Virtual Piggy, Inc.
 
CONTENTS
 
Virtual Piggy, Inc.
March 31, 2016 and December 31, 2015
       
   
March 31, 2016
   
December 31, 2015
 
   
(Unaudited)
   
(Audited)
 
ASSETS
           
             
CURRENT ASSETS
           
Cash and cash equivalents
  $ 50,808     $ 16,646  
Accounts receivable, net of allowance of $0 and $6,293
    -       360  
Assets held for sale, net of accumulated depreciation of $0 and $23,174
    -       34,071  
Prepaid expenses
    17,417       72,918  
                 
TOTAL CURRENT ASSETS
    68,225       123,995  
                 
PROPERTY AND EQUIPMENT
               
Computer equipment
    20,366       73,645  
Furniture and fixtures
    15,722       15,722  
      36,088       89,367  
Less:  accumulated depreciation
    (20,329 )     (57,823 )
      15,759       31,544  
                 
OTHER ASSETS
               
Deposit
    -       31,800  
Patents and trademarks, net of accumulated
               
amortization of $105,490 and $96,282
    580,212       589,420  
      580,212       621,220  
                 
TOTAL ASSETS
  $ 664,196     $ 776,759  
                 
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT
               
                 
CURRENT LIABILITIES
               
Accounts payable and accrued expenses
  $ 1,753,811     $ 1,702,527  
Accounts payable - related parties
    109,993       -  
Preferred stock dividend liability
    2,072,582       1,804,302  
Convertible notes payable - stockholders
    2,940,000       2,940,000  
Notes payable, net of discount of $27,679 and $37,482
    1,482,221       988,918  
                 
TOTAL CURRENT LIABILITIES
    8,358,607       7,435,747  
                 
CONTINGENCIES
               
                 
STOCKHOLDERS' DEFICIT
               
                 
Preferred stock, $.0001 par value; 2,000,000 preferred shares
               
authorized; 195,000 preferred shares Series A authorized; 108,600 shares
         
issued and outstanding at March 31, 2016 and December 31, 2015
    11       11  
                 
Preferred stock, $.0001 par value; 2,000,000 preferred shares
               
authorized; 222,222 preferred shares Series B authorized; 28,378 shares
               
issued and outstanding at March 31, 2016 and December 31, 2015
    3       3  
                 
Common stock, $ .0001 par value; 230,000,000 shares authorized;
               
117,517,626 shares issued and outstanding at March 31, 2016 and
               
December 31, 2015
    11,752       11,752  
 
               
Additional paid in capital
    55,584,628       54,203,451  
                 
Deferred compensation
    (51,563 )     (72,188 )
                 
Accumulated deficit
    (63,239,242 )     (60,802,017 )
                 
Cumulative translation adjustment
    -       -  
                 
STOCKHOLDERS'DEFICIT
    (7,694,411 )     (6,658,988 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
  $ 664,196     $ 776,759  
 
See the accompanying notes to the condensed consolidated financial statements.

Virtual Piggy, Inc.
For the Three Months Ended March 31, 2016 and 2015
(Unaudited)
 
   
For theThree Months Ended
 
   
Ended March 31,
 
   
2016
   
2015
 
             
SALES
  $ 1,025     $ 4,109  
                 
OPERATING EXPENSES
               
Sales and marketing
    35,103       889,237  
Product development
    247,573       590,870  
Integration and customer support
    34,238       61,838  
General and administrative
    1,718,228       1,492,252  
Strategic consulting
    -       135,000  
Total operating expenses
    2,035,142       3,169,197  
                 
NET OPERATING LOSS
    (2,034,117 )     (3,165,088 )
                 
OTHER INCOME (EXPENSE)
               
Interest income
    -       149  
Interest expense
    (142,231 )     (14,247 )
Gain on disposition of fixed assets
    7,403       -  
      (134,828 )     (14,098 )
                 
NET LOSS
    (2,168,945 )     (3,179,186 )
                 
Less: Accrued preferred dividends
    (268,280 )     (264,605 )
                 
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS
  $ (2,437,225 )   $ (3,443,791 )
                 
BASIC AND DILUTED NET LOSS PER
               
COMMON SHARE
  $ (0.02 )   $ (0.03 )
                 
BASIC AND DILUTED WEIGHTED AVERAGE
               
COMMON SHARES OUTSTANDING
    117,517,626       119,117,626  
 
See the accompanying notes to the condensed consolidated financial statements.

 
Virtual Piggy, Inc.
For the Three Months Ended March 31, 2016 and 2015
(Unaudited)
 
   
For the Three Months
 
   
Ended March 31,
 
   
2016
   
2015
 
             
NET LOSS
  $ (2,168,945 )   $ (3,179,186 )
                 
OTHER COMPREHENSIVE INCOME
               
Foreign currency translation adjustments, net of tax
    -       114,475  
TOTAL OTHER COMPREHENSIVE INCOME, net of tax
    -       114,475  
                 
COMPREHENSIVE LOSS
  $ (2,168,945 )   $ (3,064,711 )

See the accompanying notes to the condensed consolidated financial statements.


Virtual Piggy, Inc.
For the Three Months Ended March 31, 2016
   
Preferred
   
Preferred
   
Common
                         
   
Stock Series A
   
Stock Series B
   
Stock
   
Additional
                   
   
Number of
         
Number of
         
Number of
         
Paid-In
   
Deferred
   
Accumulated
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Compensation
   
Deficit
   
Total
 
Balance, December 31, 2015 (Audited)
    108,600     $ 11       28,378     $ 3       117,517,626     $ 11,752     $ 54,203,451     $ (72,188 )   $ (60,802,017 )   $ (6,658,988 )
                                                                                 
Issuance of warrants with notes payable
    -       -       -       -       -       -       6,359       -       -       6,359  
Revaluation of warrants
    -       -       -       -       -       -       1,305,411       -       -       1,305,411  
Fair value of options for services
    -       -       -       -       -       -       69,407       -       -       69,407  
Amortization of deferred compensation
    -       -       -       -       -       -       -       20,625       -       20,625  
Accrued preferred dividends
    -       -       -       -       -       -       -       -       (268,280 )     (268,280 )
Net loss
    -       -       -       -       -       -       -       -       (2,168,945 )     (2,168,945 )
                                                                                 
Balance, March 31, 2016 (Unaudited)
    108,600     $ 11       28,378     $ 3       117,517,626     $ 11,752     $ 55,584,628     $ (51,563 )   $ (63,239,242 )   $ (7,694,411 )
 
See the accompanying notes to the condensed consolidated financial statements.
 
Virtual Piggy, Inc.
For the Three Months Ended March 31, 2016 and 2015
(Unaudited)
 
   
Three Months Ended March 31,
 
   
2016
   
2015
 
CASH FLOWS FROM OPERATING ACTIVITIES
           
Net loss
  $ (2,168,945 )   $ (3,179,186 )
Adjustments to reconcile net loss to net cash
               
used in operating activities
               
Provision for bad debts
    360       -  
Fair value of options issued in exchange for services
    69,407       190,364  
Fair value of stock issued in exchange for services
    -       115,068  
Revaluation of options and warrants
    1,305,411       228,743  
Deferred compensation
    20,625       -  
Accretion of discount on notes payable
    38,670       -  
Depreciation and amortization
    11,467       28,719  
(Gain) Loss on abandonment of patents and disposal of fixed assets
    (7,403 )     895  
(Increase) decrease in assets
               
Accounts receivable
    -       57  
Prepaid expenses
    55,500       265,390  
Deposits
    31,800       7,253  
Increase (decrease) in liabilities
               
Accounts payable, accrued expenses and litigation settlement
    193,770       59,617  
Deferred revenue
    -       5,207  
                 
Net cash used in operating activities
    (449,338 )     (2,277,873 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES
               
Purchase of equipment
    -       (5,129 )
Patent and trademark costs
    -       (28,041 )
                 
Net cash used  in investing activities
    -       (33,170 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
Proceeds from convertible notes payable - stockholders
    -       2,000,000  
Proceeds from notes payable - stockholders
    483,500       -  
Net cash provided by financing activities
    483,500       2,000,000  
                 
EFFECT OF EXCHANGE RATE ON CASH
    -       114,475  
                 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
    34,162       (196,568 )
                 
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD
    16,646       1,652,392  
                 
CASH AND CASH EQUIVALENTS - END OF PERIOD
  $ 50,808     $ 1,455,824  
                 
                 
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
               
                 
Cash paid during year for:
               
Interest
  $ -     $ -  
Income taxes
  $ -     $ -  
                 
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
               
                 
Disposal of equipment in satisfaction of accounts payable
  $ 55,000     $ -  
      -          
Accrued preferred dividend
  $ 268,280     $ 264,605  
Fair value of warrants issued as discount for note payable
  $ 6,359     $ -  
Accrued interest as discount on notes payable
  $ 22,508     $ -  

See the accompanying notes to the condensed consolidated financial statements.
 
 
9

 
Virtual Piggy, Inc.
 
 NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Nature of the Business
 
Virtual Piggy, Inc. (the “Company”) was incorporated in the state of Delaware on February 11, 2008.   
 
The Company is a technology company that seeks to deliver an online ecommerce solution for the family. The Company’s system allows parents and their children to manage, allocate funds and track their expenditures, savings and charitable giving online. The system is designed to allow a minor to transact online without a credit card by gaining the parents’ permission ahead of time and allowing the parent to set up the rules of use.

The Company believes that a future alternative for Virtual Piggy, Inc. will revolve around the FinTech industry with a partner-first go to market model in which established payments market leaders and vertical market participants can incorporate and integrate the Company’s platform into co-branded payments solutions targeting youth and family.  The Company also believes this approach will enable the Company to reduce expenses while broadening its reach.

Within this affinity partner model, the Company will be incorporating licensing fees and customization services.  This should enable the company to begin creating shareholder value above and beyond consumer transaction fees.

The Company is also analyzing specific components of our technology for individual monetization as well as exploring opportunities in the Business to Business (“B2B”) realm.

In addition, the Company is currently adding enhancements to the platform, to enable the platform to update itself with any new regulations that are passed, in order to reduce costs associated with manually updating the platform.  This will also enable the Company to market the platform to other companies in need of a solution to comply with COPPA or other regulatory requirements.
 
Our primary strategic objective over the next 12 -18 months is to increase the value of the underlying technical assets of the company by incorporating new essential functionality that will act as a key differentiator in the financial services market.  These new technology advances will also augment our current portfolio of patents that give the company its competitive advantage.  In addition, the company is redirecting its marketing efforts to increase its user base by entering into affinity marketing agreements with companies targeting specific user communities.  This will increase our potential user community while bringing in substantial development and licensing revenue for those sectors.  This approach will greatly reduce the expense associated with direct marketing efforts.
    
The Company’s principal office is located in Sunnyvale, California and in 2013 the Company opened an office in London, England to support the sales and marketing efforts in Europe and the development of its mobile applications, which was closed in September 2015.

On December 3, 2015, Finity, Inc. was incorporated as a wholly owned subsidiary of the Company.  On December 11, 2015, Finity, Inc. changed its name to Finitii, Inc.  Finitii, Inc. was established as a not for profit entity for the purpose of teaching children financial literacy.
 
Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited financial statements should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on form 10-K for the year ended December 31, 2015 as filed with the SEC. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

The accompanying condensed consolidated financial statements of Virtual Piggy, Inc. and its wholly owned subsidiary, Finitii, Inc. (collectively the “Company”), have been prepared in accordance with accounting principles generally accepted in the United States of America.  All intercompany transactions have been eliminated in consolidation.

The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional financing to operationalized the Company’s current technology before another company develops similar technology to compete with the Company.
 
 
Recently Adopted Accounting Pronouncements

As of March 31, 2016 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company’s financial statements.
 
Recently Issued Accounting Pronouncements Not Yet Adopted
 
As of March 31, 2016, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company’s financial statements through 2017.
 
NOTE 2 – MANAGEMENT PLANS

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has incurred significant losses and experienced negative cash flow from operations since inception.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Since inception, the Company has focused on developing and implementing its business plan.  The Company believes that its existing cash resources will not be sufficient to sustain operations during the next twelve months.  The Company currently needs to generate revenue in order to sustain its operations.  In the event that the Company cannot generate sufficient revenue to sustain its operations, the Company will need to reduce expenses or obtain financing through the sale of debt and/or equity securities.  The issuance of additional equity would result in dilution to existing shareholders.  If the Company is unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms acceptable to the Company, the Company would likely be unable to execute upon the business plan or pay costs and expenses as they are incurred, which would have a material, adverse effect on the business, financial condition and results of operations.

The Company’s current monetization model is to license our platform to merchants to enable them to provide COPPA compliant services for themselves and their customers.

As of May 13, 2016, the Company has a cash position of approximately $44,000.  Based upon the current cash position and the Company’s planned expense run rate, management believes the Company has funds currently to finance its operations through May 2016.

NOTE 3 – ACCOUNTS PAYABLE – RELATED PARTIES
 
As of March 31, 2016, the former Chairman of the Board had paid expenses on behalf of the Company in the amount of $88,658.  The Company also owes the Chief Financial Officer a total of $13,848 as of March 31, 2016, including unpaid health insurance of $7,335 and unpaid accounting services, to the Chief Financial Officer’s accounting firm for services provided prior to his becoming the Chief Financial Officer of the Company, in the amount of $6,513.  Additionally, the Company owes a company owned by a beneficial owner of more than 5% of the Company $7,487.
 
NOTE 4 – CONVERTIBLE NOTES PAYABLE
 
On March 6, 2015, the Company, pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), issued $2,000,000 aggregate principal amount of its 10% Secured Convertible Promissory Notes due March 5, 2016 (the “Notes”) to certain stockholders.  On May 11, 2015, the Company issued an additional $940,000 of Notes to stockholders.  The maturity dates of the notes were extended to March 5, 2017 with the consent of the note holders.
 
The Notes are convertible by the holders, at any time, into shares of the Company’s Series B Preferred Stock at a conversion price of $90.00 per share, subject to adjustment for stock splits, stock dividends and similar transactions with respect to the Series B Preferred Stock only.  Each share of Series B Preferred Stock is currently convertible into 100 shares of the Company’s common stock at a current conversion price of $0.90 per share, subject to anti-dilution adjustment as described in the Certificate of Designation of the Series B Preferred Stock.  In addition, pursuant to the terms of a Security Agreement entered into on May 11, 2015 by and among the Company, the Investors and a collateral agent acting on behalf of the Investors (the “Security Agreement”), the Notes are secured by a lien against substantially all of the Company’s business assets.  Pursuant to the Purchase Agreement, the Company also granted piggyback registration rights to the holders of the Series B Preferred Stock upon a conversion of the Notes.
 
 
The Notes are recorded as a current liability as of March 31, 2016.  Interest accrued on the notes was $298,751 and $225,452 as of March 31, 2016 and December 31, 2015.  Interest expense related to these notes payable was $73,299 and $14,247 for the three months ended March 31, 2016 and 2015.
 
NOTE 5 – NOTES PAYABLE - STOCKHOLDERS
 
On January 15 and 19, 2016, the Company entered into agreements with two stockholders that includes notes payable in the aggregate amount of $62,500, and two-year warrants to purchase 12,500 shares of the Company’s common stock at $0.90. The notes bear interest at 10% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.
 
On January 29 and February 3, 2016, the Company entered into agreements with two stockholders that includes notes payable in the aggregate amount of $90,000, and two-year warrants to purchase 18,000 shares of the Company’s common stock at $0.90. The notes bear interest at 10% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.
 
On February 23, 2016, the Company entered into agreements with three stockholders that includes notes payable in the aggregate amount of $26,000, and two-year warrants to purchase 5,200 shares of the Company’s common stock at $0.90 per share.  The notes bear interest at 10% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.
 
On February 23, 2016, the Company entered into Amendments to Promissory Note Agreements (the “Amendments”) with five holders of the Company’s outstanding unsecured Promissory Notes in the aggregate principal amount of $475,300 (the “Outstanding Notes”), pursuant to which the maturity date of such Outstanding Notes was extended to the twelve (12) month anniversary of the original issuance date (formerly the six (6) month anniversary of the original issuance date) or such earlier date that (i) the Company completes the closing of  specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.  The Outstanding Notes were previously to mature between January 20, 2016 and March 18, 2016 and will now mature not later than dates between July 20, 2016 and September 18, 2016.  The Amendments took effect retroactive to the prior applicable maturity date.
 
On March 2, 2016, the Company entered into an agreement with a stockholder that includes a note payable in the amount of $5,000, and two-year warrants to purchase 1,000 shares of the Company’s common stock at $0.90. The note bears interest at 10% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.
 
On March 4, 2016, the Company entered into an agreement with a stockholder that includes a note payable in the amount of $100,100, and two-year warrants to purchase 20,020 shares of the Company’s common stock at $0.90. The note bears interest at 10% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.  This note contains a 7.5% commitment fee, which is payable upon maturity of the note.
 
 
On March 15, 2016, the Company entered into an agreement with a stockholder that includes notes payable in the amount of $200,000, and two-year warrants to purchase 40,000 shares of the Company’s common stock at $0.90 per share.  The note bears interest at 10% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.  This note contains a 7.5% commitment fee, which is payable upon maturity of the note.
 
The 7.5% commitment fees, amounting to $76,913 and $54,405 as of March 31, 2016 and December 31, 2015, on the Notes Payable were treated as a discount to the value of the notes payable in accordance with FASB ASC 835-30-25, Recognition and are being accreted over the term of the note payable for financial statement purposes. The same amount is included in accrued interest until the liability is paid. 
 
The notes payable are recorded as a current liability as of March 31, 2016.  Interest accrued including the 7.5% commitment fee on the notes as of March 31, 2016 and December 31, 2015 was $134,601 and $81,831.  Interest expense, including accretion of discounts, related to these notes payable was $68,932 and $0 for the three months ended March 31, 2016 and 2015.
 
NOTE 6 – INCOME TAXES
 
Income tax expense was $0 for the three months ended March 31, 2016 and 2015.
 
As of January 1, 2016, the Company had no unrecognized tax benefits, and accordingly, the Company did not recognize interest or penalties during 2015 related to unrecognized tax benefits. There has been no change in unrecognized tax benefits during the three months ended March 31, 2016, and there was no accrual for uncertain tax positions as of March 31, 2016. Tax years from 2012 through 2015 remain subject to examination by major tax jurisdictions.
 
There is no income tax benefit for the losses for the three months ended March 31, 2016 and 2015, since management has determined that the realization of the net tax deferred asset is not assured and has created a valuation allowance for the entire amount of such benefits.

NOTE 7 – CONVERTIBLE PREFERRED STOCK

As of March 31, 2016, the value of the cumulative 8% dividends for all preferred stock was $2,072,582.  Such dividends will be paid when and if declared payable by the Company’s board of directors or upon the occurrence of certain liquidation events.  In accordance with FASB ASC 260-10-45-11, the Company has recorded these accrued dividends as a current liability.
 
NOTE 8 – STOCKHOLDERS’ EQUITY

In February 2015, the Board of Directors of the Company approved amendments extending the term of outstanding warrants to purchase in the aggregate 3,877,970 shares of common stock of the Company at exercise prices ranging from $0.01 per share to $1.00 per share.  These warrants were scheduled to expire at various dates during 2015 and were each extended for an additional one year period from the applicable current expiration date, with the new expiration dates ranging from February 23, 2016 to December 28, 2016.  The increase in fair value of this term extension was $219,051, which was expensed in 2015.

In February 2015, the Company extended options previously granted to two of its executive officers, which included 3,500,000 options exercisable at $0.04 per share.  The increase in fair value of this term extension was $9,692 which was expensed during the period. The Company used the Black-Scholes option pricing model to calculate the increase in fair value after the extension, with the following assumptions: no dividend yield, expected volatility of 96.4%, risk free interest rate of 0.64%, and expected option life of 2 years.

 
On January 25, 2016, the Board of Directors approved amendments extending the term of outstanding warrants to purchase in the aggregate 24,372,838 shares of common stock of the Company at exercise prices ranging from $0.01 per share to $3.00 per share (the “Warrants”).  These Warrants were scheduled to expire at various dates during 2016 and were each extended for an additional one year period from the applicable current expiration date, with the new expiration dates ranging from January 26, 2017 to December 28, 2017.  The increase in fair value of this term extension was $1,305,411 which was expensed during the three months ended March 31, 2016. The Company used the Black-Scholes option pricing model to calculate the increase in fair value, with the following assumptions for the extended warrants: no dividend yield, expected volatility of 161.3%, risk free interest rate of 0.47%, and expected warrant life of 1.27 years.
 
NOTE 9 – STOCK OPTIONS AND WARRANTS
 
During 2008, the Board of Directors (“Board”) of the Company adopted the 2008 Equity Incentive Plan (“2008 Plan”) that was approved by the shareholders.  Under the Plan, the Company is authorized to grant options to purchase up to 25,000,000 shares of common stock to any officer, other employee or director of, or any consultant or other independent contractor who provides services to the Company.  The Plan is intended to permit stock options granted to employees under the 2008 Plan to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”).  All options granted under the 2008 Plan, which are not intended to qualify as Incentive Stock Options are deemed to be non-qualified options (“Non-Statutory Stock Options”).  As of March 31, 2016, options to purchase 6,101,664 shares of common stock have been issued and are unexercised, and 9,048,336 shares are available for grants under the 2008 Plan.  
 
During 2013, the Board adopted the 2013 Equity Incentive Plan (“2013 Plan”), which was approved by stockholders at the 2013 annual meeting of stockholders.  Under the 2013 Plan, the Company is authorized to grant awards of stock options, restricted stock, restricted stock units and other stock-based awards of up to an aggregate of 5,000,000 shares of common stock to any officer, employee, director or consultant.  The 2013 Plan is intended to permit stock options granted to employees under the 2013 Plan to qualify as Incentive Stock Options.  All options granted under the 2013 Plan, which are not intended to qualify as Incentive Stock Options are deemed to be Non-Statutory Stock Options.  As of March 31, 2016, under the 2013 Plan grants of restricted stock and options to purchase 2,105,000 shares of common stock have been issued and are unvested or unexercised, and 2,895,000 shares of common stock remain available for grants under the 2013 Plan.  
 
The 2008 Plan and 2013 Plan are administered by the Board or its compensation committee, which determines the persons to whom awards will be granted, the number of awards to be granted, and the specific terms of each grant, including the vesting thereof, subject to the terms of the applicable Plan.
 
In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company).
 
Prior to January 1, 2014, volatility in all instances presented is the Company’s estimate of volatility that is based on the volatility of other public companies that are in closely related industries to the Company.  Beginning January 1, 2014, volatility in all instances presented is the Company’s estimate of volatility that is based on the historical volatility of the Company’s stock history.
 
 
The following table summarizes the activities for our stock options for the three months ended March 31, 2016:
 
   
Options Outstanding
 
               
Weighted -
       
               
Average
       
               
Remaining
   
Aggregate
 
         
Weighted-
   
Contractual
   
Intrinsic
 
   
Number of
   
Average
   
Term
   
Value
 
   
Shares
   
Exercise Price
   
in years)
   
(in 000's) (1)
 
Balance December 31, 2015
    8,822,500     $ 0.76       2.6        
                               
Cancelled/forfeited
    (535,837 )   $ (0.57 )              
                               
Balance March 31, 2016
    8,286,663     $ 0.77       2.2     $ -  
                                 
Exercisable at March 31, 2016
    5,345,824     $ 0.86       1.3     $ -  
                                 
Exercisable at March 31, 2016 and expected to
                               
vest thereafter
    8,286,663     $ 0.77       2.2     $ -  
 
 
(1) 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.11 for our common stock on March 31, 2016.
 
 For the three months ended March 31, 2016 and 2015, the Company expensed $69,407 and $305,432 with respect to the options.

As of March 31, 2016 there was $499,572 of unrecognized compensation cost related to outstanding stock options. This amount is expected to be recognized over a weighted-average period of 2.4 years. To the extent the actual forfeiture rate is different from what the Company has estimated, stock-based compensation related to these awards will be different from the Company’s expectations. The difference between the stock options exercisable at March 31, 2016 and the stock options exercisable and expected to vest relates to management’s estimate of options expected to vest in the future.

 
The following table summarizes the activities for our warrants for the three months ended March 31, 2016:
 
               
Remaining
   
Aggregate
 
         
Weighted-
   
Contractual
   
Intrinsic
 
   
Number of
   
Average
   
Term
   
Value
 
   
Shares
   
Exercise Price
   
in years)
   
(in 000's) (1)
 
Balance December 31, 2015
    26,365,896     $ 1.02       0.4        
                               
Expired
    (1,142,858 )     (0.04 )     -        
Granted
    96,700     $ 0.90       2.0        
                               
Balance March 31, 2016
    25,319,738     $ 1.07       1.1     $ -  
                                 
Exercisable at March 31, 2016
    25,319,738     $ 1.07       1.1     $ -  
                                 
Exercisable at March 31, 2016 and expected to
                               
vest thereafter
    25,319,738     $ 1.07       1.1     $ -  

 
(1) 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.11 for our common stock on March 31, 2016.
 
 All warrants were vested on the date of grant.
 
NOTE 10 – OPERATING LEASES
 
For the three months ended March 31, 2016 and 2015, total rent expense under leases amounted to $7,998 and $156,677. As of March 31, 2016, the Company was not obligated under any non-cancelable operating lease arrangements.
 
NOTE 11 – SUBSEQUENT EVENTS

On April 14, 2016, the Company appointed a new Chief Executive Officer and Chairman of the Board, with such appointments taking effect on April 18, 2016.  In this connection with his appointment, the Company also simultaneously entered into an Employment Agreement with the Chief Executive Officer and Chairman of the Board, pursuant to which he will be employed on an at will basis at an annual salary of $240,000 during the first year of employment.  He also received options to purchase 3,000,000 shares of the Company’s common stock at an exercise price of $0.90 per share, vesting over three years and 250,000 restricted stock units.

On April 18, 2016, the Company issued $20,000 in aggregate principal amount of unsecured Promissory Notes to two accredited investors pursuant to Promissory Note Agreements (the “Notes”).  The Investors also received two-year Warrants to purchase an aggregate of 4,000 shares of Company common stock at an exercise price of $0.90 per share.  The Notes bear interest at a rate of ten percent (10%) per annum and mature on the six (6) month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.

On April 25, 2016, the Company issued a $50,000 principal amount unsecured Promissory Note to an accredited investor pursuant to a Promissory Note Agreement (the “Note”).  The Investor also received two-year Warrants to purchase an aggregate of 10,000 shares of Company common stock at an exercise price of $0.90 per share.  The Note bears interest at a rate of ten percent (10%) per annum and matures on the six (6) month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.
 

On May 5, 2016, the Company issued $100,000 aggregate principal amount of its 10% Secured Convertible Promissory Notes due March 6, 2017 (the “New Notes”) to an accredited investor.  The New Notes are in addition to currently outstanding promissory notes of the same series, in the principal amount of $2,940,000 (the “Prior Notes”), which were originally due March 5, 2016 and the maturity date thereof was subsequently extended to March 6, 2017 with the consent of the Note holders.
 
On May 11, 2016, the Company entered into a consulting agreement with a company owned by a beneficial owner of more than 5% of the Company.  The agreement requires the payment of $12,500 per month and continues on a monthly basis until terminated.
 
 
Overview
 
Virtual Piggy, Inc. (the “Company,” “we”, or “us”) was incorporated in Delaware on February 11, 2008 under the name Chimera International Group, Inc.  On April 4, 2008, we amended our certificate of incorporation and changed our name to Moggle, Inc.  On August 22, 2011, we filed a Certificate of Ownership with the Secretary of State of Delaware, pursuant to which the Company’s newly-formed wholly-owned subsidiary, Virtual Piggy Incorporated was merged into and with the Company (the “Merger”). In connection with the Merger and in accordance with Section 253 of the Delaware General Corporation Law, the name of the Company was changed from “Moggle, Inc.” to “Virtual Piggy, Inc.”  Our principal offices are located at 100 S. Murphy Avenue, Suite 200, Sunnyvale, California 94086 and our telephone number is (310) 853-1950.
 
On December 3, 2015, the Company incorporated a newly-formed wholly-owned Subsidiary, Finity, Inc.  On December 11, 2015, the Company filed a Statement of Correction with the Pennsylvania Department of State, to change the name of Finity, Inc. to Finitii, Inc.  The purpose of Finitii, Inc. is to teach children financial responsibility as a not for profit organization.
 
Management believes that a future alternative for Virtual Piggy, Inc. will revolve around the FinTech industry with a partner-first go to market model in which established payments market leaders and vertical market participants can incorporate and integrate the company’s platform into co-branded payments solutions targeting youth and family.  Management believes this approach will enable the company to reduce expenses while broadening its reach.
 
Within this partner-first model, the company will be incorporating licensing fees and customization services.  This should enable the company to begin creating shareholder value above and beyond consumer transaction fees.
 
In addition, we are analyzing specific components of our technology for individual monetization as well as exploring opportunities in the Business to Business (“B2B”) realm.
 
To date we have not generated material revenues.  For the first quarter of 2016, we earned revenue by charging a percentage to the merchant or gaming publisher for each transaction processed, which continued until March 2016, when the decision was made to discontinue the Oink product offering.  As we proceed through 2016, we expect to generate additional revenue streams by generating licensing and customization fees from our co-branding partners.
 
The Company is currently adding enhancements to the platform, to enable the platform to update itself with any new regulations that are passed, in order to reduce costs associated with manually updating the platform.  This will enable the Company to market the platform to other companies in need of a solution to comply with COPPA or other regulatory requirements.

 
Strategic Outlook
 
We believe that the virtual goods market and the FinTech industry will continue to grow over the long term.  Within the market and industry, we intend to provide services to allow transactions with children in compliance with COPPA and similar international privacy laws.  We believe that this particular opportunity is relatively untapped and will seek to be a leading provider of online transactions for children.
 
Sustained spending on technology, our ability to raise additional financing, the continued growth of the FinTech industry, and compliance with regulatory and reporting requirements are all external conditions that may affect our ability to execute our business plan.  In addition, the FinTech industry is intensely competitive, and most participants have longer operating histories, significantly greater financial, technical, marketing, customer service and other resources, and greater name recognition.  In addition, certain potential customers, particularly large organizations, may view our small size and limited financial resources as a negative even if they prefer our offering to those of our competitors.
 
 
Our primary strategic objective over the next 12 -18 months is to increase the value of the underlying technical assets of the company by incorporating new essential functionality that will act as a key differentiator in the financial services market.  These new technology advances will also augment our current portfolio of patents that give the company its competitive advantage.  In addition, the company is redirecting its marketing efforts to increase its user base by entering into affinity marketing agreements with companies targeting specific user communities.  This will increase our potential user community while bringing in substantial development and licensing revenue for those sectors.  This approach will greatly reduce the expense associated with direct marketing efforts.
 
Within this affinity partner model, the Company is incorporating licensing fees and customization services.  This should enable the Company to begin creating shareholder value above and beyond consumer transaction fees.
 
As our service grows, we intend to hire additional information technology staff to maintain our product offerings and develop new products to increase our market share.
 
We believe that our near-term success will depend particularly on our ability to develop customer awareness and confidence in our service.  Since we have limited capital resources, we will need to closely manage our expenses and conserve our cash by continually monitoring any increase in expenses and reducing or eliminating unnecessary expenditures. Our prospects must be considered in light of the risks, expenses and difficulties encountered by companies at an early stage of development, particularly given that we operate in new and rapidly evolving markets, that we have limited financial resources, and face an uncertain economic environment. We may not be successful in addressing such risks and difficulties.
 
 
Results of Operations
 
Comparison of the Three Months Ended March 31, 2016 and 2015
 
The following discussion analyzes our results of operations for the three months ended March 31, 2016 and 2015. The following information should be considered together with our condensed financial statements for such period and the accompanying notes thereto.
 
Net Revenue/Net Loss
 
We have not generated significant revenue since our inception. For the three months ended March 31, 2016 and 2015, we generated sales of $1,025 and $4,109.  For the three months ended March 31, 2016 and 2015, we had a net loss of $2,168,945 and $3,179,186. 

Sales and Marketing
 
Sales and marketing expenses for the three months ended March 31, 2016 were $35,103 as compared to $889,237 for the three months ended March 31, 2015, a decrease of $854,134. The Company closed its sales office in England in September of 2015 and reduced the sales force in 2015 that was not replenished in 2016, as the Company focuses on enhancements to the platform.

Product Development
 
Product development expenses were $247,573 and $590,870 for the three months ended March 31, 2016 and 2015, a decrease of $343,297. The decrease is related to cost containment initiatives, while still emphasizing enhancements to the platform, which will benefit the Company.

Integration and Customer Support
 
Integration and customer support expenses decreased $27,600 to $34,238 for the three months ended March 31, 2016 from $61,838 for the three months ended March 31, 2015. The decrease was a result of the Company scaling back its prepaid card business, thus requiring less customer support.
 
 
General and Administrative Expenses
 
General and administrative expenses increased $225,976 to $1,718,226 for the three months ended March 31, 2016 from $1,492,252 for the three months ended March 31, 2015. The increase resulted from the revaluation of warrants for the three months ended March 31, 2016 exceeding the revaluation of warrants for the three months ended March 31, 2015.

Strategic Consulting
 
Strategic consulting expenses were $0 for the three months ended March 31, 2016, a decrease of $135,000 from the three months ended March 31, 2015. The Company did not require any strategic consulting for the three months ended March 31, 2016.

Interest Expense
 
During the three months ended March 31, 2016, the Company incurred interest expense of $142,231 as compared to $14,247 for the three months ended March 31, 2015, an increase of $127,984. The increase in interest expense was a result of issuing short term notes in latter part of 2015 and continuing this process in the first quarter of 2016, in order to continue its operations.

 
Liquidity and Capital Resources
 
As of May 13, 2016, we had cash on hand of approximately $44,000.
 
Net cash used in operating activities decreased $1,828,535 to $449,338 for the three months ended March 31, 2016 as compared to $2,277,873 for the three months ended March 31, 2015.  The decrease resulted primarily from a decline in the net loss from operations as explained previously.
 
Net cash used in investing activities was $0 for the three months ended March 31, 2016, compared to $33,170 for the three months ended March 31, 2015.  As a result of cost containment measures, the Company did not invest in any capital expenditures.
 
Net cash provided by financing activities decreased by $1,516,500 to $483,500 for the three months ended March 31, 2016 from $2,000,000 for the three months ended March 31, 2015.  Cash provided by financing activities during the three months ended March 31, 2016, consisted of short-term notes payable to provide capital to continue operations.
 
Subsequent to March 31, 2016, the Company raised gross proceeds of $170,000 through the issuance of notes payable.
 
As we have not realized significant revenues since our inception, we have financed our operations through public and private offerings of debt and equity securities.  We do not currently maintain a line of credit or term loan with any commercial bank or other financial institution.  

Since our inception, we have focused on developing and implementing our business plan.  We believe that our existing cash resources will not be sufficient to sustain our operations during the next twelve months.  We currently need to generate sufficient revenues to support our cost structure to enable us to pay ongoing costs and expenses as they are incurred, finance the development of our platform, and execute the business plan.  If we cannot generate sufficient revenue to fund our business plan, we intend to seek to raise such financing through the sale of debt and/or equity securities.  The issuance of additional equity would result in dilution to existing shareholders.  If we are unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms acceptable to us, we will be unable to execute upon the business plan or pay costs and expenses as they are incurred, which would have a material, adverse effect on our business, financial condition and results of operations.
 
Even if we are successful in generating sufficient revenue or in raising sufficient capital in order to complete the platform, our ability to continue in business as a viable going concern can only be achieved when our revenues reach a level that sustains our business operations.  The launch of the platform is expected in the fourth quarter of 2016, however, we do not project that significant revenue will be developed until later in 2017. There can be no assurance that we will raise sufficient proceeds, or any proceeds, for us to implement fully our proposed business plan.  Moreover there can be no assurance that even if platform is developed and launched, that we will generate revenues sufficient to fund our operations.  In either such situation, we may not be able to continue our operations and our business might fail.
 

As of May 13, 2016, the Company has a cash position of approximately $44,000.  Based upon the current cash position and the Company’s planned expense run rate, management believes the Company will not be able to finance its operations through May 2016.
 
The foregoing forward-looking information was prepared by us in good faith based upon assumptions that we believe to be reasonable. No assurance can be given, however, regarding the attainability of the projections or the reliability of the assumptions on which they are based. The projections are subject to the uncertainties inherent in any attempt to predict the results of our operations, especially where new products and services are involved. Certain of the assumptions used will inevitably not materialize and unanticipated events will occur. Actual results of operations are, therefore, likely to vary from the projections and such variations may be material and adverse to us. Accordingly, no assurance can be given that such results will be achieved. Moreover due to changes in technology, new product announcements, competitive pressures, system design and/or other specifications we may be required to change the current plans. 

 
Off-Balance Sheet Arrangements
 
As of March 31, 2016, we do not have any off-balance sheet arrangements.

 
Critical Accounting Policies

Our financial statements are impacted by the accounting policies used and the estimates and assumptions made by management during their preparation. A complete summary of these policies is included in Note 1 of the Notes to Financial Statements included in the Company’s Form 10-K for the year ended December 31, 2015. We have identified below the accounting policies that are of particular importance in the presentation of our financial position, results of operations and cash flows and which require the application of significant judgment by management.
 
Stock-based Compensation

We have adopted the fair value recognition provisions Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 718. In addition, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 107 “Share-Based Payment” (“SAB 107”) in March, 2005, which provides supplemental FASB ASC 718 application guidance based on the views of the SEC. Under FASB ASC 718, compensation cost recognized includes compensation cost for all share-based payments granted beginning January 1, 2006, based on the grant date fair value estimated in accordance with the provisions of FASB ASC 718.

We have used the Black-Scholes option-pricing model to estimate the option fair values. The option-pricing model requires a number of assumptions, of which the most significant are, expected stock price volatility, the expected pre-vesting forfeiture rate and the expected option term (the amount of time from the grant date until the options are exercised or expire).

All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued.  Non-employee equity based payments that do not vest immediately upon grant are recorded as an expense over the service period, as if the Company had paid cash for the services.  At the end of each financial reporting period, prior to the completion of the services, the fair value of the equity based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly.  Since the fair value of equity based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the equity based payments are fully vested or the service is completed.
 
   
Revenue Recognition

In accordance with Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 104, Revenue Recognition (Codified in FASB ASC 605), we will recognize revenue when (i) persuasive evidence of a customer or distributor arrangement exists or acceptance occurs, (ii) a retailer, distributor or wholesaler receives the goods, (iii) the price is fixed or determinable, and (iv) collectability of the sales revenues is reasonably assured. Subject to these criteria, we have generally recognized revenue from Oink and ParentMatch at the time of the sale of the associated product.

Recently Issued Accounting Pronouncements
 
Recently issued accounting pronouncements are discussed in Note 1 of the Notes to Financial Statements contained elsewhere in this report.
 
Not Applicable.

As of March 31, 2016, we carried out the evaluation of the effectiveness of our disclosure controls and procedures required by Rule 13a-15(e) under the Exchange Act under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2016, our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There has been no change in our internal control over financial reporting that occurred during our fiscal quarter ended March 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
 
PART II - OTHER INFORMATION
 
None.
 
 
Not applicable.
 
 
None.
 
 
Not applicable.
 
 
On May 11, 2016, the Company entered into a consulting agreement with a company owned by a beneficial owner of more than 5% of the Company. The agreement requires the payment of $12,500 per month and continues on a monthly basis until terminated.
  
10.1
Coyne Employment Agreement
   
10.2
ICM Consulting Agreement
   
31.1
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
31.2
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
32.1
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
32.2
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS
XBRL Instance Document
   
101.SCH
XBRL Taxonomy Extension Schema Document
   
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
VIRTUAL PIGGY, INC.
 
       
 
By:
/s/ Scott McPherson
 
   
Scott McPherson
 
   
Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
 
Date: May 13, 2016
     
 
 
24
 
EX-10.1 2 ex10_1.htm EXHIBIT 10.1 Unassociated Document
Exhibit 10.1
 
EMPLOYMENT AGREEMENT
 
 
THIS EMPLOYMENT AGREEMENT, entered into April 18, 2016, by and between Virtual Piggy, Inc., a Delaware corporation (the “Company”) and John Coyne (the “Employee”).
 
WITNESSETH:
 
WHEREAS, the Company wishes to employ the Employee as President, Chief Executive Officer and Chairman of the Board of the Company and the Employee is willing to serve the Company in such capacity.
 
NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the parties hereto agree as follows:
 
Section 1.
Employment
 
The Company will employ the Employee, and the Employee will perform services for the Company and its subsidiaries, on the terms and conditions set forth in this Agreement.
 
Section 2.
Duties
 
The Employee will serve the Company as its President, Chief Executive Officer and Chairman of the Board.  The Employee will have such duties and responsibilities as are assigned to him by the Board of Directors of the Company commensurate with the Employee’s position, including responsibility for all strategic and operational matters relating to the Company and its subsidiaries, subject to the direction of the Board of Directors.  The Employee will perform his duties hereunder faithfully and to the best of his abilities and in furtherance of the business of the Company and its subsidiaries, and will devote his full business time, energy, attention and skill to the business of the Company and its subsidiaries and to the promotion of its interests, except as otherwise agreed by the Company.
 
Section 3.
Term
 
This Agreement shall have an initial term of two years, beginning as of the Employee’s first day of work, April 18, 2016 (the “Effective Date”).  It shall renew for successive one-year periods unless either party gives notice of an intent to not renew this Agreement at least 60 days prior to the renewal date.  Notwithstanding the foregoing Section 3, this Agreement and the Employee’s employment hereunder shall be “at will” and is terminable at any time by either party, without further economic obligation beyond the termination date except as required by law.
 
 
 

 
 
Section 4.
Salary
 
The Employee will receive as compensation for his duties and obligations to the Company pursuant to this Agreement during its effectiveness a base salary at the annual rate of (i) Two Hundred Forty Thousand Dollars ($240,000) during the first year after the Effective Date, (ii) Two Hundred Sixty Four Thousand ($264,000) during the second year after the Effective Date, and (iii) Two Hundred and Ninety Thousand Dollars ($290,000) during the third year after the Effective Date and thereafter, payable in substantially equal installments in accordance with the Company’s standard payroll practices.  It is agreed between the parties that the Company will review the base annual salary annually and, in light of such review, may (but will not be obligated to), in the discretion of the Board of Directors of the Company or any Compensation Committee thereof, increase such applicable annual base salary taking into account any change in the Employee’s responsibilities, increases in the cost of living, performance by the Employee, and other pertinent factors.  In order to secure the payment thereof, the Company shall, within 60 days, place into escrow an amount sufficient to fund the Employee’s base salary payments during the first year after the Effective Date.
 
Section 5.
Bonus
 
The Employee will be eligible for an annual bonus in the form of cash or Company common stock as determined at the sole discretion of the Board of Directors of the Company or any Compensation Committee thereof.
 
Annual bonuses payable hereunder shall be calculated after the close of the end of the calendar year, and thereafter paid in a single lump sum by no later than the 15th day of the third month following the end of the calendar year in which the right to the bonus is no longer subject to a substantial risk of forfeiture (as defined for purposes of Internal Revenue Code Section 409A, including Treasury Regulations Section 1.409A-1(d)).
 
Section 6.
Equity Compensation
 
(a)           Options.  As of the Effective Date or promptly thereafter following approval of the Board of Directors of the Company, the Employee will be granted non-statutory stock options to acquire 3,000,000 shares of the common stock of the Company at an exercise price of $0.90 per share (or if greater, the fair market value of such stock on the grant date).  The options will vest in three equal annual installments over a three (3) year period that begins on the Effective Date (i.e. on the first, second and third anniversaries of the Effective Date) provided the Employee is then still employed by the Company.  The grant of options will be memorialized in, and the options subject to, a separate option agreement to be entered into between the Employee and Company in accordance with the existing equity incentive plans of the Company. Additionally Mr. Coyne will receive a half of a point in options at $.90 for every $100 Million over the sale price of $300 Million for the company.
 
(b)           Restricted Stock.  As of the Effective Date or promptly thereafter following approval of the Board of Directors of the Company, the Employee will be granted 500,000 shares of the common stock of the Company, subject to certain restrictions.  The restricted shares will vest in the following manner:  (i) 250,000 shares shall vest immediately upon grant and (ii) 250,000 shares shall vest on the first anniversary of the Effective Date provided the Employee is then still employed by the Company.  The grant of the restricted shares will be memorialized in, and the restricted shares subject to, a separate restricted stock award agreement to be entered into between the Employee and Company in accordance with the existing equity incentive plans of the Company. All shares accelerate with a sale of the company.
 
 
2

 
 
Section 7.
Employee Benefits
 
Subject to any applicable probationary or similar periods, during the period of his employment with the Company, the Employee will be entitled to participate in all employee benefit programs of the Company applicable to senior officers of the Company, as such programs may be in effect from time to time.  Subject to any applicable probationary or similar periods, during his period of employment with the Company, the Employee will also be entitled to participate in all retirement programs of the Company for which current employees are eligible, as such programs may be in effect from time to time (including the Company’s 401(k) plan).
 
Section 8.
Business Expenses
 
All reasonable travel and other out-of-pocket expenses incidental to the rendering of services by the Employee hereunder will be paid by the Company, and, if expenses are paid in the first instance by the Employee, the Company will reimburse his therefor upon presentation of proper invoices, subject in each case to compliance with the Company’s reimbursement policies and procedures.  All reimbursements will be paid in the same taxable year in which the expense is incurred, provided that expenses incurred toward the end of the calendar year that cannot administratively be reimbursed before the year end shall be reimbursed by no later than March 15th of the calendar year following the calendar year in which the expense was incurred.
 
Section 9.
Vacations and Sick Leave
 
The Employee will be entitled to holidays, reasonable vacation and reasonable sick leave each year, in accordance with policies of the Company, as determined by the Board of Directors, provided, however, that the Employee will be entitled to a minimum of four (4) weeks’ vacation per year.
 
Section 10.
Confidential Information
 
The Employee agrees to keep secret and retain in the strictest confidence all confidential matters which relate to the Company or any affiliate of the Company, including, without limitation, customer lists, client lists, trade secrets, pricing policies and other business affairs of the Company and any affiliate of the Company learned by his from the Company or any such affiliate or otherwise before or after the date of this Agreement, and not to disclose any such confidential matter to anyone outside the Company, or any of its affiliates, whether during or after her period of service with the Company, except as may be required in the course of a legal or governmental proceeding.  Upon request by the Company, the Employee agrees to deliver promptly to the Company upon termination of his services for the Company, or at any time thereafter as the Company may request, all Company or affiliate memoranda, notes, records, reports, manuals, drawings, designs, computer files in any media and other documents (and all copies thereof) relating to the Company’s or any affiliate’s business and all property of the Company or any affiliate associated therewith, which she may then possess or have under his control.
 
 
3

 
 
Section 11.
Successors and Assigns
 
This Agreement will be binding upon and inure to the benefit of the Employee, his heirs, executors, administrators and beneficiaries, and the Company and its successors and assigns.
 
Section 12.
Governing Law
 
This Agreement will be governed by and construed and enforced in accordance with the laws of the State of Pennsylvania, without reference to rules relating to conflicts of law.
 
Section 13.
Entire Agreement
 
This Agreement constitutes the full and complete understanding and agreement of the parties and supersedes all prior understandings and agreements as to employment of the Employee.  This Agreement cannot be amended, changed, modified or terminated without the written consent of the parties hereto.
 
Section 14.
Waiver of Breach
 
The waiver of either party of a breach of any term of this Agreement will not operate nor be construed as a waiver of any subsequent breach thereof.
 
Section 15.
Notices
 
Any notice, report, request or other communication given under this Agreement will be written and will be effective upon delivery when delivered personally, by overnight courier or by fax.  Unless otherwise notified by any of the parties, notices will be sent to the parties as follows: (i) if to the Employee, at the address set forth in the Company’s records; and (ii) if to the Company, to Virtual Piggy, Inc., 1618 South Broad Street, Philadelphia PA 19145, Attention: Board of Directors.
 
Section 16.
Severability
 
If any one or more of the provisions contained in this Agreement will be invalid, illegal or unenforceable in any respect under any applicable law, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby.
 
Section 17.
Counterparts
 
This Agreement may be executed in counterparts, each of which will be deemed to be an original but all of which together will constitute one and the same instrument.  Delivery of signatures by facsimile or electronic image shall be valid for all purposes hereunder.
 
Section 18.
Internal Revenue Code Section 409A Compliance.
 
(a)         The parties hereto recognize that certain provisions of this Agreement may be affected by Section 409A of the Internal Revenue Code and guidance issued thereunder, and agree to amend this Agreement, or take such other action as may be necessary or advisable, to comply with Section 409A.
 
 
4

 
 
(b)         Notwithstanding anything herein to the contrary, it is expressly understood that at any time the Company (or any successor or related employer treated as the service recipient for purposes of Internal Revenue Code Section 409A) is publicly traded on an established securities market (as defined for purposes of Internal Revenue Code Section 409A), if a payment or provision of an amount or benefit constituting a deferral of compensation is to be made pursuant to the terms of this Agreement to the Employee on account of a Separation from Service at a time when the Employee is a Specified Employee (as defined for purposes of Internal Revenue Code Section 409A(a)(2)(B)(i)), such deferred compensation shall not be paid to the Employee prior to the date that is six (6) months after the Separation from Service or as otherwise permitted under Treasury Regulations Section 1.409A-3(i)(2).
 
(c)         For purposes of this Agreement, the following definitions shall apply:
 
 
(i)
“Separation from Service” means, generally, a termination of employment with the Company (or any successor or related employer treated as the service recipient for purposes of Internal Revenue Code Section 409A), and shall have the same meaning as such term has for purposes of Internal Revenue Code Section 409A (including Treasury Regulation Section 1.409A-1(h)).
 
 
(ii)
“Involuntary Separation from Service” means a Separation from Service due to the independent exercise of the unilateral authority of the Company (or any successor or related employer treated as the service recipient for purposes of Internal Revenue Code Section 409A) to terminate the Employee’s employment, other than due to the Employee’s implicit or explicit request, where the Employee was willing and able to continue employment with the Company.  Notwithstanding the foregoing, a termination for Good Reason may constitute an Involuntary Separation from Service.  Involuntary Separation from Service shall have the same meaning as such term has for purposes of Internal Revenue Code Section 409A (including Treasury Regulation Section 1.409A-1(n)).
 
[signature page follows]
 
 
5

 
 
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
 
The Company:
 
VIRTUAL PIGGY, INC.
 
 
 
By: ____________________________________
Name: Ernie Cimadamore
Title: Secretary
 
 
 
Employee:
 
 
_______________________________________
John Coyne

 
6

EX-10.2 3 ex10_2.htm EXHIBIT 10.2 Unassociated Document
Exhibit 10.2
 
CONSULTING AGREEMENT
 
This CONSULTING AGREEMENT (“Agreement”) is made and entered into May 11, 2016 by and between Virtual Piggy, Inc., a Delaware corporation (the “Company“), and International Corporate Management, LLC. a company who’s office is located at 1246-49 South 26th Street, Building J mailbox 6, Philadelphia PA 19146 (“Consultant”).

In consideration of the mutual premises herein contained and intending to be legally bound hereby, the parties agree as follows:
 
1.    Consulting Services.

1.1.          Services.  During the term of this Agreement, Consultant shall provide consulting services to the Company as set forth on Schedule 1 hereto (the “Consulting Services”).  The Consultant will perform the Consulting Services faithfully, diligently and to the best of the Consultant’s skill and ability.

1.2           Consulting Term.  The term of this Agreement shall begin on the date hereof May 11, 2016 and shall continue on a monthly basis. The (“Term”), unless terminated prior thereto pursuant to Section 3 below.
 
1.3           Independent Contractor.  Consultant and Company acknowledge and agree that the relationship hereunder created is one of an independent contractor and not one of employment.  Consultant shall at all times during the Consulting Term act as an independent contractor and nothing hereunder shall be construed to be inconsistent with this relationship or status or  create or imply a relationship of employer-employee between the Company and Consultant.  Consultant shall not hold himself out to third parties as an employee of Company, and shall have no authority to bind or commit Company, legally or otherwise.  The Consultant shall not be entitled to any benefits paid by the Company to its employees.  The Consultant shall be solely responsible for any tax consequences applicable to him by reason of this Agreement and the relationship established hereunder, and the Company shall not be responsible for the payment of any federal, state or local taxes or contributions imposed under any employment insurance, social security, income tax or other tax law or regulation with respect to the Consultant’s performance of consulting services hereunder.  Company and Consultant shall report any and all payments made by Company pursuant to this Agreement to the appropriate governmental agencies in a manner consistent with Consultant's status as an independent contractor.
 
2.              Compensation; Expenses.
 
 (a)           The Company shall pay Consultant a fee equal to $12,500.00 per month during the Term hereof, which shall be paid no later than the fifth business day of that month.
 
 (b)           The Company shall reimburse the Consultant for any reasonable costs and expenses incurred by the Consultant on the Company’s behalf, provided, however, that the Consultant shall not incur any expenses greater than $1,000 on behalf of the Company without obtaining prior consent from the Chairman of the Company.
 
 
 

 
 
3.             Termination.
 
3.1.          Either party may terminate this Agreement upon ten (10) days written notice to the other. In the event of a termination pursuant to this Section 3.1, the Company shall not be responsible to make any further payment of any kind to Consultant except for payment of fees earned prior to the date of termination.

3.2           This Agreement shall terminate upon the execution of a definitive employment agreement between the Consultant and the Company; or automatically in the event of Consultant's death.


4.         Confidentiality.   Consultant understands that Consultant's work as a consultant of the Company creates a relationship of trust and confidence between Consultant and the Company.  During and after the Term of this Agreement, Consultant will not use or disclose or allow anyone else to use or disclose any "Confidential Information" (as defined below) relating to the Company, its subsidiaries, its products, services, suppliers or customers except (i) as may be necessary in the performance of Consultant's work for the Company which use or disclosure shall be solely for the benefit of the Company in connection with the Company’s business and in accordance with the Company’s business practices and employee policies or (ii) as may be specifically authorized in advance by appropriate officers of the Company.  "Confidential Information" shall include, but shall not be limited to, information consisting of research and development, patents, trademarks and copyrights and applications thereto, technical information, computer programs, software, methodologies, innovations, software tools, know-how, knowledge, designs, drawings, specifications, concepts, data, reports, processes, techniques, documentation, pricing, marketing plans, customer and prospect lists, trade secrets, financial information, salaries, business affairs, suppliers, profits, markets, sales strategies, forecasts, employee information and any other information not available to the general public, whether written or oral, which Consultant knows or has reason to know the Company or its subsidiaries would like to treat as confidential for any purpose, such as maintaining a competitive advantage or avoiding undesirable publicity.  Consultant will keep Confidential Information secret and will not allow any unauthorized use of the same, whether or not any document containing it is marked as confidential.  These restrictions, however, will not apply to Confidential Information that has become known to the public generally through no fault or breach of Consultant's or that the Company regularly gives to third parties without restriction on use or disclosure.  Consultant further understands and acknowledges that (a) the Confidential Information is the property of the Company, constitutes a major asset of the Company and is crucial to the successful operation of the Company's business; (b) the use, misappropriation or disclosure of the Confidential Information would constitute a breach of trust and could cause irreparable injury to the Company; and (c) it is essential to the protection of the Company's goodwill and to the maintenance of the Company's competitive position that the Confidential Information be kept secret.
 
 
 

 
 
5.          Return of Company Property.  Promptly upon the expiration or sooner termination of the term of this Agreement, and earlier if requested by the Company at any time, Consultant shall deliver to the Company (and will not keep in Consultant’s possession or deliver to anyone else) all Confidential Information and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, materials, equipment, other documents or property, or reproductions of any aforementioned items developed by Consultant as part of or in connection with the Consulting Services or otherwise belonging to the Company.
 
6          Equitable Relief.

6.1         Injunction.  Consultant acknowledges that the restrictions contained in Sections 4 and 5 hereof are reasonable and necessary to protect the legitimate interests of the Company, its subsidiaries, and its affiliate, that such restrictions are deemed to be material, that the Company would not have entered into this Agreement in the absence of such restrictions, that it would be impossible or inadequate to measure and calculate the Company’s or its subsidiary’s or affiliate’s damages from any violation of those Sections and that any violation of any provision of those Sections may result in irreparable injury to the Company, its subsidiaries or affiliate (each of which shall be deemed a third party beneficiary of such restriction).  Consultant agrees that each of the Company, its subsidiaries, its affiliate shall, whether or not it is pursuing any potential remedies at law, be entitled to seek in any court of competent jurisdiction, preliminary and permanent injunctive relief and to specific performance of any such provision of this Agreement, without the necessity of proving actual damages as well as to an equitable accounting of all earnings, profits and other benefits arising from any actual or threatened breach of Section 4 or 5 hereof, which rights shall be cumulative and in addition to any other rights or remedies to which the Company or any subsidiary or affiliate of the Company may be entitled.  Consultant further agrees that no bond or other security shall be required in obtaining such equitable relief and Consultant hereby consents to the issuance of such injunction and to the ordering of specific performance.

6.2           Jurisdiction.  The parties irrevocably and unconditionally (a) agree that any suit, action or other legal proceeding seeking equitable relief under this Section 6, including without limitation, any action commenced by the Company or any of its subsidiaries for preliminary and permanent injunctive relief and other equitable relief, and any suit, action or other legal proceeding brought against the Company or any of its subsidiaries or affiliates, shall be brought and adjudicated in any court of competent civil jurisdiction sitting in Los Angeles County, California or the United States District Court for the Southern District of California, (b) consents to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding and (c) waives any objection which Consultant may have to the laying of venue of any such suit, action or proceeding in any such court.  Consultant also irrevocably and unconditionally consents to the service of any process, pleading, notices or other papers in any manner permitted by the notice provisions of Section 9 hereof.

7.             Representations, Warranties and Covenants.  The Consultant hereby represents, warrants and covenants to the Company as follows:

7.1.           Neither the execution and delivery of this Agreement, the performance of the transactions contemplated hereby, nor compliance by the Consultant with any of the provisions hereof will: (a) violate any order, writ, injunction, decree, law, statue, rule or regulation applicable in any respect to the Consultant or with respect to any of his obligations hereunder; or (b) require the consent, approval, permission or other authorization of, or qualification or filing with or notice to, any court, arbitrator or other tribunal or any governmental, administrative, regulatory or self-regulatory agency or any other third party, except for those that have been obtained;
 
 
 

 
 
7.2         Consultant: (a) is not and will not become a party to, and is not and will not become subject to, any employment agreement, non-competition agreement or covenant, non-disclosure agreement or covenant or any other agreement, covenant, understanding or restriction that would prohibit the Consultant from executing this Agreement, engaging in the transactions contemplated hereby or performing fully his duties and responsibilities hereunder; and (b) can perform his obligations hereunder without disclosing or using any confidential or proprietary information of any third party; and
 
7.3         To Consultant’s knowledge, this Agreement and the transactions contemplated hereby will not infringe or conflict with, and are not inconsistent with, the rights of any other person.
 
8.           Governing Law.  This Agreement shall be governed by and all questions relating to its validity, interpretation, enforcement and performance (including, without limitation, provisions concerning limitations of actions) shall be construed in accordance with the laws of the State of California without regard to its choice of law statutes and/or case law.  The parties hereto consent to the jurisdiction of the Superior Court of Los Angeles County, California, and the United States District Court for the Southern District of California as the exclusive courts of jurisdiction with respect to the interpretation or enforcement of the provisions of this Agreement.

9.           Notices.  All notices and other communications hereunder or in connection herewith shall be in writing and shall be deemed to have been given when delivered by hand, reputable express delivery service, mailed by certified or registered mail, return receipt requested, or sent via facsimile and followed up by hand delivery, reputable express delivery service or mailed by certified or registered mail, return receipt requested to the party as follows (provided that notice of change of address shall be deemed given only when received):
 
 
 

 
 
If to the Company, to:

Virtual Piggy, Inc.
1618 South Broad Street
Philadelphia, PA 19145
Fax:     (215) 465-2013
Attention:  Corporate Secretary


If to Consultant, to:

International Corporate Management, LLC.
1246-49 South 26th Street
Building J Mailbox 6
Philadelphia, Pa 19146
Attn: Peter Pelullo


or to such other names or addresses as Company or Consultant, as the case may be, shall designate by notice to the other person in the manner specified in this Section.

10.           Miscellaneous.  This Agreement: (a) constitutes the entire agreement and supersedes any prior and contemporaneously-made written or oral agreements between the parties relating to the subject matter hereof; (b) except as specifically provided herein, may be modified only in a writing duly executed by the parties hereto; (c) shall be binding upon and inure to the benefit of and be enforceable by the successors and permitted assigns of the Company; and (d) shall not be assignable or delegable in whole or in part by Consultant without the prior written consent of the Company.
 
11.           Severability.  The covenants in this Agreement are severable, and if any covenant or portion thereof is held to be invalid or unenforceable for any reason, such covenant or portion thereof shall be modified or adjusted by a court or other tribunal exercising its equitable powers to the extent necessary to cure such invalidity or unenforceability, and all other covenants and provisions shall remain valid and enforceable.
 
12.           Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed an original, and both of which together shall constitute one and the same instrument.  The Agreement may further be delivered by facsimile or electronic transmission, and the facsimile or electronic signatures may be deemed original signatures for all purposes, including for purposes of the Best Evidence Rule and all other rules or doctrines of similar effect.
 
13.           Survival.  Notwithstanding any termination or expiration of this Agreement, Sections 4, 5, 6, 7 and 8 of this Agreement shall survive and remain in full force and effect in accordance with their respective terms.
 
 
 

 
 
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above written.
 
 
VIRTUAL PIGGY, INC.
 
       
       
       
 
By:
   
       
 
Name: Ernest Cimadamore

Title: Secretary
 
     
     
 
CONSULTANT
 International Corporate Management, LLC
 
     
     
     
     
 
Officer: Peter S. Pelullo
 
 
 
 

 

SCHEDULE 1


The Consultant shall provide consulting and other services to the Company, including but not limited to the analysis of the Company’s products and services to merchants, and such other services as determined by the Company’s Chairman and Board of Directors from time to time during the term hereof.

 


EX-31.1 4 ex31_1.htm EXHIBIT 31.1 ex31_1.htm
Exhibit 31.1
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
I, Ernest Cimadamore, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Virtual Piggy, Inc. (the “Registrant”);
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
 
4. The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
             
Date: May 13, 2016
     
By:
 
/s/ Ernest Cimadamore
           
Ernest Cimadamore
           
Interim Chief Executive Officer
 
 
 

 
EX-31.2 5 ex31_2.htm EXHIBIT 31.2 ex31_2.htm
Exhibit 31.2
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
I, Scott McPherson, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Virtual Piggy, Inc. (the “Registrant”);
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;
 
4. The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
             
Date: May 13, 2016
     
By:
 
/s/ Scott McPherson
           
Scott McPherson
           
Chief Financial Officer
 
 
 

 
EX-32.1 6 ex32_1.htm EXHIBIT 32.1 ex32_1.htm
Exhibit 32.1

 
Certification Pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 
In connection with this Quarterly Report of Virtual Piggy, Inc. (the “Registrant”) on Form 10-Q for the quarter ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Ernest Cimadamore, Interim Chief Executive Officer (Principal Executive Officer) of the Registrant, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
 
1)
This Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
2)
The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
 
             
Date: May 13, 2016
     
By:
 
/s/ Ernest Cimadamore
           
Ernest Cimadamore
           
Interim Chief Executive Officer




 
EX-32.2 7 ex32_2.htm EXHIBIT 32.2 ex32_2.htm
Exhibit 32.2
 
Certification Pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
In connection with this Quarterly Report of Virtual Piggy, Inc. (the “Registrant”) on Form 10-Q for the quarter ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Scott McPherson, Chief Financial Officer (Principal Financial Officer) of the Registrant, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
 
1)
This Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
2)
The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
 
             
Date: May 13, 2016
     
By:
 
/s/ Scott McPherson
           
Scott McPherson
           
Chief Financial Officer


 

EX-101.INS 8 vpig-20160331.xml EXHIBIT 101.INS 0001437283 2016-01-01 2016-03-31 0001437283 2016-03-31 0001437283 2015-12-31 0001437283 us-gaap:SeriesAPreferredStockMember 2016-03-31 0001437283 us-gaap:SeriesAPreferredStockMember 2015-12-31 0001437283 us-gaap:SeriesBPreferredStockMember 2016-03-31 0001437283 us-gaap:SeriesBPreferredStockMember 2015-12-31 0001437283 vpig:IssuedOnMarchSixMember 2016-03-31 0001437283 vpig:IssuedOnMayElevenMember 2016-03-31 0001437283 us-gaap:PreferredClassBMember us-gaap:ConvertibleNotesPayableMember 2016-03-31 0001437283 us-gaap:PreferredClassBMember us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-03-31 0001437283 2015-01-01 2015-12-31 0001437283 2015-01-01 2015-03-31 0001437283 2016-01-01 0001437283 us-gaap:PreferredStockMember 2016-01-01 2016-03-31 0001437283 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2016-03-31 0001437283 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2015-12-31 0001437283 us-gaap:CommonStockMember 2015-12-31 0001437283 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001437283 us-gaap:RetainedEarningsMember 2015-12-31 0001437283 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2016-01-01 2016-03-31 0001437283 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2016-01-01 2016-03-31 0001437283 us-gaap:CommonStockMember 2016-01-01 2016-03-31 0001437283 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-03-31 0001437283 us-gaap:RetainedEarningsMember 2016-01-01 2016-03-31 0001437283 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2016-03-31 0001437283 us-gaap:CommonStockMember 2016-03-31 0001437283 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0001437283 us-gaap:RetainedEarningsMember 2016-03-31 0001437283 us-gaap:WarrantMember 2015-02-28 0001437283 us-gaap:WarrantMember us-gaap:MinimumMember 2015-02-28 0001437283 us-gaap:WarrantMember us-gaap:MaximumMember 2015-02-28 0001437283 us-gaap:WarrantMember 2015-02-01 2015-02-28 0001437283 us-gaap:EmployeeStockOptionMember us-gaap:ExecutiveOfficerMember 2015-02-01 2015-02-28 0001437283 us-gaap:EmployeeStockOptionMember us-gaap:ExecutiveOfficerMember 2015-02-28 0001437283 2014-12-31 0001437283 2015-03-31 0001437283 vpig:EquityIncentivePlan2008Member 2016-03-31 0001437283 vpig:EquityIncentivePlan2013Member 2016-03-31 0001437283 us-gaap:EmployeeStockOptionMember 2016-03-31 0001437283 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0001437283 us-gaap:EmployeeStockOptionMember 2015-12-31 0001437283 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0001437283 us-gaap:NotesPayableOtherPayablesMember 2016-01-01 2016-03-31 0001437283 us-gaap:NotesPayableOtherPayablesMember 2015-01-01 2015-03-31 0001437283 us-gaap:BoardOfDirectorsChairmanMember 2016-03-31 0001437283 us-gaap:ChiefFinancialOfficerMember 2016-03-31 0001437283 us-gaap:ChiefFinancialOfficerMember vpig:UnpaidHealthInsuranceMember 2016-03-31 0001437283 us-gaap:ChiefFinancialOfficerMember vpig:UnpaidAccountingServicesMember 2016-03-31 0001437283 us-gaap:BeneficialOwnerMember 2016-03-31 0001437283 vpig:IssuedOnMarchSixMember 2016-01-01 2016-03-31 0001437283 vpig:IssuedOnMarchSixMember 2015-01-01 2015-03-31 0001437283 us-gaap:DeferredCompensationShareBasedPaymentsMember 2015-12-31 0001437283 us-gaap:DeferredCompensationShareBasedPaymentsMember 2016-01-01 2016-03-31 0001437283 us-gaap:DeferredCompensationShareBasedPaymentsMember 2016-03-31 0001437283 vpig:ExtensionOfWarrantsMember 2016-01-25 0001437283 us-gaap:MinimumMember vpig:ExtensionOfWarrantsMember 2016-01-25 0001437283 us-gaap:MaximumMember vpig:ExtensionOfWarrantsMember 2016-01-25 0001437283 vpig:ExtensionOfWarrantsMember 2016-01-01 2016-03-31 0001437283 vpig:ExtensionOfWarrantsMember 2016-03-31 0001437283 us-gaap:MinimumMember vpig:ExtensionOfWarrantsMember 2016-01-24 2016-01-25 0001437283 us-gaap:MaximumMember vpig:ExtensionOfWarrantsMember 2016-01-24 2016-01-25 0001437283 us-gaap:SubsequentEventMember 2016-05-13 0001437283 us-gaap:NotesPayableOtherPayablesMember 2015-01-01 2015-12-31 0001437283 us-gaap:NotesPayableOtherPayablesMember 2016-03-31 0001437283 us-gaap:NotesPayableOtherPayablesMember 2015-12-31 0001437283 vpig:MarchFifteenth2016AgreementMember 2016-03-31 0001437283 vpig:MarchFifteenth2016AgreementMember 2016-03-01 2016-03-31 0001437283 vpig:JanuaryFifteenAndNineteen2016AgreementMember 2016-01-31 0001437283 vpig:JanuaryFifteenAndNineteen2016AgreementMember 2016-01-30 2016-01-31 0001437283 vpig:JanuaryTwentyNinethAndFebruaryThird2016AgreementMember 2016-02-28 0001437283 vpig:JanuaryTwentyNinethAndFebruaryThird2016AgreementMember 2016-01-01 2016-02-28 0001437283 vpig:FebruaryTwentyThird2016AgreementMember 2016-02-29 0001437283 vpig:FebruaryTwentyThird2016AgreementMember 2016-02-01 2016-02-29 0001437283 vpig:AmendmentToPromissoryNoteAgreementsMember 2016-02-28 0001437283 vpig:AmendmentToPromissoryNoteAgreementsMember us-gaap:MinimumMember 2016-02-01 2016-02-28 0001437283 vpig:AmendmentToPromissoryNoteAgreementsMember us-gaap:MaximumMember 2016-02-01 2016-02-28 0001437283 vpig:MarchSecond2016AgreementMember 2016-03-31 0001437283 vpig:MarchSecond2016AgreementMember 2016-03-01 2016-03-31 0001437283 us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-12-31 0001437283 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-03-31 0001437283 vpig:MarchFourth2016AgreementMember 2016-03-31 0001437283 vpig:MarchFourth2016AgreementMember 2016-03-01 2016-03-31 0001437283 vpig:ExtensionOfWarrantsMember 2016-01-24 2016-01-25 0001437283 us-gaap:WarrantMember us-gaap:MinimumMember 2015-02-01 2015-02-28 0001437283 us-gaap:WarrantMember us-gaap:MaximumMember 2015-02-01 2015-02-28 0001437283 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2015-12-31 0001437283 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0001437283 us-gaap:SubsequentEventMember vpig:ChiefExecutiveOfficerAndBoardOfDirectorsChairmanMember vpig:EmploymentAgreementMember 2016-04-13 2016-04-14 0001437283 us-gaap:SubsequentEventMember vpig:AprilEighteen2016AgreementMember 2016-04-30 0001437283 us-gaap:SubsequentEventMember vpig:AprilEighteen2016AgreementMember 2016-04-01 2016-04-30 0001437283 us-gaap:SubsequentEventMember vpig:AprilTwentyFive2016AgreementMember 2016-04-30 0001437283 us-gaap:SubsequentEventMember vpig:AprilTwentyFive2016AgreementMember 2016-04-01 2016-04-30 0001437283 us-gaap:SubsequentEventMember vpig:MayFive2016AgreementMember 2016-05-31 0001437283 us-gaap:SubsequentEventMember us-gaap:BeneficialOwnerMember 2016-05-11 0001437283 us-gaap:SubsequentEventMember us-gaap:BeneficialOwnerMember 2016-05-10 2016-05-11 0001437283 2016-05-13 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">&#160;</font><font style="display: inline; font-weight: bold;">NOTE 1 &#150; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></font><br/></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> </div> <div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; text-decoration: underline;">Nature of the Business</font></font><br/></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Virtual Piggy, Inc. (the &#147;Company&#148;) was incorporated in the state of Delaware on February 11, 2008.&#160;&#160;&#160;</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company is a technology company that seeks to deliver an online ecommerce solution for the family. The Company's system allows parents and their children to manage, allocate funds and track their expenditures, savings and charitable giving online. The system is designed to allow a minor to transact online without a credit card by gaining the parents' permission ahead of time and allowing the parent to set up the rules of use.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company believes that a future alternative for Virtual Piggy, Inc. will revolve around the FinTech industry with a partner-first go to market model in which established payments market leaders and vertical market participants can incorporate and integrate the Company's platform into co-branded payments solutions targeting youth and family.&#160;&#160;The Company also believes this approach will enable the Company to reduce expenses while broadening its reach.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Within this affinity partner model, the Company will be incorporating licensing fees and customization services.&#160;&#160;This should enable the company to begin creating shareholder value above and beyond consumer transaction fees.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company is also analyzing specific components of our technology for individual monetization as well as exploring opportunities in the Business to Business (&#147;B2B&#148;) realm.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the Company is currently adding enhancements to the platform, to enable the platform to update itself with any new regulations that are passed, in order to reduce costs associated with manually updating the platform.&#160;&#160;This will also enable the Company to market the platform to other companies in need of a solution to comply with COPPA or other regulatory requirements.</font></div><p align="justify" style=" margin: 0px; clear: left; font-family: 'times new roman'; font-size: 10pt;">&#160;</p><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Our primary strategic objective over the next <font>12</font> -<font>18</font> months is to increase the value of the underlying technical assets of the company by incorporating new essential functionality that will act as a key differentiator in the financial services market. These new technology advances will also augment our current portfolio of patents that give the company its competitive advantage. In addition, the company is redirecting its marketing efforts to increase its user base by entering into affinity marketing agreements with companies targeting specific user communities. This will increase our potential user community while bringing in substantial development and licensing revenue for those sectors. This approach will greatly reduce the expense associated with direct marketing efforts.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company's principal office is located in Sunnyvale, California and in 2013 the Company opened an office in London, England to support the sales and marketing efforts in Europe and the development of its mobile applications, which was closed in September 2015.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On December 3, 2015, Finity, Inc. was incorporated as a wholly owned subsidiary of the Company.&#160;&#160;On December 11, 2015, Finity, Inc. changed its name to Finitii, Inc.&#160;&#160;Finitii, Inc. was established as a not for profit entity for the purpose of teaching children financial literacy.</font></div> </div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"></font><br/></div> <div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; text-decoration: underline;">Basis of Presentation</font></font><br/></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation&#160;S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited financial statements should be read in conjunction with the financial statements and notes included in the Company's Annual Report on form 10-K for the year ended December 31, 2015 as filed with the SEC. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.</font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The accompanying condensed consolidated financial statements of Virtual Piggy, Inc. and its wholly owned subsidiary, Finitii, Inc. (collectively the &#147;Company&#148;), have been prepared in accordance with accounting principles generally accepted in the United States of America.&#160;&#160;All intercompany transactions have been eliminated in consolidation.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><br/></div> <font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company's activities are subject to significant risks and uncertainties, including failing to secure additional financing to operationalized the Company's current technology before another company develops similar technology to compete with the Company.</font> </div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> <div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; text-decoration: underline;">Recently Adopted Accounting Pronouncements</font></font></div> </div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">As of March 31, 2016 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company's financial statements.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"></font><br/></div> <div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; text-decoration: underline;">Recently Issued Accounting Pronouncements Not Yet Adopted</font></font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">As of March 31, 2016, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company's financial statements through 2017.</font></div> </div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;">&#160;</div> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; text-decoration: underline;">Recently Adopted Accounting Pronouncements</font></font></div> </div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">As of March 31, 2016 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company's financial statements.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; text-decoration: underline;">Recently Issued Accounting Pronouncements Not Yet Adopted</font></font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">As of March 31, 2016, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company's financial statements through 2017.</font></div> </div> </div> 44000 72918 68225 123995 20366 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; text-decoration: underline;">Nature of the Business</font></font><br/></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Virtual Piggy, Inc. (the &#147;Company&#148;) was incorporated in the state of Delaware on February 11, 2008.&#160;&#160;&#160;</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company is a technology company that seeks to deliver an online ecommerce solution for the family. The Company's system allows parents and their children to manage, allocate funds and track their expenditures, savings and charitable giving online. The system is designed to allow a minor to transact online without a credit card by gaining the parents' permission ahead of time and allowing the parent to set up the rules of use.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company believes that a future alternative for Virtual Piggy, Inc. will revolve around the FinTech industry with a partner-first go to market model in which established payments market leaders and vertical market participants can incorporate and integrate the Company's platform into co-branded payments solutions targeting youth and family.&#160;&#160;The Company also believes this approach will enable the Company to reduce expenses while broadening its reach.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Within this affinity partner model, the Company will be incorporating licensing fees and customization services.&#160;&#160;This should enable the company to begin creating shareholder value above and beyond consumer transaction fees.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company is also analyzing specific components of our technology for individual monetization as well as exploring opportunities in the Business to Business (&#147;B2B&#148;) realm.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition, the Company is currently adding enhancements to the platform, to enable the platform to update itself with any new regulations that are passed, in order to reduce costs associated with manually updating the platform.&#160;&#160;This will also enable the Company to market the platform to other companies in need of a solution to comply with COPPA or other regulatory requirements.</font></div><p align="justify" style=" margin: 0px; clear: left; font-family: 'times new roman'; font-size: 10pt;">&#160;</p><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Our primary strategic objective over the next <font>12</font> -<font>18</font> months is to increase the value of the underlying technical assets of the company by incorporating new essential functionality that will act as a key differentiator in the financial services market. These new technology advances will also augment our current portfolio of patents that give the company its competitive advantage. In addition, the company is redirecting its marketing efforts to increase its user base by entering into affinity marketing agreements with companies targeting specific user communities. This will increase our potential user community while bringing in substantial development and licensing revenue for those sectors. This approach will greatly reduce the expense associated with direct marketing efforts.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company's principal office is located in Sunnyvale, California and in 2013 the Company opened an office in London, England to support the sales and marketing efforts in Europe and the development of its mobile applications, which was closed in September 2015.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On December 3, 2015, Finity, Inc. was incorporated as a wholly owned subsidiary of the Company.&#160;&#160;On December 11, 2015, Finity, Inc. changed its name to Finitii, Inc.&#160;&#160;Finitii, Inc. was established as a not for profit entity for the purpose of teaching children financial literacy.</font></div> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-style: italic; display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;"><font style="display: inline; text-decoration: underline;">Basis of Presentation</font></font><br/></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation&#160;S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited financial statements should be read in conjunction with the financial statements and notes included in the Company's Annual Report on form 10-K for the year ended December 31, 2015 as filed with the SEC. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.</font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The accompanying condensed consolidated financial statements of Virtual Piggy, Inc. and its wholly owned subsidiary, Finitii, Inc. (collectively the &#147;Company&#148;), have been prepared in accordance with accounting principles generally accepted in the United States of America.&#160;&#160;All intercompany transactions have been eliminated in consolidation.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><br/></div> <font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company's activities are subject to significant risks and uncertainties, including failing to secure additional financing to operationalized the Company's current technology before another company develops similar technology to compete with the Company.</font> </div> </div> <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">NOTE 2 &#150; MANAGEMENT PLANS</font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;"><br/></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.&#160;&#160;The Company has incurred significant losses and experienced negative cash flow from operations since inception.&#160;&#160;These conditions raise substantial doubt about the Company's ability to continue as a going concern.&#160;&#160;The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Since inception, the Company has focused on developing and implementing&#160;its business plan.&#160;&#160;The Company believes that its existing cash resources will not be sufficient to sustain operations during the next twelve months.&#160;<font style="display: inline; font-weight: bold;">&#160;</font>The Company currently needs to generate revenue in order to sustain its operations.&#160;&#160;In the event that the Company cannot generate sufficient revenue to sustain its operations, the Company will need to reduce expenses or obtain financing through the sale of debt and/or equity securities.&#160;&#160;The issuance of additional equity would result in dilution to existing shareholders.&#160;&#160;If the Company is unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms acceptable to the Company, the Company would likely be unable to execute upon the business plan or pay costs and expenses as they are incurred, which would have a material, adverse effect on the business, financial condition and results of operations.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Company's current monetization model is to license our platform to merchants to enable them to provide COPPA compliant services for themselves and their customers.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">As of May 13, 2016, the Company has a cash position of&#160;approximately&#160;$<font>44,000</font>. Based upon the current cash position and the Company's planned expense run rate, management believes the Company has funds currently to finance its operations through&#160;May 2016.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> </div> </div> 50808 16646 0 6293 360 0 23174 34071 17417 73645 15722 15722 36088 89367 20329 57823 15759 31544 31800 105490 96282 580212 589420 580212 621220 664196 776759 1753811 1702527 109993 2072582 1804302 2940000 2940000 27679 37482 1482221 988918 8358607 7435747 0.0001 2000000 195000 108600 11 11 222222 28378 3 3 0.0001 230000000 117517626 11752 11752 55584628 54203451 51563 72188 -63239242 -60802017 -7694411 -6658988 664196 776759 88658 13848 7335 6513 0.05 7487 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">NOTE 3 &#150; ACCOUNTS PAYABLE &#150; RELATED PARTIES</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">As of March 31, 2016, the former Chairman of the Board had paid expenses on behalf of the Company in the amount of $<font>88,658</font>.&#160;&#160;The Company also owes the Chief Financial Officer a total of $<font>13,848</font> as of March 31, 2016, including unpaid health insurance of $<font>7,335</font> and unpaid accounting services, to the Chief Financial Officer's accounting firm for services provided prior to his becoming the Chief Financial Officer of the Company, in the amount of $<font>6,513</font>.&#160;&#160;Additionally, the Company owes a company owned by a beneficial owner of more than <font>5</font>% of the Company $<font>7,487</font>.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> </div> 2000000 0.10 940000 90.00 100 0.90 298751 225452 73299 14247 4109 35103 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">NOTE 4 &#150; CONVERTIBLE NOTES PAYABLE</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On March 6, 2015, the Company, pursuant to a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;), issued $<font>2,000,000</font> aggregate principal amount of its <font>10</font>% Secured Convertible Promissory Notes due March 5, 2016 (the &#147;Notes&#148;) to certain stockholders.&#160;&#160;On May 11, 2015, the Company issued an additional $<font>940,000</font> of Notes to stockholders.&#160;&#160;The maturity dates of the notes were extended to March 5, 2017 with the consent of the note holders.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Notes are convertible by the holders, at any time, into shares of the Company's Series B Preferred Stock at a conversion price of $<font>90.00</font> per share, subject to adjustment for stock splits, stock dividends and similar transactions with respect to the Series B Preferred Stock only.&#160;&#160;Each share of Series B Preferred Stock is currently convertible into <font>100</font> shares of the Company's common stock at a current conversion price of $<font>0.90</font> per share, subject to anti-dilution adjustment as described in the Certificate of Designation of the Series B Preferred Stock.&#160;&#160;In addition, pursuant to the terms of a Security Agreement entered into on May 11, 2015 by and among the Company, the Investors and a collateral agent acting on behalf of the Investors (the &#147;Security Agreement&#148;), the Notes are secured by a lien against substantially all of the Company's business assets.&#160;&#160;Pursuant to the Purchase Agreement, the Company also granted piggyback registration rights to the holders of the Series B Preferred Stock upon a conversion of the Notes.</font></div> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><br/></div><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The Notes are recorded as a current liability as of March 31, 2016.&#160;&#160;Interest accrued on the notes was $<font>298,751</font> and $<font>225,452</font> as of March 31, 2016 and December 31, 2015.&#160;&#160;Interest expense related to these notes payable was $<font>73,299</font> and $<font>14,247</font> for the three months ended March 31, 2016 and 2015.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> </div> 108600 108600 108600 195000 2000000 0.0001 28378 28378 28378 222222 117517626 117517626 117517626 230000000 0.0001 62500 P2Y 12500 0.90 0.1 90000 P2Y 18000 0.90 0.1 26000 P2Y 5200 0.90 0.1 475300 5000 P2Y 1000 0.90 0.1 100100 P2Y 20020 0.90 0.1 0.075 200000 P2Y 40000 889237 0.90 0.1 0.075 0.075 76913 54405 134601 81831 68932 0 247573 590870 34238 61838 1718228 1492252 135000 2035142 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">NOTE 5 &#150; NOTES PAYABLE - STOCKHOLDERS</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On January 15 and 19, 2016, the Company entered into agreements with two stockholders that includes notes payable in the aggregate amount of $<font>62,500</font>, and <font>two</font>-year warrants to purchase <font>12,500</font> shares of the Company's common stock at $<font>0.90</font>. The notes bear interest at <font>10</font>% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On January 29 and February 3, 2016, the Company entered into agreements with two stockholders that includes notes payable in the aggregate amount of $<font>90,000</font>, and <font>two</font>-year warrants to purchase <font>18,000</font> shares of the Company's common stock at $<font>0.90</font>. The notes bear interest at <font>10</font>% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On February 23, 2016, the Company entered into agreements with three stockholders that includes notes payable in the aggregate amount of $<font>26,000</font>, and <font>two</font>-year warrants to purchase <font>5,200</font> shares of the Company's common stock at $<font>0.90</font> per share. The notes bear interest at <font>10</font>% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On February 23, 2016, the Company entered into Amendments to Promissory Note Agreements (the &#147;Amendments&#148;) with five holders of the Company's outstanding unsecured Promissory Notes in the aggregate principal amount of $<font>475,300</font> (the &#147;Outstanding Notes&#148;), pursuant to which the maturity date of such Outstanding Notes was extended to the twelve (12) month anniversary of the original issuance date (formerly the six (6) month anniversary of the original issuance date) or such earlier date that (i) the Company completes the closing of&#160;&#160;specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.&#160;&#160;The Outstanding Notes were previously to mature between January 20, 2016 and March 18, 2016 and will now mature not later than dates between <font>July 20, 2016</font> and <font>September 18, 2016</font>.&#160;&#160;The Amendments took effect retroactive to the prior applicable maturity date.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On March 2, 2016, the Company entered into an agreement with a stockholder that includes a note payable in the amount of $<font>5,000</font>, and <font>two</font>-year warrants to purchase <font>1,000</font> shares of the Company's common stock at $<font>0.90</font>. The note bears interest at <font>10</font>% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On March 4, 2016, the Company entered into an agreement with a stockholder that includes a note payable in the amount of $<font>100,100</font>, and <font>two</font>-year warrants to purchase <font>20,020</font> shares of the Company's common stock at $<font>0.90</font>. The note bears interest at <font>10</font>% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes. This note contains a <font>7.5</font>% commitment fee, which is payable upon maturity of the note.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left">&#160;</div><div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On March 15, 2016, the Company entered into an agreement with a stockholder that includes notes payable in the amount of $<font>200,000</font>, and <font>two</font>-year warrants to purchase <font>40,000</font> shares of the Company's common stock at $<font>0.90</font> per share.&#160;&#160;The note bears interest at <font>10</font>% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.&#160;&#160;This note contains a <font>7.5</font>% commitment fee, which is payable upon maturity of the note.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The <font>7.5</font>% commitment fees, amounting to $<font>76,913</font> and $<font>54,405</font> as of March 31, 2016 and December 31, 2015, on the Notes Payable were treated as a discount to the value of the notes payable in accordance with FASB ASC 835-30-25,<font style="display: inline; font-size: 10pt;">&#160;</font><font style="font-style: italic; display: inline;">Recognition</font><font style="display: inline; font-size: 10pt;">&#160;</font>and are being accreted over the term of the note payable for financial statement purposes.&#160;The same amount is included in accrued interest until the liability is paid.&#160;</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The notes payable are recorded as a current liability as of March 31, 2016.&#160;&#160;Interest accrued including the 7.5% commitment fee on the notes as of March 31, 2016 and December 31, 2015 was $<font>134,601</font> and $<font>81,831</font>.&#160;&#160;Interest expense, including accretion of discounts, related to these notes payable was $<font>68,932</font> and $<font>0</font> for the three months ended March 31, 2016 and 2015.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> </div> 0 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;">NOTE 6 &#150; INCOME TAXES</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"> <div style="TEXT-INDENT: 0pt; DISPLAY: block;">&#160;</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">Income tax expense was $<font>0</font> for the three months ended March 31, 2016 and 2015.</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"> <div style="TEXT-INDENT: 0pt; DISPLAY: block;">&#160;</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">As of January 1, 2016, the Company had <font>no</font> unrecognized tax benefits, and accordingly, the Company did not recognize interest or penalties during 2015 related to unrecognized tax benefits. There has been <font>no</font> change in unrecognized tax benefits during the three months ended March 31, 2016, and there was <font>no</font> accrual for uncertain tax positions as of March 31, 2016. Tax years from 2012 through 2015 remain subject to examination by major tax jurisdictions.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="justify">&#160;</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">There is no income tax benefit for the losses for the three months ended March 31, 2016 and 2015, since management has determined that the realization of the net tax deferred asset is not assured and has created a valuation allowance for the entire amount of such benefits.</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"> <div style="TEXT-INDENT: 0pt; DISPLAY: block;"></div></div></div> 1025 3169197 -2034117 -3165088 149 142231 14247 7403 -134828 -14098 -2168945 -3179186 268280 264605 -2437225 -3443791 -0.02 -0.03 117517626 119117626 0.08 2072582 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;">NOTE 7 &#150; CONVERTIBLE PREFERRED STOCK</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block;"><br/> </div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">As of March 31, 2016, the value of the cumulative <font>8</font>% dividends for all preferred stock was $<font>2,072,582</font>.&#160;&#160;Such dividends will be paid when and if declared payable by the Company's board of directors or upon the occurrence of certain liquidation events.&#160;&#160;In accordance with FASB ASC 260-10-45-11, the Company has recorded these accrued dividends as a current liability.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="justify">&#160;</div></div></div> 3877970 0.01 1.00 P1Y 219051 3500000 0.04 9692 0.964 0.0064 P2Y 24372838 0.01 3.00 P1Y 1305411 1.613 0.0047 P1Y3M7D <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;">NOTE 8 &#150; STOCKHOLDERS' EQUITY</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"> <div style="TEXT-INDENT: 0pt; DISPLAY: block;"><br/> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">In February 2015, the Board of Directors of the Company approved amendments extending the term of outstanding warrants to purchase in the aggregate <font>3,877,970</font> shares of common stock of the Company at exercise prices ranging from $<font>0.01</font> per share to $<font>1.00</font> per share.&#160;&#160;These warrants were scheduled to expire at various dates during 2015 and were each extended for an additional <font>one</font> year period from the applicable current expiration date, with the new expiration dates ranging from <font>February 23, 2016</font> to <font>December 28, 2016</font>.&#160; The increase in fair value of this term extension was $<font>219,051</font>, which was expensed in 2015.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block;"><br/> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">In February 2015, the Company extended options previously granted to two of its executive officers, which included <font>3,500,000</font> options exercisable at $<font>0.04</font> per share.&#160;&#160;The increase in fair value of this term extension was $<font>9,692</font> which was expensed during the period. The Company used the Black-Scholes option pricing model to calculate the increase in fair value after the extension, with the following assumptions: <font>no</font> dividend yield, expected volatility of <font>96.4</font>%, risk free interest rate of <font>0.64</font>%, and expected option life of <font>2</font> years.</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"> <div style="TEXT-INDENT: 0pt; DISPLAY: block;"></div></div><div style="TEXT-INDENT: 0pt; DISPLAY: block;"><br/> </div><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="justify"></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">On January 25, 2016, the Board of Directors approved amendments extending the term of outstanding warrants to purchase in the aggregate <font>24,372,838</font> shares of common stock of the Company at exercise prices ranging from $<font>0.01</font> per share to $<font>3.00</font> per share (the &#147;Warrants&#148;).&#160;&#160;These Warrants were scheduled to expire at various dates during 2016 and were each extended for an additional <font>one</font> year period from the applicable current expiration date, with the new expiration dates ranging from <font>January 26, 2017</font> to <font>December 28, 2017</font>.&#160;&#160;The increase in fair value of this term extension was $<font>1,305,411</font> which was expensed during the three months ended March 31, 2016. The Company used the Black-Scholes option pricing model to calculate the increase in fair value, with the following assumptions for the extended warrants: <font>no</font> dividend yield, expected volatility of <font>161.3</font>%, risk free interest rate of <font>0.47</font>%, and expected warrant life of <font>1.27</font> years.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="justify">&#160;</div></div></div> 114475 114475 -2168945 -3064711 108600 11 28378 3 117517626 11752 54203451 -72188 -60802017 -57 6359 6359 1305411 1305411 69407 69407 20625 20625 268280 -2168945 108600 11 28378 3 117517626 11752 55584628 -51563 -63239242 0 360 69407 190364 115068 1305411 228743 20625 38670 11467 28719 -7403 895 -55500 -265390 -31800 -7253 193770 59617 5207 -449338 -2277873 5129 28041 -33170 2000000 483500 483500 2000000 114475 34162 -196568 1652392 1455824 55000 268280 264605 6359 22508 25000000 6101664 9048336 5000000 2105000 2895000 8822500 0.76 P2Y7M6D 535837 0.57 8286663 0.77 P2Y2M12D 5345824 0.86 P1Y3M18D 8286663 0.77 P2Y2M12D 0.11 69407 305432 499572 P2Y4M24D 26365896 1.02 P4M24D 1142858 0.04 96700 0.90 P2Y 25319738 1.07 P1Y1M6D 25319738 1.07 P1Y1M6D 25319738 1.07 P1Y1M6D 0.11 250000 20000 P2Y 4000 0.90 0.1 50000 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">NOTE 9 &#150; STOCK OPTIONS AND WARRANTS</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">During 2008, the Board of Directors (&#147;Board&#148;) of the Company adopted the 2008 Equity Incentive Plan (&#147;2008 Plan&#148;) that was approved by the shareholders.&#160;&#160;Under the Plan, the Company is authorized to grant options to purchase up to <font>25,000,000</font> shares of common stock to any officer, other employee or director of, or any consultant or other independent contractor who provides services to the Company.&#160;&#160;The Plan is intended to permit stock options granted to employees under the 2008 Plan to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (&#147;Incentive Stock Options&#148;).&#160;&#160;All options granted under the 2008 Plan, which are not intended to qualify as Incentive Stock Options are deemed to be non-qualified options (&#147;Non-Statutory Stock Options&#148;).&#160;&#160;As of March 31, 2016, options to purchase <font>6,101,664</font>&#160;shares of common stock have been issued and are unexercised, and <font>9,048,336</font>&#160;shares are available for grants under the 2008 Plan.&#160;&#160;</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">During 2013, the Board adopted the 2013 Equity Incentive Plan (&#147;2013 Plan&#148;), which was approved by stockholders at the 2013 annual meeting of stockholders.&#160;&#160;Under the 2013 Plan, the Company is authorized to grant awards of stock options, restricted stock, restricted stock units and other stock-based awards of up to an aggregate of <font>5,000,000</font> shares of common stock to any officer, employee, director or consultant.&#160;&#160;The 2013 Plan is intended to permit stock options granted to employees under the 2013 Plan to qualify as Incentive Stock Options.&#160;&#160;All options granted under the 2013 Plan, which are not intended to qualify as Incentive Stock Options are deemed to be Non-Statutory Stock Options.&#160;&#160;As of March 31, 2016, under the 2013 Plan grants of restricted stock and options to purchase <font>2,105,000</font> shares of common stock have been issued and are unvested or unexercised, and <font>2,895,000</font> shares of common stock remain available for grants under the 2013 Plan.&#160;&#160;</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The 2008 Plan and 2013 Plan are administered by the Board or its compensation committee, which determines the persons to whom awards will be granted, the number of awards to be granted, and the specific terms of each grant, including the vesting thereof, subject to the terms of the applicable Plan.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company).</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">Prior to January 1, 2014, volatility in all instances presented is the Company's estimate of volatility that is based on the volatility of other public companies that are in closely related industries to the Company.&#160;&#160;Beginning January 1, 2014, volatility in all instances presented is the Company's estimate of volatility that is based on the historical volatility of the Company's stock history.</font></div> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The following table summarizes the activities for our stock options for the three months ended March 31, 2016:</font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;"> <div> <div> <table style="font-family: times new roman; font-size: 10pt;" cellpadding="0" cellspacing="0" width="100%"> <tr> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;"></td> <td style="font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;"></td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="14" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Options Outstanding</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td nowrap="nowrap" valign="bottom" colspan="2"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;Weighted -</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td nowrap="nowrap" valign="bottom" colspan="2"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td nowrap="nowrap" valign="bottom" colspan="2"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;Average</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td nowrap="nowrap" valign="bottom" colspan="2"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Remaining</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Aggregate</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted-</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Contractual</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Intrinsic</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Number of</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Term</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Value</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Shares</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise Price</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">in years)</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">(in 000's) (1)</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance December 31, 2015</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>8,822,500</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>0.76</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>2.6</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cancelled/forfeited</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>(535,837</font></td> <td style="text-align: left;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;padding-right: 10px;white-space: nowrap;" nowrap="nowrap">)</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;padding-right: 10px;white-space: nowrap;">$</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>(0.57</font></td> <td style="text-align: left;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;padding-right: 10px;white-space: nowrap;" nowrap="nowrap">)</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="text-align: right;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" colspan="2" nowrap="nowrap">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="padding: 0px; width: 52%;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance March 31, 2016</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>8,286,663</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>0.77</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>2.2</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; width: 1%;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercisable at March 31, 2016</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>5,345,824</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>0.86</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.3</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercisable at March 31, 2016 and expected to</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="margin-left: 9pt; padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">vest thereafter</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>8,286,663</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>0.77</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>2.2</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap;" nowrap="nowrap">&#160;</td> </tr> </table> </div> </div> <div><font style="font-family: Times New Roman; font-size: 10pt;">&#160;</font></div> </div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <table style="font-family: times new roman; font-size: 10pt;" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr valign="top"> <td style="width: 18pt;" align="right"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-family: 'times new roman', times; font-size: 10pt;">(1)&#160;</font></div> </td> <td align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <div><font style="font-family: 'times new roman', times; font-size: 10pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $<font>0.11</font> for our common stock on March 31, 2016.</font></div> </div> </td> </tr> </table> </div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;For the three months ended March 31, 2016 and 2015, the Company expensed $<font>69,407</font> and $<font>305,432</font> with respect to the options.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">As of March 31, 2016 there was $<font>499,572</font> of unrecognized compensation cost related to outstanding stock options. This amount is expected to be recognized over a weighted-average period of <font>2.4</font>&#160;years. To the extent the actual forfeiture rate is different from what the Company has estimated, stock-based compensation related to these awards will be different from the Company's expectations.&#160;The difference between the stock options exercisable at March 31, 2016 and the stock options exercisable and expected to vest relates to management's estimate of options expected to vest in the future.</font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">The following table summarizes the activities for our warrants for the three months ended March 31, 2016:</font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <div> <table style="font-family: times new roman; font-size: 10pt;" cellpadding="0" cellspacing="0" width="100%"> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Remaining</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Aggregate</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted-</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Contractual</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Intrinsic</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Number of</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Term</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Value</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;"></td> <td style="font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;"></td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Shares</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;"></td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise Price</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">in years)</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">(in 000's) (1)</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance December 31, 2015</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>26,365,896</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.02</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>0.4</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expired</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>(1,142,858</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;" nowrap="nowrap">)</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>(0.04</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;" nowrap="nowrap">)</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>96,700</font></td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;padding-right: 10px;white-space: nowrap;">$</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>0.90</font></td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>2.0</font></td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" colspan="2" nowrap="nowrap">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="padding: 0px; width: 52%;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance March 31, 2016</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>25,319,738</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>1.07</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>1.1</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; width: 1%;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercisable at March 31, 2016</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>25,319,738</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.07</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.1</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercisable at March 31, 2016 and expected to</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="margin-left: 9pt; padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">vest thereafter</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>25,319,738</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.07</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.1</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap;" nowrap="nowrap">&#160;</td> </tr> </table> </div> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <table style="font-family: times new roman; font-size: 10pt;" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr valign="top"> <td style="width: 18pt;" align="right"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-family: 'times new roman', times; font-size: 10pt;">(1)&#160;</font></div> </td> <td align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <div><font style="font-family: 'times new roman', times; font-size: 10pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $<font>0.11</font> for our common stock on March 31, 2016.</font></div> </div> </td> </tr> </table> </div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">&#160;All warrants were vested on the date of grant.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> </div> </div> P2Y 10000 0.90 0.10 100000 0.10 2940000 0.05 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;"> <div> <div> <table style="font-family: times new roman; font-size: 10pt;" cellpadding="0" cellspacing="0" width="100%"> <tr> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;"></td> <td style="font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;"></td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="14" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Options Outstanding</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td nowrap="nowrap" valign="bottom" colspan="2"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;Weighted -</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td nowrap="nowrap" valign="bottom" colspan="2"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-family: 'Times New Roman';" nowrap="nowrap" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="font-family: 'Times New Roman';" nowrap="nowrap" valign="bottom" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td nowrap="nowrap" valign="bottom" colspan="2"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt; text-align: center;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;Average</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td nowrap="nowrap" valign="bottom" colspan="2"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Remaining</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Aggregate</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted-</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Contractual</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Intrinsic</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Number of</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Term</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Value</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Shares</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise Price</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">in years)</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">(in 000's) (1)</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance December 31, 2015</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>8,822,500</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>0.76</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>2.6</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cancelled/forfeited</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>(535,837</font></td> <td style="text-align: left;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;padding-right: 10px;white-space: nowrap;" nowrap="nowrap">)</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;padding-right: 10px;white-space: nowrap;">$</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>(0.57</font></td> <td style="text-align: left;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;padding-right: 10px;white-space: nowrap;" nowrap="nowrap">)</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="text-align: right;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" colspan="2" nowrap="nowrap">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="padding: 0px; width: 52%;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance March 31, 2016</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>8,286,663</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>0.77</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>2.2</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; width: 1%;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercisable at March 31, 2016</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>5,345,824</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>0.86</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.3</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercisable at March 31, 2016 and expected to</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="margin-left: 9pt; padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">vest thereafter</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>8,286,663</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>0.77</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>2.2</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap;" nowrap="nowrap">&#160;</td> </tr> </table> </div> </div> <div><font style="font-family: Times New Roman; font-size: 10pt;">&#160;</font></div> </div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <table style="font-family: times new roman; font-size: 10pt;" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr valign="top"> <td style="width: 18pt;" align="right"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-family: 'times new roman', times; font-size: 10pt;">(1)&#160;</font></div> </td> <td align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <div><font style="font-family: 'times new roman', times; font-size: 10pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $<font>0.11</font> for our common stock on March 31, 2016.</font></div> </div> </td> </tr> </table> </div> </div> 12500 2016-07-20 2016-09-18 2016-02-23 2016-12-28 2017-01-26 2017-12-28 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <div> <table style="font-family: times new roman; font-size: 10pt;" cellpadding="0" cellspacing="0" width="100%"> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Remaining</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Aggregate</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;"> </font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Weighted-</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Contractual</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Intrinsic</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td style="font-weight: bold; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom"></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Number of</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;"> </font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Average</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Term</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'Times New Roman';" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td colspan="2" nowrap="nowrap" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Value</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;"></td> <td style="font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;"></td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Shares</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap"></td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;"></td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise Price</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">in years)</font></div> </td> <td style="text-align: left;font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-weight: bold;font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="border-bottom: #000000 2pt solid !important;padding: 0px;" colspan="2" nowrap="nowrap"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="center"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">(in 000's) (1)</font></div> </td> <td style="text-align: left; font-family: 'times new roman'; font-weight: bold; font-size: 10pt; padding: 0px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance December 31, 2015</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>26,365,896</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.02</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>0.4</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Expired</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>(1,142,858</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;" nowrap="nowrap">)</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>(0.04</font></td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;" nowrap="nowrap">)</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" align="right" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;">&#160;</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>96,700</font></td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;padding-right: 10px;white-space: nowrap;">$</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>0.90</font></td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="text-align: right;font-family: 'times new roman';border-bottom: #000000 2pt solid !important;padding: 0px;font-size: 10pt;vertical-align: bottom;white-space: nowrap;"><font>2.0</font></td> <td style="text-align: left;font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;">&#160;</td> <td style="font-family: 'times new roman';font-size: 10pt;border-bottom: #000000 2pt solid !important;padding: 0px;white-space: nowrap;padding-right: 5px;padding-left: 5px;" colspan="2" nowrap="nowrap">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" colspan="2" nowrap="nowrap" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="padding: 0px; width: 52%;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Balance March 31, 2016</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>25,319,738</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>1.07</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>1.1</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 1%;">$</td> <td style="text-align: right; font-family: 'times new roman'; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; border-bottom-color: rgb(0, 0, 0) !important; width: 9%;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap; width: 1%;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercisable at March 31, 2016</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>25,319,738</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.07</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.1</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: #cceeff;"> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="vertical-align: top; text-align: left; font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td align="left" valign="bottom"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercisable at March 31, 2016 and expected to</font></div> </td> <td style="font-size: 10pt; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-size: 10pt; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';" valign="bottom">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> </tr> <tr style="background-color: white;"> <td style="margin-left: 9pt; padding: 0px;" align="left"> <div style="text-indent: 0pt; display: block; margin-left: 9pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: times new roman; font-size: 10pt;">vest thereafter</font></div> </td> <td style="font-family: 'times new roman'; font-size: 10pt; padding: 0px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>25,319,738</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.07</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;">&#160;</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>1.1</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" nowrap="nowrap">&#160;</td> <td style="font-family: 'times new roman'; font-size: 10pt; border-bottom: #000000 2.80pt double !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;" align="right">&#160;</td> <td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; padding-right: 10px; white-space: nowrap;">$</td> <td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; font-size: 10pt; vertical-align: bottom; white-space: nowrap;"><font>-</font></td> <td style="text-align: left; font-family: 'times new roman'; font-size: 10pt; padding: 0px 5px; white-space: nowrap;" nowrap="nowrap">&#160;</td> </tr> </table> </div> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <table style="font-family: times new roman; font-size: 10pt;" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr valign="top"> <td style="width: 18pt;" align="right"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="font-family: 'times new roman', times; font-size: 10pt;">(1)&#160;</font></div> </td> <td align="left"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"> <div><font style="font-family: 'times new roman', times; font-size: 10pt;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $<font>0.11</font> for our common stock on March 31, 2016.</font></div> </div> </td> </tr> </table> </div> </div> 7998 156677 <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"><div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;">NOTE 10 &#150; OPERATING LEASES</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"> <div style="TEXT-INDENT: 0pt; DISPLAY: block;">&#160;</div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;">For the three months ended March 31, 2016 and 2015, total rent expense under leases amounted to $<font>7,998</font> and $<font>156,677</font>. As of March 31, 2016, the Company was not obligated under any non-cancelable operating lease arrangements.</font></div> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt;"> <div style="TEXT-INDENT: 0pt; DISPLAY: block;">&#160;</div></div></div> 240000 3000000 0.90 P3Y <div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt; font-weight: bold;">NOTE 11 &#150; SUBSEQUENT EVENTS</font></div> </div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On April 14, 2016, the Company appointed a new Chief Executive Officer and Chairman of the Board, with such appointments taking effect on April 18, 2016.&#160;&#160;In this connection with his appointment, the Company also simultaneously entered into an Employment Agreement with the Chief Executive Officer and Chairman of the Board, pursuant to which he will be employed on an at will basis at an annual salary of $<font>240,000</font> during the first year of employment.&#160;&#160;He also received options to purchase <font>3,000,000</font> shares of the Company's common stock at an exercise price of $<font>0.90</font> per share, vesting over <font>three</font> years and <font>250,000</font> restricted stock units.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On April 18, 2016, the Company issued $<font>20,000</font> in aggregate principal amount of unsecured Promissory Notes to two accredited investors&#160;pursuant to Promissory Note Agreements (the &#147;Notes&#148;).&#160;&#160;The Investors also received <font>two</font>-year Warrants to purchase an aggregate of <font>4,000</font> shares of Company common stock at an exercise price of $<font>0.90</font> per share.&#160;&#160;The Notes bear interest at a rate of ten percent (<font>10</font>%) per annum and mature on the six (6) month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.</font></div> <div style="text-indent: 0pt; display: block;"><br/></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On April 25, 2016, the Company issued a $<font>50,000</font> principal amount unsecured Promissory Note to an accredited investor&#160;pursuant to a Promissory Note Agreement (the &#147;Note&#148;).&#160;&#160;The Investor also received <font>two</font>-year Warrants to purchase an aggregate of <font>10,000</font> shares of Company common stock at an exercise price of $<font>0.90</font> per share.&#160;&#160;The Note bears interest at a rate of ten percent (<font>10</font>%) per annum and matures on the six (6) month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.</font></div> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"> <div> <div style="width: 100%;" align="center"><br/></div> </div> </div></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On May 5, 2016, the Company issued $<font>100,000</font> aggregate principal amount of its <font>10</font>% Secured Convertible Promissory Notes due March 6, 2017 (the &#147;New Notes&#148;) to an accredited investor.&#160;&#160;The New Notes are in addition to currently outstanding promissory notes of the same series, in the principal amount of $<font>2,940,000</font> (the &#147;Prior Notes&#148;), which were originally due March 5, 2016 and the maturity date thereof was subsequently extended to March 6, 2017 with the consent of the Note holders.</font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="left"><font style="display: inline; font-family: Times New Roman; font-size: 10pt;">On May 11, 2016, the Company entered into a consulting agreement with <font style="display: inline;">a company owned by a beneficial owner of more than <font>5</font>% of the Company.&#160;&#160;The agreement requires the payment of $<font>12,500</font> per month and continues on a monthly basis until terminated.</font></font></div> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;" align="justify">&#160;</div> </div> VIRTUAL PIGGY, INC. 0001437283 10-Q 2016-03-31 --12-31 Smaller Reporting Company 117517626 2016 Q1 false Yes P12M P18M The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.11 for our common stock on March 31, 2016. The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.11 for our common stock on March 31, 2016. EX-101.SCH 9 vpig-20160331.xsd EXHIBIT 101.SCH 001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 006 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 102 - Disclosure - MANAGEMENT PLANS link:presentationLink link:calculationLink link:definitionLink 8540 - Disclosure - PATENTS AND TRADEMARKS link:presentationLink link:calculationLink link:definitionLink 104 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 105 - Disclosure - NOTES PAYABLE - STOCKHOLDERS link:presentationLink link:calculationLink link:definitionLink 106 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 8560 - Disclosure - LITIGATION link:presentationLink link:calculationLink link:definitionLink 107 - Disclosure - CONVERTIBLE PREFERRED STOCK link:presentationLink link:calculationLink link:definitionLink 108 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 109 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 110 - Disclosure - OPERATING LEASES link:presentationLink link:calculationLink link:definitionLink 111 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 8590 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 8580 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 309 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 8600 - Disclosure - OPERATING LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 8001 - Statement - Statement of Changes in Stockholders' Equity (Deficit) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 8002 - Disclosure - INCOME TAXES (Schedule of Income Tax (Benefit) Provision) (Details) link:presentationLink link:calculationLink link:definitionLink 8003 - Disclosure - INCOME TAXES (Schedule of Effective Tax Rate Reconciliation) (Details) link:presentationLink link:calculationLink link:definitionLink 8004 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 8005 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Schedule of Liabilities Measured at Fair Value on a Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 8006 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Fair Value Measurements Within the Fair Value Hierarchy of the Company's Derivative Liabilities using Level 2 Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 8007 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 8008 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 8500 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 8510 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 8520 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 8530 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - MANAGEMENT PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 8550 - Disclosure - PATENTS AND TRADEMARKS (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - NOTES PAYABLE - STOCKHOLDERS (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 8570 - Disclosure - LITIGATION (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - CONVERTIBLE PREFERRED STOCK (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - STOCK OPTIONS AND WARRANTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 8610 - Disclosure - STOCK OPTIONS AND WARRANTS (Weighted Average Assumptions Used to Estimate Fair Value of Stock Option and Warrant Grants) (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - STOCK OPTIONS AND WARRANTS (Schedule of Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 8620 - Disclosure - STOCK OPTIONS AND WARRANTS (Summary of Activities of Unvested Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - STOCK OPTIONS AND WARRANTS (Schedule of Warrant Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - OPERATING LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 8630 - Disclosure - OPERATING LEASES (Schedule of Non Cancelable Operating Lease Arrangements) (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 103 - Disclosure - ACCOUNTS PAYABLE - RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - ACCOUNTS PAYABLE - RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 vpig-20160331_cal.xml EXHIBIT 101.CAL EX-101.DEF 11 vpig-20160331_def.xml EXHIBIT 101.DEF EX-101.LAB 12 vpig-20160331_lab.xml EXHIBIT 101.LAB Disclosure of accounting policy for the nature of business. Nature of Business [Policy Text Block] Nature of the Business The policy for a new accounting pronouncement that has been issued but not yet adopted New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block] Recently Issued Accounting Pronouncements Not Yet Adopted Agreement One [Member] Agreement One [Member] Agreement Two [Member] Agreement Two [Member] The fair value of equity issued during the period. Fair Value Of Equity Issued Fair value of stock options Fair value of options or warrants Number of shares of common stock that have been issued and are unexercised under the plan. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued And Unexercised Number of shares of common stock that have been issued and are unexercised under the plan 2008 Equity Incentive Plan [Member] Equity Incentive Plan 2008 [Member] 2008 Equity Incentive Plan [Member] The fair value of equity granted during the period. Fair Value Of Equity Granted Weighted average fair value of stock options granted Granted, fair value 2013 Equity Incentive Plan [Member] Equity Incentive Plan 2013 [Member] 2013 Equity Incentive Plan [Member] Weighted average price at which grantees can acquire the shares reserved for issuance under the unvested stock option plan. Share Based Compensation Arrangement by Share Based Payment Award Options Nonvested Options Outstanding Weighted Average Exercise Price Unvested stock options at September 30, 2015 Unvested stock options at December 31, 2014 Weighted average price of nonvested stock options that were either cancelled or forfeited. Sharebased Compensation Arrangement by Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Exercise Price Cancelled/Forfeited Amendment Flag Amendment Flag Number of non-vested options expired. Sharebased Compensation Arrangement by Sharebased Payment Award Options Nonvested Options Expired Number of Shares Expired Weighted average price of nonvested stock options that were expired. Sharebased Compensation Arrangement by Sharebased Payment Award Options Nonvested Options Expired Weighted Average Exercise Price Expired Weighted average grant-date fair value of options expired. Sharebased Compensation Arrangement by Sharebased Payment Award Options Expired Weighted Average Grant Date Fair Value Expired Weighted average price of nonvested stock options that were vested. Sharebased Compensation Arrangement by Sharebased Payment Award Options Nonvested Options Vested Weighted Average Exercise Price Vested Weighted average remaining contractual term for unvested stock options outstanding, in ''PnYnMnDTnHnMnS'' format, for example, ''P1Y5M13D'' represents the reported fact of one year, five months, and thirteen days. Sharebased Compensation Arrangement by Sharebased Payment Award Options Nonvested Weighted Average Remaining Amortization Term Unvested stock options at September 30, 2015 Represents the information pertaining to unvested stock options. Nonvested Stock Options [Member] Unvested Stock Options [Member] Weighted average price at which grantees can acquire the shares reserved for issuance. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price Balance March 31, 2016 Balance December 31, 2015 Weighted average per share amount at which grantees can acquire shares of common stock by exercise equity instruments other than options. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price Granted Weighted average price at which option holders acquired shares when converting their equity instruments other than options into shares. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price Exercised Weighted average price at which grantees could have acquired the underlying shares with respect to equity instruments other than options that were terminated. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Cancelled Weighted Average Exercise Price Forfeited/canceled Weighted average price at which grantees could have acquired the underlying shares with respect to equity instruments other than options of the plan that expired. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Exercise Price Expired The number of shares into which fully or partially vested equity instruments other than options outstanding and expected to vest as of the balance sheet date can be currently converted under the option plan. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable And Expected To Vest Exercisable at March 31, 2016 and expected to vest thereafter The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on exercisable and expected to vest portions of equity instruments other than options outstanding and currently exercisable under the plan. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable And Expected To Vest Weighted Average Exercise Price Exercisable at March 31, 2016 and expected to vest thereafter Weighted average remaining contractual term for vested portions of equity instruments other than options outstanding and currently exercisable or expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Exercisable And Expected To Vest Weighted Average Remaining Contractual Terms Exercisable at March 31, 2016 and expected to vest thereafter Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of equity instruments other than options outstanding and currently exercisable and expected to vest. Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable And Expected To Vest Intrinsic Value Exercisable as of March 31, 2016 and expected to vest thereafter Number of share options (or share units) and warrants exercised during the current period. Stock Issued During Period Shares Stock Options And Warrants Exercised Exercise of stock options and warrants, shares Current Fiscal Year End Date Current Fiscal Year End Date Value of stock issued as a result of the exercise of stock options and warrants. Stock Issued During Period Value Stock Options And Warrants Exercised Exercise of stock options and warrants The fair value of derivative liability as discount against preferred stock in noncash investing or financing activities. Fair Value Of Warrant Liability As Discount Against Preferred Stock Fair value of warrant liability as discount against Preferred Stock Deemed dividend distribution in conjunction with warrant exchange offering. Deemed Dividend Distribution In Conjunction With Warrant Exchange Offering Deemed dividend distribution in conjunction with warrant exchange Deemed dividend distribution in conjunction with warrant exchange offering The monthly payment for consulting services per agreement for a term of one year. Monthly Payment For Consulting Services Per Agreement Monthly payment for consulting services per agreement Consultant And Beneficial Owner [Member] Consultant And Beneficial Owner [Member] Consultant and Beneficial Owner [Member] Consulting Agreement With Company Partly Owned By Director [Member] Consulting Agreement with a Company partly owned by a Director [Member] The period of time between a start and end date of consulting agreement. Consulting Agreement Term Consulting agreement term Proceeds from issuance of preferred stock. Preferred Stock Value Issued Preferred Stock issued The effective price per share of the conversion feature embedded in the debt instrument. Debt Instrument Convertible Effective Conversion Price Series A Preferred Stock Effective Conversion Price Series A and B Preferred Stock Effective Conversion Price Equity Issuance [Axis] Equity Issuance [Axis] Exchange of Warrants and Deemed Dividend [Member] Exchange Of Warrants And Deemed Dividend [Member] Exchange of Warrants and Deemed Dividend [Member] Document Period End Date Document Period End Date Extension Of Warrants [Member] Extension Of Warrants [Member] Extension of Warrants [Member] Warrant Type One [Member] Warrant Type One [Member] Warrant Type Two [Member]. Warrant Type Two [Member] Issuance of Restricted Shares [Member] Issuance Of Restricted Shares [Member] Issuance of Restricted Shares [Member] Period for which the expiration date for the warrants has been extended. Warrant Extension Period Warrant extension Warrant extension period Award Type [Axis] Issuance of shares of common stock from exercise of warrants through warrant exchange offering, value. Issuance Of Common Stock From Exercise Of Warrant Exchange Offering Value Issuance of shares of common stock from exercise of warrants through warrant exchange offering at $.50 per share Issuance of shares of common stock from exercise of warrants through warrant exchange offering, shares. Issuance Of Common Stock From Exercise Of Warrant Exchange Offering Shares Issuance of shares of common stock from exercise of warrants through warrant exchange offering at $.50 per share, shares Additional preferred stock. Additional Preferred Stock [Member] Additional Preferred Stock [Member] Amount of increase in additional paid in capital (APIC) resulting from the revaluation of options and warrants. Adjustments To Additional Paid In Capital Revaluation Of Options And Warrants Revaluation of options and warrants Deemed dividend distribution in conjunction with warrant exchange offering. Adjustment To Additional Paid In Capital Deemed Dividend Distribution In Conjunction With Warrant Exchange Offering Deemed dividend distribution in conjunction with warrant exchange offering The period from issuance to expiration for an equity instrument. Equity Instrument Period From Issuance To Expiration Expiration period after issuance April Two Thousand Thirteen Issuance [Member] April Two Thousand Thirteen Issuance [Member] April 15, 2013 Issuance [Member] Common Stock Subscribed [Member] Common Stock Subscribed [Member] Common stock subscription for units issued through private placement. Common Stock Subscription For Units Issued Through Private Placement Common stock subscription for 62,500 units through private placement at $.80 per unit ConsultingAgreementWithFormerManagerMember Consulting Agreement With Former Manager [Member] Consulting Agreement with Former Manager [Member] Deemed dividend distribution in conjunction with Preferred Series A offering Deemed Dividend Distribution In Conjunction With Preferred Seriesa Offering Deemed dividend distribution in conjunction with Preferred Series A offering Document and Entity Information [Abstract] Document and Entity Information [Abstract] Equity Issuance [Domain] Equity Issuance [Domain] Equity Issuance Number Of Units Authorized Equity Issuance Number Of Units Authorized Units authorized The number of warrants per unit for an equity issuance. Equity Issuance Number Of Warrants Per Unit Warrants per unit Equity Issued [Line Items] Equity Issued [Line Items] Expense allowance for placement agent fees. Expense Allowance For Placement Agent Fees Expense allowance The fair value of stock issued for prepaid expenses. Fair Value Of Stock Issued For Prepaid Expenses Fair value of stock issued for prepaid expenses Fair Value Per Share Common Stock Maximum Fair Value Per Share Common Stock Maximum Fair value per share, common stock, maximum Fair value per share, common stock Fair Value Per Share Common Stock Minimum Fair value per share, common stock, minimum General and administrative expense related to patent and trademark. General And Administrative Expense Related To Patent And Trademark General and administrative expense related to patent and trademark Number of shares of common stock and warrants issued through private placement, transaction one. Issuance Of Common Stock And Warrants Through Private Placement Shares Transaction One Issuance of shares of common stock and 93,750 warrants through private placement at $.80 per unit, shares Number of shares of common stock and warrants issued through private placement, transaction two. Issuance Of Common Stock And Warrants Through Private Placement Shares Transaction Two Issuance of shares of common stock and 1,436,277 warrants through a private placement at $1.80 per share, shares Value of common stock and warrants issued through private placement, transaction one. Issuance Of Common Stock And Warrants Through Private Placement Value Transaction One Issuance of shares of common stock and 93,750 warrants through private placement at $.80 per unit Value of common stock and warrants issued through private placement, transaction two. Issuance Of Common Stock And Warrants Through Private Placement Value Transaction Two Issuance of shares of common stock and 1,436,277 warrants through a private placement at $1.80 per share Number of shares issued from convertible preferred stock and warrants issued through private placement. Issuance Of Convertible Preferred Stock And Warrants Through Private Placement Shares Issuance of shares of convertible preferred stock and warrants through private placement, shares Issuance of shares of convertible preferred stock and 10,860,000 warrants through private placement at $100 per unit, shares Value of convertible preferred stock and warrants issued through private placement. Issuance Of Convertible Preferred Stock And Warrants Through Private Placement Value Issuance of shares of convertible preferred stock and 10,860,000 warrants through private placement at $100 per unit May Two Thousand Thirteen Securities Purchase Agreement [Member] May Two Thousand Thirteen Securities Purchase Agreement [Member] May 2013 Securities Purchase Agreement [Member] Arrangements and Non-arrangement Transactions [Domain] Number of merchant agreements with gift card providers agreeing to deploy technology on their websites. Number Of Merchant Agreements With Gift Card Providers To Deploy Technology On Their Websites Number of merchant agreements with gift card providers to deploy technology on their websites Number of merchant agreements with merchants agreeing to deploy technology on their websites. Number Of Merchant Agreements With Merchants To Deploy Technology On Their Websites Number of merchant agreements with merchants to deploy technology on their websites Number of merchant agreements with partners agreeing to deploy technology on their websites. Number Of Merchant Agreements With Partners To Deploy Technology On Their Websites Number of merchant agreements with partners to deploy technology on their websites Number Of Merchants Using Technology In Live Use Number Of Merchants Using Technology In Live Use Number of merchants using technology in live use The cash outflow for fees to the placement agent. Payment Of Placement Agent Fees Placement agent fees Quarter One Two Thousand Thirteen Issuance [Member] Quarter One Two Thousand Thirteen Issuance [Member] Q1 2013 Issuance [Member] The amount of sales proceeds received at which the note becomes payable. Sale Proceeds Threshold Sale proceeds amount Schedule Of Equity Issued [Table] Schedule Of Equity Issued [Table] Schedule of weighted-average assumptions used to estimate the fair values of the warrants granted. Schedule of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block] Schedule of Weighted-Average Assumptions Used to Estimate the Fair Values of the Warrants Granted The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of equity instruments other than options outstanding and currently exercisable. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Exercise Price Exercisable at March 31, 2016 Weighted average remaining contractual term for vested portions of equity instruments other than options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Exercisable Weighted Average Remaining Contractual Terms Exercisable at March 31, 2016 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Term [Abstract] Weighted- Average Remaining Contractual Term: The number of non option shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number Exercisable at March 31, 2016 Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value: Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Weighted Average Remaining Contractual Term: Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of equity instruments other than options outstanding and currently exercisable. Sharebased Compensation Arrangement By Sharebased Payment Award Other Than Options Exercisable Intrinsic Value 1 Exercisable at March 31, 2016 Period of time between grant and expiration of warrant, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Warrant Term Warrant Term Value of convertible preferred stock and warrants issued through private placement, transaction two. Issuance Of Convertible Preferred Stock And Warrants Through Private Placement Value Transaction Two Issuance of shares of convertible preferred stock and 28,378 warrants through private placement at $90 per unit Number of shares issued from convertible preferred stock and warrants issued through private placement, transaction two. Issuance Of Convertible Preferred Stock And Warrants Through Private Placement Shares Transaction Two Issuance of shares of convertible preferred stock and 28,378 warrants through private placement at $90 per unit, shares Deemed dividend distribution in conjunction with Preferred Series B offering. Deemed Dividend Distribution In Conjunction With Preferred Series B Offering Deemed dividend distribution in conjunction with Preferred Series B offering Deemed dividend distribution in conjunction with Preferred Series B offering Entity Well-known Seasoned Issuer Issuance Of Shares Of Common Stock And Warrants Through Private Placement [Member] Issuance Of Shares Of Common Stock And Warrants Through Private Placement [Member] Issuance of Shares of Common Stock and Warrants Through Private Placement [Member] Entity Voluntary Filers Issuance of Shares of Common Stock Through Private Placement [Member] Issuance of Shares of Common Stock Through Private Placement [Member] Issuance of Shares of Common Stock Through Private Placement [Member] Entity Current Reporting Status The number of units subscribed. Units Subscribed Units subscribed Entity Filer Category Entity Filer Category Common Stock Subscription for Units Through Private Placement [Member] Common Stock Subscription for Units Through Private Placement [Member] Entity Public Float Series A security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Warrant Series A [Member] Series A Warrants [Member] Entity Registrant Name Entity Registrant Name Series B security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Warrant Series B [Member] Series B Warrants [Member] Entity Central Index Key Entity Central Index Key GOING CONCERN [Abstract] The entire disclosure for information about going concern. Going Concern Disclosure [Text Block] GOING CONCERN Schedule that describes and identifies a going concern concept. Schedule of Going Concern [Table] Going Concern [Line Items] Going concern [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amount of expense (income) related to adjustment to fair value of option and warrants liability. Fair Value Adjustment of Options and Warrants Revaluation of options and warrants Sharebased Compensation Arrangement by Sharebased Payment Award Options Nonvested Weighted Average Exercise Price [Roll forward] Weighted Average Exercise Price Sharebased Compensation Arrangement by Sharebased Payment Award Options Nonvested Weighted Average Remaining Amortization Term [Abstract] Weighted Average Remaining Amortization Period (Years) Represents the information pertaining to number of convertible shares in a specific lot size. Stockholders Equity Note Stock Number of ConversionShares in Specific Lot Size Number of convertible shares in specific lot size The conversion price at which preferred stock is convertible into common stock. Stockholders Equity Conversion Price Conversion price at which preferred stock is convertible into common stock (in dollars per share) Transaction One Member. Transaction One [Member] Transaction Two [Member]. Transaction Two [Member] Number of warrants or rights issued during period. Class Of Warrant Or Right, Number Of Securities Issued Equity issuance, number of warrants issued Issuance Of Shares Of Convertible Preferred Stock And Warrants Through Private Placement [Member] Issuance Of Shares Of Convertible Preferred Stock And Warrants Through Private Placement [Member] Issuance of Shares of Convertible Preferred Stock And Warrants Through Private Placement [Member] Issuance Of Shares Of Common Stock Replacing Warrants [Member] Issuance Of Shares Of Common Stock Replacing Warrants [Member] Issuance of Shares of Common Stock Replacing Warrants [Member] Value of common stock and warrants issued through private placement, transaction three. Issuance of Common Stock and Warrants through Private Placement Value Transaction Three Issuance of shares of common stock and warrants through private placement at $.70 per unit Number of shares of common stock and warrants issued through private placement, transaction three. Issuance of Common Stock and Warrants through Private Placement Shares Transaction Three Issuance of shares of common stock and warrants through private placement at $.70 per unit, shares Value of common stock and warrants issued through private placement, transaction four. Issuance of Common Stock and Warrants through Private Placement Value Transaction Four Issuance of shares of common stock and warrants through private placement at $.80 per unit Number of shares of common stock and warrants issued through private placement, transaction four. Issuance of Common Stock and Warrants through Private Placement Shares Transaction Four Issuance of shares of common stock and warrants through private placement at $.80 per unit, shares Value of common stock issued for services. Issuance of Common Stock Value for Service Issuances of shares of common stock for services Number of shares of common stock issued for services. Issuance of Common Stock Shares for Service Issuances of shares of common stock for services, shares Document Fiscal Year Focus Document Fiscal Year Focus Value of common stock issued for discharge notes payable and interest. Issuance of Common Stock Value for Discharge of Notes Payable and Interest Issuances of shares of commons stock to discharge notes payable and interest at $.70 per unit Document Fiscal Period Focus Document Fiscal Period Focus Number of shares of common stock issued for discharge notes payable and interest. Issuance of Common Stock Shares for Discharge of Notes Payable and Interest Issuances of shares of commons stock to discharge notes payable and interest at $.70 per unit, shares Value of stock issued in lieu of with respect to settlement agreement. Stock Issued During Period Value Issued with Respect to Settlement Agreement Issuance of shares of common stock with respect to settlement agreement valued at $.85 per share Number of shares issued during the period as a result of with respect to settlement agreement. Stock Issued During Period Shares Issued with Respect to Settlement Agreement Issuance of shares of common stock with respect to settlement agreement valued at $.85 per share, shares Value of common stock issued through private placement, transaction one. Issuance of Common Stock through Private Placement Value Transaction One Issuance of shares of common stock through private placement at $.70 per share Number of shares of common stock issued through private placement, transaction one. Issuance of Common Stock through Private Placement Shares Transaction One Issuance of shares of common stock through private placement at $.70 per share, shares Value of common stock issued through private placement, transaction two. Issuance of Common Stock through Private Placement Value Transaction Two Issuance of shares of common stock through private placement at $.75 per share Number of shares of common stock issued through private placement, transaction two. Issuance of Common Stock through Private Placement Shares Transaction Two Issuance of shares of common stock through private placement at $.75 per share, shares Transaction Three Member. Transaction Three [Member] Transaction Three [Member] Transaction Four Member. Transaction Four [Member] Transaction Four [Member] Issuance of shares of common stock to discharge notes payable and interest. Issuance of Shares of Common Stock Discharge to Notes Payable and Interest [Member] Issuance of Shares of Common Stock to Discharge Notes Payable and Interest [Member] Issuance of shares of common stock with respect to the Settlement Agreement. Issuance of Shares of Common Stock with Respect to Settlement Agreement [Member] Issuance of Shares of Common Stock with Respect to Settlement Agreement [Member] April Two Thousand Twelve Issuance [Member]. April Two Thousand Twelve Issuance [Member] April 26, 2012 [Member] Document Type Document Type The value of common stock authorized in private placement. Equity Issuance Common Shares Authorized during Period Value Common stock authorized in private placement, value The number of shares authorized in private placement. Equity Issuance Common Shares Authorized during Period Shares Common stock authorized in private placement, shares The number of warrants authorized in private placement. Equity Issuance Number of Warrants Authorized Warrants authorized in private placement The number of shares per units of equity. Equity Issuance Number of Shares Per Unit Shares per unit December Two Zero One One Private Placement [Member]. December Two Zero One One Private Placement [Member] December 2011 Private Placement [Member] April 5, 2012 Issuance [Member]. April Fifth Two Thousand Twelve Private Placement [Member] April 5, 2012 Private Placement [Member] April 2, 2012 Issuance [Member] April Two Thousand Twelve Issuance of Equity [Member] April 2, 2012 Issuance [Member] May 2, 2012 Issuance [Member] May Second Two Thousand Twelve Issuance [Member] May 2, 2012 Issuance [Member] May 21, 2012 Issuance [Member]. May Twenty First Two Thousand Twelve Issuance [Member] May 21, 2012 Issuance [Member] July 5th, 2012 Issuance [Member]. July Fifth Two Thousand Twelve Issuance [Member] July 5th, 2012 Issuance [Member] November And December Two Thousand Ten Issuance [Member]. November and December Two Thousand Ten Issuance [Member] November and December 2010 Issuance [Member] December 2012 Issuance [Member]. December Two Thousand Twelve Issuance [Member] December 2012 Issuance [Member] MANAGEMENT PLANS [Abstract] The entire disclosure for management plans. Management Plans Disclosure [Text Block] MANAGEMENT PLANS Represents the fair value of options issued in exchange for services and extension of warrants. Fair Value of Options Issued In Exchange For Services And Extension of Warrants Fair value of options issued in exchange for services Issued On March Six [Member] Issued On March Six [Member] Convertible Promissory Notes due March 5, 2016, Issued on March 6, 2015 [Member] Convertible Promissory Notes due March 5, 2016, Issued on March 6, 2015 [Member] Issued On May Eleven [Member] Issued On May Eleven [Member] Convertible Promissory Notes due March 5, 2016, Issued on May 11, 2015 [Member] Convertible Promissory Notes due March 5, 2016, Issued on May 11, 2015 [Member] Represents the extension of options. Extension of Options [Member] Extension of Options [Member] Represents the revaluation of options. Revaluation of Options [Member] Revaluation of Options [Member] Represents the employee stock option one. Employee Stock Option One [Member] Employee Stock Option One [Member] Represents the employee stock option two. Employee Stock Option Two [Member] Employee Stock Option Two [Member] Represents the information pertaining to consultant. Consultant [Member] Consultant [Member] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] Information by share issuance period. Share Issuance Period [Axis] Period upon which share issuance was executed. Share Issuance Period [Domain] Represents the information pertaining to share issuance period, one. Share Issuance Period One [Member] Share issuance period, one [Member] Represents the information pertaining to share issuance period, two. Share Issuance Period Two [Member] Share issuance period, two [Member] Represents the information pertaining to share issuance period, three. Share Issuance Period Three [Member] Share issuance period, three [Member] Carrying values as of the balance sheet date of the portions of long-term notes payable excluding convertible notes payable due within one year or the operating cycle if longer. Notes Payable Excluding Convertible Notes Payable Current Notes payable - stockholders, net of discount of $32,294 Represents the reclassified amount of cumulative translation adjustment to retained earning during the reporting period. Reclassifications of Cumulative Translation Adjustment to Retained Earnings Cumulative translation adjustment reclassified for closure of office in England The income and losses included in earning resulting from forfeiture of restricted stock. Income (Loss) from Forfeiture of Restricted Stock Income from forfeiture of restricted stock Forfeiture of restricted stock Amount of expense (income) related to adjustment to fair value of option liability. Fair Value Adjustment of Options Revaluation of options The cash inflow from a convertible notes payable made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Proceeds from Related Party Convertible Notes Payable Proceeds from convertible notes payable - stockholders Represents the reclassified amount of cumulative translation adjustment to addition paid in capital during the reporting period. Reclassifications of Cumulative Translation Adjustment to Additional Paid In Capital Forfeited stock reclassified as additional paid in capital Disclosure of accounting policy for convertible notes payable. Convertible Notes Payable [Policy Text Block] Convertible Notes Payable CONVERTIBLE NOTES PAYABLE [Abstract] The entire disclosure for convertible notes payable to stockholders. Convertible Notes Payable to Stockholders Disclosure [Text Block] CONVERTIBLE NOTES PAYABLE Represents the amount of interest accrued including commitment fee under the credit facility. Debt Instrument Increase Accrued Interest Including Commitment Fee Amount Interest accrued including commitment fee amount Represents the additional inducement amount of notes payable. Debt Instrument Additional Inducement Amount Additional inducement amount Amount of foreign currency translation adjustment reclassified as retained earnings. Foreign Currency Translation Adjustment Reclassified Foreign currency translation adjustment reclassified as retained earnings upon closing of England office October 2015 Unsecured Promissory Notes [Member] October 2015 Unsecured Promissory Notes [Member] October 2015 Warrants To Investors [Member] October 2015 Warrants To Investors [Member] Extension period of equity-based award, in ''PnYnMnDTnHnMnS'' format, for example, ''P1Y5M13D'' represents the reported fact of one year, five months, and thirteen days. Sharebased Compensation Arrangement by Sharebased Payment Award Extension Period Extension period of options The fair value of beneficial conversion value as discount against preferred stock in noncash investing or financing activities. Fair Value of Beneficial Conversion Value as Discount Against Preferred Stock Beneficial conversion feature Fair value of beneficial conversion value as discount against Preferred Stock Represents the fair value of options issued in exchange for services. Fair Value of Options Issued in Exchange for Services Fair value of stock issued in exchange for services July 2015 Agreements [Member] July 2015 Agreements [Member] August 2015 Agreement [Member] August 2015 Agreement [Member] Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses September 2015 Agreement [Member] September 2015 Agreement [Member] December 2013 Agreement [Member] December 2013 Agreement [Member] Notes payable amount that contains a commitment fee. Notes Payable That Contains Commision Fee Notes payable that contains commission fee Represents information pertaining to unpaid health insurance. Unpaid Health Insurance [Member] Unpaid health insurance [Member] Represents information pertaining to unpaid accounting services. Unpaid Accounting Services [Member] Unpaid accounting services [Member] January Twenty Nineth and FebruaryT hird 2016 Agreement [Member] January 29 and February 3, 2016 Agreement [Member] January Fifteen and Nineteen 2016 Agreement [Member] January 15 and 19, 2016 Agreement [Member] Assets held for sale, accumulated depreciation. Accumulated Depreciation Assets Held For Sale Assets held for sale, accumulated depreciation Amount of increase in additional paid in capital (APIC) resulting from the revaluation of warrants. Adjustments To Additional Paid In Capital Revaluation of Warrants Revaluation of warrants Accounts Receivable, Net, Current Accounts receivable, net of allowance of $0 and $6,293 Represents the amount of amortization of deferred compensation during the reporting period. Amortization of Deferred Compensation Amortization of deferred compensation Loss on abandonment of patents and disposal of fixed assets. Loss on Abandonment of Patents And Disposal of Fixed Assets (Gain) Loss on abandonment of patents and disposal of fixed assets Amount of disposal of equipment in satisfaction of accounts payable settled through noncash transactions. Disposal of Equipment In Satisfaction of Accounts Payable Disposal of equipment in satisfaction of accounts payable Fair value of extended warrants. Fair Value of Extended Warrants Fair value of extended warrants February 23, 2016 Agreement [Member] February Twenty Third 2016 Agreement [Member] February 23, 2016 Agreement [Member] Amendment to Promissory Note Agreements [Member] Amendment To Promissory Note Agreements [Member] Amendment To Promissory Note Agreements [Member] March 2, 2016 Agreement [Member] March Second 2016 Agreement [Member] March 2, 2016 Agreement [Member] March 4, 2016 Agreement [Member] March Fourth 2016 Agreement [Member] March 4, 2016 Agreement [Member] March 15, 2016 Agreement [Member] March Fifteenth 2016 Agreement [Member] March 15, 2016 Agreement [Member] Represents the monthly cash out-flow for consulting services. Monthly Payment For Consulting Services Monthly payment for consulting services Leader of the entity''s board of directors who presides over board meetings and other board activities. The chairman is often the chief executive officer as well, and in such a case would be the entity''s highest ranking officer and highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. In addition, the chief executive officer (CEO) may also be the chairman of the board or president. Chief Executive Officer And Board Of Directors Chairman [Member] Chief Executive Officer and Chairman of the Board [Member] Represents information pertaining to Employment Agreement of entity. Employment Agreement [Member] Employment Agreement [Member] Represents information pertaining to consulting agreement of entity. Consulting Agreement [Member] Consulting agreement [Member] Represents the minimum period for increase to value of underlying technical assets. Minimum Term to Increase Value of Underlting Technical Assets Minimum period for increase to value of underlying technical assets April 18, 2016 Agreement [Member] April Eighteen 2016 Agreement [Member] April 18, 2016 Agreement [Member] April 25, 2016 Agreement [Member] April Twenty Five 2016 Agreement [Member] April 25, 2016 Agreement [Member] Represents the maximum period for increase to value of underlying technical assets. Maximum Term to Increase Value of Underlting Technical Assets Maximum period for increase to value of underlying technical assets May 05, 2016 Agreement [Member] May Five 2016 Agreement [Member] May 05, 2016 Agreement [Member] Weighted average remaining contractual term for equity-based awards excluding options granted, in ''PnYnMnDTnHnMnS'' format, for example, ''P1Y5M13D'' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms Granted Weighted average remaining contractual term for equity-based awards excluding options, in ''''PnYnMnDTnHnMnS'''' format, for example, ''''P1Y5M13D'''' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Outstanding Weighted Average Remaining Contractual Terms Balance March 31, 2016 Weighted average remaining contractual term for equity-based awards excluding options expired, in ''PnYnMnDTnHnMnS'' format, for example, ''P1Y5M13D'' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Remaining Contractual Terms Expired Accrued preferred dividend. Accrued Preferred Dividend Accrued preferred dividend Accrued interest as discount on notes payable. Accrued Interest as Discount on Notes Payable Accrued interest as discount on notes payable Accounts Payable, Related Parties, Current Due to related party Accounts payable - related parties Accretion Expense Accreted interest on notes payable Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Less: accumulated depreciation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Cumulative Translation Adjustment [Member] Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Cumulative translation adjustment Additional Paid in Capital Additional paid in capital Additional Paid-In Capital [Member] Additional Paid-In Capital [Member] Adjustment of Warrants Granted for Services Fair value of warrants issued in exchange for services Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Value of stock options granted Fair value of options for services Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Stock issuance costs Stock issuance costs Adjustments to Additional Paid in Capital, Share-based Compensation, Restricted Stock Unit or Restricted Stock Award, Requisite Service Period Recognition Issuance of equity for services Adjustments to Additional Paid in Capital, Warrant Issued Fair value of warrants issued with notes payable Issuance of warrants with notes payable Advertising Costs, Policy [Policy Text Block] Advertising Costs Advertising Expense Advertising costs Allocated Share-based Compensation Expense Non-cash compensation charge Share-based compensation Compensation expense Allowance for Doubtful Accounts Receivable, Current Accounts receivable, allowance Amortization of Debt Discount (Premium) Accretion of discount on notes payable Amortization of Deferred Charges Deferred compensation Amortization of Intangible Assets Amortization expense for patents Amortization of Financing Costs Amortization of deferred costs Assets [Abstract] ASSETS Assets TOTAL ASSETS Assets Held-for-sale, Not Part of Disposal Group, Current Assets held for sale, net of accumulated depreciation of $0 and $23,174 Assets, Current TOTAL CURRENT ASSETS Assets, Current [Abstract] CURRENT ASSETS Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Beneficial Owner [Member] Beneficial owner [Member] Board of Directors Chairman [Member] Chairman of Board [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS - END OF PERIOD CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD Cash and cash equivalents Cash position Cash and Cash Equivalents, Period Increase (Decrease) NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash, FDIC Insured Amount FDIC insured limit Chief Financial Officer [Member] Firm Owned by CFO [Member] Chief Financial Officer [Member] Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Exercise prices (in dollars per share) Class of Stock [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Axis] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrant to purchase a number of shares of common stock Number of shares entitled by warrants Shares issuable upon exercise of warrants Class of Stock [Domain] Class of Warrant or Right, Outstanding Warrants outstanding Commitments and Contingencies CONTINGENCIES Common Stock, Value, Issued Common stock, $.0001 par value; 230,000,000 shares authorized; 117,517,626 shares issued and outstanding at March 31, 2016 and December 31, 2015 Common Stock, Shares, Issued Common stock, shares issued Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Common stock subscription receivable Common stock subscription receivable Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Par or Stated Value Per Share Common stock, par value per share Common Stock [Member] Common Stock [Member] Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Value, Subscriptions Common stock subscription Comprehensive Income, Policy [Policy Text Block] Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent COMPREHENSIVE LOSS Computer Equipment [Member] Computer equipment [Member] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Involving Cash Convertible Notes Payable [Member] Convertible Promissory Notes due March 5, 2016 [Member] Convertible Promissory Notes [Member] Convertible Notes Payable, Current Convertible notes payable - stockholders Costs and Expenses [Abstract] OPERATING EXPENSES Costs and Expenses Total operating expenses Current Income Tax Expense (Benefit) Current Debt Instrument [Line Items] Debt Conversion, Original Debt, Amount Conversion of notes payable and accrued interest into common stock Debt Conversion, Converted Instrument, Warrants or Options Issued Fair value of warrants issued as discount for notes payable Debt Conversion, Converted Instrument, Shares Issued Common shares issued for notes payable conversion Shares issued upon conversion of notes payable and accrued interest Debt Instrument, Term Note payable maturity term NOTES PAYABLE - STOCKHOLDERS [Abstract] Debt Conversion, Converted Instrument, Amount Fair value of warrants issued as discount for note payable Debt Instrument, Issuance Date Issuance date Debt Instrument [Axis] Debt Disclosure [Text Block] NOTES PAYABLE - STOCKHOLDERS Long-term Debt, Gross Outstanding debt amount Debt Instrument, Convertible, Conversion Price Conversion price (in dollars per share) Conversion price Debt Instrument, Maturity Date, Description Maturity date description Debt Instrument, Unamortized Discount Notes payable, discount Debt discount Debt Instrument, Maturity Date Note payable maturity date Debt Instrument, Increase, Accrued Interest Interest accrued Debt Instrument, Payment Terms Repayment terms Debt Instrument, Name [Domain] Debt Instrument, Face Amount Note payable included per unit Principal amount Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Fair value of common stock issued as discount for notes payable Debt Instrument, Interest Rate, Stated Percentage Interest rate Interest rate Deferred Compensation Equity Deferred compensation Deferred Charges, Policy [Policy Text Block] Deferred Financing Costs Deferred Compensation, Share-based Payments [Member] Deferred Compensation [Member] Deferred Income Tax Expense (Benefit) Deferred Deferred Revenue, Current Deferred revenue Deferred Tax Assets, Net of Valuation Allowance Total deferred tax assets, net of valuation allowance Deferred Tax Assets, Operating Loss Carryforwards Deferred tax asset for NOL carryforwards Deferred Tax Assets, Valuation Allowance Valuation allowance Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred tax asset for stock based compensation Deposit Assets Deposit Depreciation, Depletion and Amortization Depreciation and amortization Depreciation Depreciation Derivative, by Nature [Axis] Derivative, Name [Domain] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK OPTIONS AND WARRANTS STOCK OPTIONS AND WARRANTS [Abstract] Dividends, Preferred Stock Dividends declared Accrued preferred dividends Less: Accrued preferred dividends Dividends Payable, Current Preferred stock dividend liability Accrued preferred dividend Earnings Per Share, Policy [Policy Text Block] Loss Per Share Earnings Per Share, Basic and Diluted BASIC AND DILUTED NET LOSS PER COMMON SHARE Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations EFFECT OF EXCHANGE RATE ON CASH Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State tax, net of federal tax effect, percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Non-deductible other expenses, percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Non-deductible share-based compensation, percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Change in valuation allowance, percent Effective Income Tax Rate Reconciliation, Percent Income tax benefit (provision), percent Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent U.S. federal income tax benefit at Federal statutory rate, percent Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Change in fair value of embedded derivative liability Change in fair value of embedded derivative liability Change in fair value of derivative liabilities Change in fair value of embedded derivative liability Change in fair value of derivative liabilities Embedded Derivative, Fair Value of Embedded Derivative Liability Balance at December 31, 2014 Balance at January 1, 2014 Beneficial conversion feature at a fair market value Embedded derivative liability Derivative liability related to fair value of beneficial conversion feature Employee Stock Option [Member] Stock Options [Member] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost related to stock options, period of recognition Unrecognized compensation cost, period of recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation cost related to stock options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Unrecognized compensation cost recorded in prepaid expense Unrecognized compensation cost Equity Component [Domain] Executive Officer [Member] Executive officers [Member] Fair Value Assumptions, Expected Volatility Rate Expected volatility Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract] Fair Value, Hierarchy [Axis] Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block] Schedule of Market Based Inputs Fair Value Disclosures [Text Block] FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value, Measurements, Fair Value Hierarchy [Domain] Level 3 [Member] Level 1 [Member] Level 2 [Member] Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule Liabilities Measured at Fair Value on a Recurring Basis Finite-Lived Intangible Assets, Accumulated Amortization Patents and trademarks, accumulated amortization Finite-Lived Intangible Assets, Net Patents and trademarks, net of accumulated amortization of $105,490 and $96,282 Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Patents, Gross Unamortized capitalized patent costs, net of accumulated amortization Finite-Lived Intangible Asset, Useful Life Amortization period Estimated useful life of patents Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign Currency Translation Foreign Currency Transaction Gain (Loss), before Tax Cumulative translation adjustment upon closing of England office Foreign currency translation adjustment from closing England office Furniture and Fixtures, Gross Furniture and fixtures Furniture and Fixtures [Member] Furniture and fixtures [Member] Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Gain on disposition of fixed assets Loss on disposal of fixed assets Gain (Loss) on Disposition of Intangible Assets Loss on abandonment of patents General and Administrative Expense General and administrative PATENTS AND TRADEMARKS [Abstract] Condensed Consolidated Statements of Operations [Abstract] INCOME TAXES [Abstract] Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Change in valuation allowance Income Tax Expense (Benefit) Income tax expense Income tax benefit (provision) Income Tax Disclosure [Text Block] INCOME TAXES Income Taxes Paid Income taxes paid Cash paid during year for: Income taxes Income Tax, Policy [Policy Text Block] Income Taxes Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount U.S. federal income tax benefit at Federal statutory rate Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Non-deductible other expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount Non-deductible share-based compensation Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount State tax, net of federal tax effect Increase (Decrease) in Deposit Assets Deposits Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Other Current Liabilities Increase in preferred stock dividend liability Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable, accrued expenses and litigation settlement Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Operating Liabilities [Abstract] Increase (decrease) in liabilities Increase (Decrease) in Insurance Settlements Receivable Insurance receivable Increase (Decrease) in Other Receivables Other receivable Increase (Decrease) in Operating Assets [Abstract] (Increase) decrease in assets Increase (Decrease) in Prepaid Expense Prepaid expenses Insurance Settlements Receivable, Current Insurance receivable Intangible Assets Disclosure [Text Block] PATENTS AND TRADEMARKS Intangible Assets, Finite-Lived, Policy [Policy Text Block] Patents and Trademarks Interest Payable Accrued interest payable Accrued interest Interest Expense Interest expense Interest expense Interest Expense, Debt Interest expense, notes payable Interest Paid Interest Cash paid during year for: Interest Investment Income, Interest Interest income Issuance of Stock and Warrants for Services or Claims Fair value of stock issued in exchange for services Labor and Related Expense Payroll Leasehold Improvements, Gross Leasehold improvements Leasehold Improvements [Member] Leasehold improvements [Member] OPERATING LEASES [Abstract] Leases of Lessee Disclosure [Text Block] OPERATING LEASES Legal Matters and Contingencies [Text Block] LITIGATION Liabilities, Current TOTAL CURRENT LIABILITIES Liabilities, Current [Abstract] CURRENT LIABILITIES Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Financial and Nonfinancial Liabilities, Fair Value Disclosure Total Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Liability for Uncertain Tax Positions, Current Accrual for uncertain tax positions Limited Liability Company [Member] Marketing Company Owned by Secretary [Member] Line of Credit Facility, Commitment Fee Percentage Commitment fee, percentage Line of Credit Facility, Commitment Fee Amount Accrued interest as discount on notes payable Commitment fees, amount Loss Contingency Accrual, at Carrying Value Litigation settlement LITIGATION [Abstract] Machinery and Equipment, Gross Computer equipment Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Noncontrolling Interest, Ownership Percentage by Parent Ownership percentage Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES Net Income (Loss) Available to Common Stockholders, Basic NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities Net Income (Loss) Attributable to Parent NET LOSS NET LOSS Net loss Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements Noncash Investing and Financing Items [Abstract] SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES: Nonoperating Income (Expense) Total other income (expense) Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE) Notes Payable, Other Payables [Member] Note Payable [Member] Notes Payable, Current Note payable Notes payable, net of discount of $27,679 and $37,482 Notes payable Officers' Compensation Annual salary Operating Leases, Future Minimum Payments Due, Next Twelve Months 2015 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2014 Operating Leases, Rent Expense, Net Total rent expense under leases Operating Leases, Future Minimum Payments, Due in Two Years 2016 Operating Income (Loss) NET OPERATING LOSS Operating Leases, Future Minimum Payments Due Total Operating Loss Carryforwards, Expiration Date Net operating loss carryforward expiration date Operating Loss Carryforwards Net operating loss carryforwards Operating Leases, Future Minimum Payments, Due in Three Years 2016 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Cumulative translation adjustment Foreign currency translation adjustments, net of tax Other Assets Total other assets Other Assets [Abstract] OTHER ASSETS Other Cost and Expense, Operating Product development Other General Expense Integration and customer support Other Selling, General and Administrative Expense Reimbursable business expenses Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] OTHER COMPREHENSIVE INCOME Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent TOTAL OTHER COMPREHENSIVE INCOME, net of tax Patents [Member] Patents and trademarks [Member] Payments for Legal Settlements Cash payment for settlement Payments to Acquire Machinery and Equipment Purchase of equipment Payments of Stock Issuance Costs Stock issuance costs Stock issuance costs Payments to Acquire Intangible Assets Patent and trademark costs Plan Name [Axis] Plan Name [Domain] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value per share Preferred Stock, Dividend Rate, Percentage Dividend rate Preferred Stock, Accretion of Redemption Discount Accretion of discount on preferred stock as deemed distribution Preferred Class A [Member] Preferred Class B [Member] Preferred Stock, Value, Issued Preferred stock, $.0001 par value; 2,000,000 shares authorized; 108,600 shares issued and outstanding at September 30, 2014 and none issued and outstanding at December 31, 2013 Preferred stock Preferred Stock [Text Block] CONVERTIBLE PREFERRED STOCK CONVERTIBLE PREFERRED STOCK [Abstract] Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock [Member] Preferred Stock [Member] Prepaid Expense, Current Prepaid expenses Prior Period Reclassification Adjustment, Description Reclassifications Proceeds from Warrant Exercises Proceeds from exercise of warrants Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Proceeds from issuance of preferred stock and warrants Proceeds from (Repayments of) Related Party Debt Proceeds (repayment) from notes payable - stockholders Proceeds from Related Party Debt Proceeds from notes payable - stockholders Proceeds from Notes Payable Proceeds from note payable Proceeds from Issuance of Private Placement Amount raised from private placement Proceeds from Insurance Settlement, Operating Activities Proceeds from insurance carrier Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Proceeds from Stock Options Exercised Proceeds from exercise of options and warrants Proceeds from exercise of options Professional and Contract Services Expense Strategic consulting Professional Fees Professional fees Property, Plant and Equipment [Table Text Block] Schedule of Property and Equipment, Useful Life Property, Plant and Equipment, Impairment [Policy Text Block] Long-Lived Assets Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Property, Plant and Equipment, Useful Life Useful life Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Estimated Useful Lives Useful life Property, Plant and Equipment, Net Total property and equipment Property, Plant and Equipment, Gross Gross property and equipment Property, Plant and Equipment [Line Items] Provision for Doubtful Accounts Provision for bad debt Provision for bad debts Range [Domain] Range [Domain] Range [Axis] Range [Axis] Receivables from Stockholder [Member] Common Stock Subscription Receivable [Member] Redeemable Preferred Stock Dividends Less: Deemed dividend distributions Related Party Transaction [Domain] Related Party Transactions Disclosure [Text Block] ACCOUNTS PAYABLE - RELATED PARTIES Related Party Transaction [Line Items] Accounts payable - related parties [Line Items] Related Party Transaction [Axis] Related Party Transactions, by Related Party [Axis] Related Party Transaction, Expenses from Transactions with Related Party Related party expenses Related Party [Domain] ACCOUNTS PAYABLE - RELATED PARTIES [Abstract] Repayments of Notes Payable Repayments of notes payable Repayment of note payable Repayments of Related Party Debt Repayment of note payable - stockholders Research and Development Expense Research and development expenses Research and Development Expense, Policy [Policy Text Block] Product Development Costs Restricted Stock [Member] Deficit Accumulated During the Development Stage [Member] Accumulated Deficit [Member] Retained Earnings (Accumulated Deficit) Accumulated deficit Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Revenues SALES Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Balance March 31, 2016 Option term Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Unvested stock options at September 30, 2015 Unvested stock options at December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Number of Awards Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Exercisable at March 31, 2016 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Exercisable at March 31, 2016 and expected to vest thereafter Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Unvested stock options at September 30, 2015 Unvested stock options at December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Cancelled/Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Cancelled/Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Balance March 31, 2016 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Exercisable at March 31, 2016 Scenario, Unspecified [Domain] Schedule of Nonvested Share Activity [Table Text Block] Summary of the activities of unvested stock options Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Stock Option Activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Weighted-average Assumptions Used to Estimate the Fair Values of Stock Options Granted Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Components of Income Tax (Benefit) Provision Schedule of Derivative Liabilities at Fair Value [Table Text Block] Schedule of Fair Value Measurement s of Derivative Liabilities Using Level 2 Inputs Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Reconciliation of the Statutory Tax Rate to the Company's Effective Income Tax Rate Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Deferred Tax Assets, Liabilities and Related Valuation Allowances Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Future Minimum Rental Commitments Under Non-Cancelable Operating Lease Arrangements Schedule of Finite-Lived Intangible Assets [Table] Schedule of Property, Plant and Equipment [Table] Schedule of Property, Plant and Equipment [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Short-term Debt [Table] Schedule of Stock by Class [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Warrant Activity Segment Reporting, Policy [Policy Text Block] Segment Information Selling and Marketing Expense Sales and marketing Series A preferred shares [Member] Series A [Member] Preferred stock, $.0001 par value; 2,000,000 preferred shares authorized; 195,000 preferred shares Series A authorized; 108,600 shares issued and outstanding at September 30, 2015 and December 31, 2014 Series B preferred shares [Member] Series B [Member] Preferred stock, $.0001 par value; 2,000,000 preferred shares authorized; 222,222 preferred shares Series B authorized; 28,378 shares issued and outstanding at September 30, 2015 and December 31, 2014 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Weighted Average Exercise Price: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share Intrinsic value of conversion option per share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Shares granted Options to purchase restricted stock unit Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Balance as of September 30, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Number of Shares: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average estimated fair value of warrants granted during the period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures Forfeited/canceled Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Share-based Compensation Fair value of options issued in exchange for services Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Granted Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date Warrants/Options expiration date Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price: Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Cancelled/forfeited Cancelled/forfeited Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Shares option issued Granted Granted, shares Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations Expired Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Balance March 31, 2016 Balance December 31, 2015 Balance as of December 31, 2014 Share Price Share price (in dollars per share) Closing stock price Market price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at March 31, 2016 Price exercisable Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used Pricing model used in calculation of grant-date fair value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Cancelled/forfeited Cancelled/forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable at March 31, 2016 Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares authorized under plan Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value of stock options exercised Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based Payments Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercisable at March 31, 2016 and expected to vest thereafter Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Exercisable at March 31, 2016 and expected to vest thereafter Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Balance March 31, 2016 Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Warrants issued Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Exercisable at March 31, 2016 and expected to vest thereafter Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Balance March 31, 2016 Balance December 31, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance March 31, 2016 Balance December 31, 2015 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Shares: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average estimated fair value of options granted during the period Granted Shares Issued, Price Per Share Share issued price (in dollars per share) Equity issuance, price or exercise price per security issued Equity issuance, price per share Shares, Outstanding Balance, shares Balance, shares Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Start-up Activities, Cost Policy [Policy Text Block] Start-up Costs Statement [Line Items] Condensed Consolidated Statement of Changes in Stockholders' Deficit [Abstract] Condensed Consolidated Statements of Cash Flows [Abstract] Condensed Consolidated Statements of Comprehensive Loss [Abstract] Statement, Equity Components [Axis] Statement [Table] Scenario [Axis] Condensed Consolidated Balance Sheets [Abstract] Class of Stock [Axis] Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Purchase price of preferred stock and warrants Stock Issued During Period, Value, Issued for Services Issuance of equity for services Issuance of equity for services Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options, shares Options to purchase company's common stock Exercised Stock Issued During Period, Value, Restricted Stock Award, Forfeitures Forfeited restricted stock Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Restricted shares forfeited Forfeited restricted stock, shares Stock Issued During Period, Shares, Other Exercise of warrants, shares Stock Issued During Period, Value, New Issues Value of share issued Issuance of shares of common stock, value Issuance of shares of common stock at $0.70 replacing warrants Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock (in shares) Stock Issued Issuance of common stock for settlement of payable Stock Issued During Period, Shares, New Issues Shares issued Issuance of shares of common stock, shares Issuance of shares of common stock at $0.70 replacing warrants, shares Stock Issued During Period, Value, Other Exercise of warrants Stock Issued During Period, Shares, Issued for Services Issuance of equity for services, shares Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] STOCKHOLDERS' DEFICIT STOCKHOLDERS' EQUITY [Abstract] Stockholders' Equity Attributable to Parent Balance Balance STOCKHOLDERS' DEFICIT Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent event [Line Items] Chief Financial Officer [Member] Subsequent Event [Member] Subsequent event [Member] Subsequent Events [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS [Abstract] Subsequent Event Type [Domain] Subsequent Event [Table] Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Relationship to Entity [Domain] Title of Individual [Axis] Travel and Entertainment Expense Travel Type of Arrangement and Non-arrangement Transactions [Axis] Unrecognized Tax Benefits Unrecognized tax benefits Unrecognized Tax Benefits, Period Increase (Decrease) Change in unrecognized tax benefits Use of Estimates, Policy [Policy Text Block] Use of Estimates Warrant [Member] Warrants [Member] Weighted Average Number of Shares Outstanding, Basic and Diluted BASIC AND DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING EX-101.PRE 13 vpig-20160331_pre.xml EXHIBIT 101.PRE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
May. 13, 2016
Document and Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Entity Registrant Name VIRTUAL PIGGY, INC.  
Entity Central Index Key 0001437283  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2016  
Document Period End Date Mar. 31, 2016  
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Common Stock, Shares Outstanding   117,517,626
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2016
Dec. 31, 2015
CURRENT ASSETS    
Cash and cash equivalents $ 50,808 $ 16,646
Accounts receivable, net of allowance of $0 and $6,293 360
Assets held for sale, net of accumulated depreciation of $0 and $23,174 34,071
Prepaid expenses $ 17,417 72,918
TOTAL CURRENT ASSETS 68,225 123,995
PROPERTY AND EQUIPMENT    
Computer equipment 20,366 73,645
Furniture and fixtures 15,722 15,722
Gross property and equipment 36,088 89,367
Less: accumulated depreciation (20,329) (57,823)
Total property and equipment $ 15,759 31,544
OTHER ASSETS    
Deposit 31,800
Patents and trademarks, net of accumulated amortization of $105,490 and $96,282 $ 580,212 589,420
Total other assets 580,212 621,220
TOTAL ASSETS 664,196 776,759
CURRENT LIABILITIES    
Accounts payable and accrued expenses 1,753,811 $ 1,702,527
Accounts payable - related parties 109,993
Preferred stock dividend liability 2,072,582 $ 1,804,302
Convertible notes payable - stockholders 2,940,000 2,940,000
Notes payable, net of discount of $27,679 and $37,482 1,482,221 988,918
TOTAL CURRENT LIABILITIES $ 8,358,607 $ 7,435,747
CONTINGENCIES
STOCKHOLDERS' DEFICIT    
Common stock, $.0001 par value; 230,000,000 shares authorized; 117,517,626 shares issued and outstanding at March 31, 2016 and December 31, 2015 $ 11,752 $ 11,752
Additional paid in capital 55,584,628 54,203,451
Deferred compensation (51,563) (72,188)
Accumulated deficit $ (63,239,242) $ (60,802,017)
Cumulative translation adjustment
STOCKHOLDERS' DEFICIT $ (7,694,411) $ (6,658,988)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT 664,196 776,759
Series A [Member]    
STOCKHOLDERS' DEFICIT    
Preferred stock 11 11
Series B [Member]    
STOCKHOLDERS' DEFICIT    
Preferred stock $ 3 $ 3
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Accounts receivable, allowance $ 0 $ 6,293
Assets held for sale, accumulated depreciation 0 23,174
Patents and trademarks, accumulated amortization 105,490 96,282
Notes payable, discount $ 27,679 $ 37,482
Preferred stock, par value per share $ 0.0001 $ 0.0001
Preferred stock, shares authorized 2,000,000 2,000,000
Common stock, par value per share $ 0.0001 $ 0.0001
Common stock, shares authorized 230,000,000 230,000,000
Common stock, shares issued 117,517,626 117,517,626
Common stock, shares outstanding 117,517,626 117,517,626
Series A [Member]    
Preferred stock, shares authorized 195,000 195,000
Preferred stock, shares issued 108,600 108,600
Preferred stock, shares outstanding 108,600 108,600
Series B [Member]    
Preferred stock, shares authorized 222,222 222,222
Preferred stock, shares issued 28,378 28,378
Preferred stock, shares outstanding 28,378 28,378
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Condensed Consolidated Statements of Operations [Abstract]    
SALES $ 1,025 $ 4,109
OPERATING EXPENSES    
Sales and marketing 35,103 889,237
Product development 247,573 590,870
Integration and customer support 34,238 61,838
General and administrative $ 1,718,228 1,492,252
Strategic consulting 135,000
Total operating expenses $ 2,035,142 3,169,197
NET OPERATING LOSS $ (2,034,117) (3,165,088)
OTHER INCOME (EXPENSE)    
Interest income 149
Interest expense $ (142,231) $ (14,247)
Gain on disposition of fixed assets 7,403
Total other income (expense) (134,828) $ (14,098)
NET LOSS (2,168,945) (3,179,186)
Less: Accrued preferred dividends (268,280) (264,605)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (2,437,225) $ (3,443,791)
BASIC AND DILUTED NET LOSS PER COMMON SHARE $ (0.02) $ (0.03)
BASIC AND DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING 117,517,626 119,117,626
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Condensed Consolidated Statements of Comprehensive Loss [Abstract]    
NET LOSS $ (2,168,945) $ (3,179,186)
OTHER COMPREHENSIVE INCOME    
Foreign currency translation adjustments, net of tax 114,475
TOTAL OTHER COMPREHENSIVE INCOME, net of tax 114,475
COMPREHENSIVE LOSS $ (2,168,945) $ (3,064,711)
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statement of Changes in Stockholders' Deficit - 3 months ended Mar. 31, 2016 - USD ($)
Total
Preferred Stock [Member]
Series A [Member]
Preferred Stock [Member]
Series B [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Deferred Compensation [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2015 $ (6,658,988) $ 11 $ 3 $ 11,752 $ 54,203,451 $ (72,188) $ (60,802,017)
Balance, shares at Dec. 31, 2015   108,600 28,378 117,517,626      
Issuance of warrants with notes payable 6,359 6,359
Revaluation of warrants 1,305,411 1,305,411
Fair value of options for services 69,407 $ 69,407
Amortization of deferred compensation 20,625 $ 20,625
Accrued preferred dividends (268,280) $ (268,280)
Net loss (2,168,945)       (2,168,945)
Balance at Mar. 31, 2016 $ (7,694,411) $ 11 $ 3 $ 11,752 $ 55,584,628 $ (51,563) $ (63,239,242)
Balance, shares at Mar. 31, 2016   108,600 28,378 117,517,626      
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (2,168,945) $ (3,179,186)
Adjustments to reconcile net loss to net cash used in operating activities    
Provision for bad debts 360
Fair value of options issued in exchange for services $ 69,407 $ 190,364
Fair value of stock issued in exchange for services 115,068
Revaluation of options and warrants $ 1,305,411 $ 228,743
Deferred compensation 20,625
Accretion of discount on notes payable 38,670
Depreciation and amortization 11,467 $ 28,719
(Gain) Loss on abandonment of patents and disposal of fixed assets $ (7,403) 895
(Increase) decrease in assets    
Accounts receivable 57
Prepaid expenses $ 55,500 265,390
Deposits 31,800 7,253
Increase (decrease) in liabilities    
Accounts payable, accrued expenses and litigation settlement $ 193,770 59,617
Deferred revenue 5,207
Net cash used in operating activities $ (449,338) (2,277,873)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of equipment (5,129)
Patent and trademark costs (28,041)
Net cash used in investing activities (33,170)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from convertible notes payable - stockholders $ 2,000,000
Proceeds from notes payable - stockholders $ 483,500
Net cash provided by financing activities $ 483,500 $ 2,000,000
EFFECT OF EXCHANGE RATE ON CASH 114,475
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS $ 34,162 (196,568)
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD 16,646 1,652,392
CASH AND CASH EQUIVALENTS - END OF PERIOD $ 50,808 $ 1,455,824
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid during year for: Interest
Cash paid during year for: Income taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:    
Disposal of equipment in satisfaction of accounts payable $ 55,000
Accrued preferred dividend 268,280 $ 264,605
Fair value of warrants issued as discount for note payable 6,359
Accrued interest as discount on notes payable $ 22,508
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Nature of the Business
 
Virtual Piggy, Inc. (the “Company”) was incorporated in the state of Delaware on February 11, 2008.   
 
The Company is a technology company that seeks to deliver an online ecommerce solution for the family. The Company's system allows parents and their children to manage, allocate funds and track their expenditures, savings and charitable giving online. The system is designed to allow a minor to transact online without a credit card by gaining the parents' permission ahead of time and allowing the parent to set up the rules of use.

The Company believes that a future alternative for Virtual Piggy, Inc. will revolve around the FinTech industry with a partner-first go to market model in which established payments market leaders and vertical market participants can incorporate and integrate the Company's platform into co-branded payments solutions targeting youth and family.  The Company also believes this approach will enable the Company to reduce expenses while broadening its reach.

Within this affinity partner model, the Company will be incorporating licensing fees and customization services.  This should enable the company to begin creating shareholder value above and beyond consumer transaction fees.

The Company is also analyzing specific components of our technology for individual monetization as well as exploring opportunities in the Business to Business (“B2B”) realm.

In addition, the Company is currently adding enhancements to the platform, to enable the platform to update itself with any new regulations that are passed, in order to reduce costs associated with manually updating the platform.  This will also enable the Company to market the platform to other companies in need of a solution to comply with COPPA or other regulatory requirements.

 

Our primary strategic objective over the next 12 -18 months is to increase the value of the underlying technical assets of the company by incorporating new essential functionality that will act as a key differentiator in the financial services market. These new technology advances will also augment our current portfolio of patents that give the company its competitive advantage. In addition, the company is redirecting its marketing efforts to increase its user base by entering into affinity marketing agreements with companies targeting specific user communities. This will increase our potential user community while bringing in substantial development and licensing revenue for those sectors. This approach will greatly reduce the expense associated with direct marketing efforts.

The Company's principal office is located in Sunnyvale, California and in 2013 the Company opened an office in London, England to support the sales and marketing efforts in Europe and the development of its mobile applications, which was closed in September 2015.

On December 3, 2015, Finity, Inc. was incorporated as a wholly owned subsidiary of the Company.  On December 11, 2015, Finity, Inc. changed its name to Finitii, Inc.  Finitii, Inc. was established as a not for profit entity for the purpose of teaching children financial literacy.

Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited financial statements should be read in conjunction with the financial statements and notes included in the Company's Annual Report on form 10-K for the year ended December 31, 2015 as filed with the SEC. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

The accompanying condensed consolidated financial statements of Virtual Piggy, Inc. and its wholly owned subsidiary, Finitii, Inc. (collectively the “Company”), have been prepared in accordance with accounting principles generally accepted in the United States of America.  All intercompany transactions have been eliminated in consolidation.

The Company's activities are subject to significant risks and uncertainties, including failing to secure additional financing to operationalized the Company's current technology before another company develops similar technology to compete with the Company.

Recently Adopted Accounting Pronouncements

As of March 31, 2016 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company's financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted
 
As of March 31, 2016, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company's financial statements through 2017.
 
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
MANAGEMENT PLANS
3 Months Ended
Mar. 31, 2016
MANAGEMENT PLANS [Abstract]  
MANAGEMENT PLANS
NOTE 2 – MANAGEMENT PLANS

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The Company has incurred significant losses and experienced negative cash flow from operations since inception.  These conditions raise substantial doubt about the Company's ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Since inception, the Company has focused on developing and implementing its business plan.  The Company believes that its existing cash resources will not be sufficient to sustain operations during the next twelve months.  The Company currently needs to generate revenue in order to sustain its operations.  In the event that the Company cannot generate sufficient revenue to sustain its operations, the Company will need to reduce expenses or obtain financing through the sale of debt and/or equity securities.  The issuance of additional equity would result in dilution to existing shareholders.  If the Company is unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms acceptable to the Company, the Company would likely be unable to execute upon the business plan or pay costs and expenses as they are incurred, which would have a material, adverse effect on the business, financial condition and results of operations.

The Company's current monetization model is to license our platform to merchants to enable them to provide COPPA compliant services for themselves and their customers.

As of May 13, 2016, the Company has a cash position of approximately $44,000. Based upon the current cash position and the Company's planned expense run rate, management believes the Company has funds currently to finance its operations through May 2016.

XML 23 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACCOUNTS PAYABLE - RELATED PARTIES
3 Months Ended
Mar. 31, 2016
ACCOUNTS PAYABLE - RELATED PARTIES [Abstract]  
ACCOUNTS PAYABLE - RELATED PARTIES
NOTE 3 – ACCOUNTS PAYABLE – RELATED PARTIES
 
As of March 31, 2016, the former Chairman of the Board had paid expenses on behalf of the Company in the amount of $88,658.  The Company also owes the Chief Financial Officer a total of $13,848 as of March 31, 2016, including unpaid health insurance of $7,335 and unpaid accounting services, to the Chief Financial Officer's accounting firm for services provided prior to his becoming the Chief Financial Officer of the Company, in the amount of $6,513.  Additionally, the Company owes a company owned by a beneficial owner of more than 5% of the Company $7,487.
 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONVERTIBLE NOTES PAYABLE
3 Months Ended
Mar. 31, 2016
CONVERTIBLE NOTES PAYABLE [Abstract]  
CONVERTIBLE NOTES PAYABLE
NOTE 4 – CONVERTIBLE NOTES PAYABLE
 
On March 6, 2015, the Company, pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), issued $2,000,000 aggregate principal amount of its 10% Secured Convertible Promissory Notes due March 5, 2016 (the “Notes”) to certain stockholders.  On May 11, 2015, the Company issued an additional $940,000 of Notes to stockholders.  The maturity dates of the notes were extended to March 5, 2017 with the consent of the note holders.
 
The Notes are convertible by the holders, at any time, into shares of the Company's Series B Preferred Stock at a conversion price of $90.00 per share, subject to adjustment for stock splits, stock dividends and similar transactions with respect to the Series B Preferred Stock only.  Each share of Series B Preferred Stock is currently convertible into 100 shares of the Company's common stock at a current conversion price of $0.90 per share, subject to anti-dilution adjustment as described in the Certificate of Designation of the Series B Preferred Stock.  In addition, pursuant to the terms of a Security Agreement entered into on May 11, 2015 by and among the Company, the Investors and a collateral agent acting on behalf of the Investors (the “Security Agreement”), the Notes are secured by a lien against substantially all of the Company's business assets.  Pursuant to the Purchase Agreement, the Company also granted piggyback registration rights to the holders of the Series B Preferred Stock upon a conversion of the Notes.

The Notes are recorded as a current liability as of March 31, 2016.  Interest accrued on the notes was $298,751 and $225,452 as of March 31, 2016 and December 31, 2015.  Interest expense related to these notes payable was $73,299 and $14,247 for the three months ended March 31, 2016 and 2015.
 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
NOTES PAYABLE - STOCKHOLDERS
3 Months Ended
Mar. 31, 2016
NOTES PAYABLE - STOCKHOLDERS [Abstract]  
NOTES PAYABLE - STOCKHOLDERS
NOTE 5 – NOTES PAYABLE - STOCKHOLDERS
 
On January 15 and 19, 2016, the Company entered into agreements with two stockholders that includes notes payable in the aggregate amount of $62,500, and two-year warrants to purchase 12,500 shares of the Company's common stock at $0.90. The notes bear interest at 10% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.
 
On January 29 and February 3, 2016, the Company entered into agreements with two stockholders that includes notes payable in the aggregate amount of $90,000, and two-year warrants to purchase 18,000 shares of the Company's common stock at $0.90. The notes bear interest at 10% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.
 
On February 23, 2016, the Company entered into agreements with three stockholders that includes notes payable in the aggregate amount of $26,000, and two-year warrants to purchase 5,200 shares of the Company's common stock at $0.90 per share. The notes bear interest at 10% per annum, and mature on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.
 
On February 23, 2016, the Company entered into Amendments to Promissory Note Agreements (the “Amendments”) with five holders of the Company's outstanding unsecured Promissory Notes in the aggregate principal amount of $475,300 (the “Outstanding Notes”), pursuant to which the maturity date of such Outstanding Notes was extended to the twelve (12) month anniversary of the original issuance date (formerly the six (6) month anniversary of the original issuance date) or such earlier date that (i) the Company completes the closing of  specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.  The Outstanding Notes were previously to mature between January 20, 2016 and March 18, 2016 and will now mature not later than dates between July 20, 2016 and September 18, 2016.  The Amendments took effect retroactive to the prior applicable maturity date.
 
On March 2, 2016, the Company entered into an agreement with a stockholder that includes a note payable in the amount of $5,000, and two-year warrants to purchase 1,000 shares of the Company's common stock at $0.90. The note bears interest at 10% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.
 
On March 4, 2016, the Company entered into an agreement with a stockholder that includes a note payable in the amount of $100,100, and two-year warrants to purchase 20,020 shares of the Company's common stock at $0.90. The note bears interest at 10% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes. This note contains a 7.5% commitment fee, which is payable upon maturity of the note.
 
On March 15, 2016, the Company entered into an agreement with a stockholder that includes notes payable in the amount of $200,000, and two-year warrants to purchase 40,000 shares of the Company's common stock at $0.90 per share.  The note bears interest at 10% per annum, and matures on the six month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of the 10% Secured Convertible Promissory Notes.  This note contains a 7.5% commitment fee, which is payable upon maturity of the note.
 
The 7.5% commitment fees, amounting to $76,913 and $54,405 as of March 31, 2016 and December 31, 2015, on the Notes Payable were treated as a discount to the value of the notes payable in accordance with FASB ASC 835-30-25, Recognition and are being accreted over the term of the note payable for financial statement purposes. The same amount is included in accrued interest until the liability is paid. 
 
The notes payable are recorded as a current liability as of March 31, 2016.  Interest accrued including the 7.5% commitment fee on the notes as of March 31, 2016 and December 31, 2015 was $134,601 and $81,831.  Interest expense, including accretion of discounts, related to these notes payable was $68,932 and $0 for the three months ended March 31, 2016 and 2015.
 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
INCOME TAXES
3 Months Ended
Mar. 31, 2016
INCOME TAXES [Abstract]  
INCOME TAXES
NOTE 6 – INCOME TAXES
 
Income tax expense was $0 for the three months ended March 31, 2016 and 2015.
 
As of January 1, 2016, the Company had no unrecognized tax benefits, and accordingly, the Company did not recognize interest or penalties during 2015 related to unrecognized tax benefits. There has been no change in unrecognized tax benefits during the three months ended March 31, 2016, and there was no accrual for uncertain tax positions as of March 31, 2016. Tax years from 2012 through 2015 remain subject to examination by major tax jurisdictions.
 
There is no income tax benefit for the losses for the three months ended March 31, 2016 and 2015, since management has determined that the realization of the net tax deferred asset is not assured and has created a valuation allowance for the entire amount of such benefits.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONVERTIBLE PREFERRED STOCK
3 Months Ended
Mar. 31, 2016
CONVERTIBLE PREFERRED STOCK [Abstract]  
CONVERTIBLE PREFERRED STOCK
NOTE 7 – CONVERTIBLE PREFERRED STOCK

As of March 31, 2016, the value of the cumulative 8% dividends for all preferred stock was $2,072,582.  Such dividends will be paid when and if declared payable by the Company's board of directors or upon the occurrence of certain liquidation events.  In accordance with FASB ASC 260-10-45-11, the Company has recorded these accrued dividends as a current liability.
 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY
3 Months Ended
Mar. 31, 2016
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY
NOTE 8 – STOCKHOLDERS' EQUITY

In February 2015, the Board of Directors of the Company approved amendments extending the term of outstanding warrants to purchase in the aggregate 3,877,970 shares of common stock of the Company at exercise prices ranging from $0.01 per share to $1.00 per share.  These warrants were scheduled to expire at various dates during 2015 and were each extended for an additional one year period from the applicable current expiration date, with the new expiration dates ranging from February 23, 2016 to December 28, 2016.  The increase in fair value of this term extension was $219,051, which was expensed in 2015.

In February 2015, the Company extended options previously granted to two of its executive officers, which included 3,500,000 options exercisable at $0.04 per share.  The increase in fair value of this term extension was $9,692 which was expensed during the period. The Company used the Black-Scholes option pricing model to calculate the increase in fair value after the extension, with the following assumptions: no dividend yield, expected volatility of 96.4%, risk free interest rate of 0.64%, and expected option life of 2 years.

On January 25, 2016, the Board of Directors approved amendments extending the term of outstanding warrants to purchase in the aggregate 24,372,838 shares of common stock of the Company at exercise prices ranging from $0.01 per share to $3.00 per share (the “Warrants”).  These Warrants were scheduled to expire at various dates during 2016 and were each extended for an additional one year period from the applicable current expiration date, with the new expiration dates ranging from January 26, 2017 to December 28, 2017.  The increase in fair value of this term extension was $1,305,411 which was expensed during the three months ended March 31, 2016. The Company used the Black-Scholes option pricing model to calculate the increase in fair value, with the following assumptions for the extended warrants: no dividend yield, expected volatility of 161.3%, risk free interest rate of 0.47%, and expected warrant life of 1.27 years.
 
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND WARRANTS
3 Months Ended
Mar. 31, 2016
STOCK OPTIONS AND WARRANTS [Abstract]  
STOCK OPTIONS AND WARRANTS
NOTE 9 – STOCK OPTIONS AND WARRANTS
 
During 2008, the Board of Directors (“Board”) of the Company adopted the 2008 Equity Incentive Plan (“2008 Plan”) that was approved by the shareholders.  Under the Plan, the Company is authorized to grant options to purchase up to 25,000,000 shares of common stock to any officer, other employee or director of, or any consultant or other independent contractor who provides services to the Company.  The Plan is intended to permit stock options granted to employees under the 2008 Plan to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”).  All options granted under the 2008 Plan, which are not intended to qualify as Incentive Stock Options are deemed to be non-qualified options (“Non-Statutory Stock Options”).  As of March 31, 2016, options to purchase 6,101,664 shares of common stock have been issued and are unexercised, and 9,048,336 shares are available for grants under the 2008 Plan.  
 
During 2013, the Board adopted the 2013 Equity Incentive Plan (“2013 Plan”), which was approved by stockholders at the 2013 annual meeting of stockholders.  Under the 2013 Plan, the Company is authorized to grant awards of stock options, restricted stock, restricted stock units and other stock-based awards of up to an aggregate of 5,000,000 shares of common stock to any officer, employee, director or consultant.  The 2013 Plan is intended to permit stock options granted to employees under the 2013 Plan to qualify as Incentive Stock Options.  All options granted under the 2013 Plan, which are not intended to qualify as Incentive Stock Options are deemed to be Non-Statutory Stock Options.  As of March 31, 2016, under the 2013 Plan grants of restricted stock and options to purchase 2,105,000 shares of common stock have been issued and are unvested or unexercised, and 2,895,000 shares of common stock remain available for grants under the 2013 Plan.  
 
The 2008 Plan and 2013 Plan are administered by the Board or its compensation committee, which determines the persons to whom awards will be granted, the number of awards to be granted, and the specific terms of each grant, including the vesting thereof, subject to the terms of the applicable Plan.
 
In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company).
 
Prior to January 1, 2014, volatility in all instances presented is the Company's estimate of volatility that is based on the volatility of other public companies that are in closely related industries to the Company.  Beginning January 1, 2014, volatility in all instances presented is the Company's estimate of volatility that is based on the historical volatility of the Company's stock history.
 
The following table summarizes the activities for our stock options for the three months ended March 31, 2016:
 
Options Outstanding
               
 Weighted -
   
 
 
               
 Average
   
 
 
Remaining
   
Aggregate
 
         
Weighted-
   
Contractual
   
Intrinsic
 
   
Number of
   
Average
   
Term
   
Value
 
   
Shares
   
Exercise Price
   
in years)
   
(in 000's) (1)
 
Balance December 31, 2015
    8,822,500     $ 0.76       2.6        
                               
Cancelled/forfeited
    (535,837 )   $ (0.57 )              
                               
Balance March 31, 2016
    8,286,663     $ 0.77       2.2     $ -  
                                 
Exercisable at March 31, 2016
    5,345,824     $ 0.86       1.3     $ -  
                                 
Exercisable at March 31, 2016 and expected to
                               
vest thereafter
    8,286,663     $ 0.77       2.2     $ -  
 
(1) 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.11 for our common stock on March 31, 2016.
 
 For the three months ended March 31, 2016 and 2015, the Company expensed $69,407 and $305,432 with respect to the options.

As of March 31, 2016 there was $499,572 of unrecognized compensation cost related to outstanding stock options. This amount is expected to be recognized over a weighted-average period of 2.4 years. To the extent the actual forfeiture rate is different from what the Company has estimated, stock-based compensation related to these awards will be different from the Company's expectations. The difference between the stock options exercisable at March 31, 2016 and the stock options exercisable and expected to vest relates to management's estimate of options expected to vest in the future.
 
The following table summarizes the activities for our warrants for the three months ended March 31, 2016:
 
     
Remaining
   
Aggregate
 
Weighted-
   
Contractual
   
Intrinsic
 
Number of
Average
   
Term
   
Value
 
Shares
Exercise Price
   
in years)
   
(in 000's) (1)
 
Balance December 31, 2015
    26,365,896     $ 1.02       0.4        
                               
Expired
    (1,142,858 )     (0.04 )     -        
Granted
    96,700     $ 0.90       2.0        
                               
Balance March 31, 2016
    25,319,738     $ 1.07       1.1     $ -  
                                 
Exercisable at March 31, 2016
    25,319,738     $ 1.07       1.1     $ -  
                                 
Exercisable at March 31, 2016 and expected to
                               
vest thereafter
    25,319,738     $ 1.07       1.1     $ -  
 
(1) 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.11 for our common stock on March 31, 2016.
 
 All warrants were vested on the date of grant.
 
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
OPERATING LEASES
3 Months Ended
Mar. 31, 2016
OPERATING LEASES [Abstract]  
OPERATING LEASES
NOTE 10 – OPERATING LEASES
 
For the three months ended March 31, 2016 and 2015, total rent expense under leases amounted to $7,998 and $156,677. As of March 31, 2016, the Company was not obligated under any non-cancelable operating lease arrangements.
 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2016
SUBSEQUENT EVENTS [Abstract]  
SUBSEQUENT EVENTS
NOTE 11 – SUBSEQUENT EVENTS

On April 14, 2016, the Company appointed a new Chief Executive Officer and Chairman of the Board, with such appointments taking effect on April 18, 2016.  In this connection with his appointment, the Company also simultaneously entered into an Employment Agreement with the Chief Executive Officer and Chairman of the Board, pursuant to which he will be employed on an at will basis at an annual salary of $240,000 during the first year of employment.  He also received options to purchase 3,000,000 shares of the Company's common stock at an exercise price of $0.90 per share, vesting over three years and 250,000 restricted stock units.

On April 18, 2016, the Company issued $20,000 in aggregate principal amount of unsecured Promissory Notes to two accredited investors pursuant to Promissory Note Agreements (the “Notes”).  The Investors also received two-year Warrants to purchase an aggregate of 4,000 shares of Company common stock at an exercise price of $0.90 per share.  The Notes bear interest at a rate of ten percent (10%) per annum and mature on the six (6) month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.

On April 25, 2016, the Company issued a $50,000 principal amount unsecured Promissory Note to an accredited investor pursuant to a Promissory Note Agreement (the “Note”).  The Investor also received two-year Warrants to purchase an aggregate of 10,000 shares of Company common stock at an exercise price of $0.90 per share.  The Note bears interest at a rate of ten percent (10%) per annum and matures on the six (6) month anniversary of the issuance date, or on such earlier date that (i) the Company completes the closing of a specified joint venture agreement or (ii) the Company completes the sale of at least an additional $1 million of 10% Secured Convertible Promissory Notes.

On May 5, 2016, the Company issued $100,000 aggregate principal amount of its 10% Secured Convertible Promissory Notes due March 6, 2017 (the “New Notes”) to an accredited investor.  The New Notes are in addition to currently outstanding promissory notes of the same series, in the principal amount of $2,940,000 (the “Prior Notes”), which were originally due March 5, 2016 and the maturity date thereof was subsequently extended to March 6, 2017 with the consent of the Note holders.
 
On May 11, 2016, the Company entered into a consulting agreement with a company owned by a beneficial owner of more than 5% of the Company.  The agreement requires the payment of $12,500 per month and continues on a monthly basis until terminated.
 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Nature of the Business
Nature of the Business
 
Virtual Piggy, Inc. (the “Company”) was incorporated in the state of Delaware on February 11, 2008.   
 
The Company is a technology company that seeks to deliver an online ecommerce solution for the family. The Company's system allows parents and their children to manage, allocate funds and track their expenditures, savings and charitable giving online. The system is designed to allow a minor to transact online without a credit card by gaining the parents' permission ahead of time and allowing the parent to set up the rules of use.

The Company believes that a future alternative for Virtual Piggy, Inc. will revolve around the FinTech industry with a partner-first go to market model in which established payments market leaders and vertical market participants can incorporate and integrate the Company's platform into co-branded payments solutions targeting youth and family.  The Company also believes this approach will enable the Company to reduce expenses while broadening its reach.

Within this affinity partner model, the Company will be incorporating licensing fees and customization services.  This should enable the company to begin creating shareholder value above and beyond consumer transaction fees.

The Company is also analyzing specific components of our technology for individual monetization as well as exploring opportunities in the Business to Business (“B2B”) realm.

In addition, the Company is currently adding enhancements to the platform, to enable the platform to update itself with any new regulations that are passed, in order to reduce costs associated with manually updating the platform.  This will also enable the Company to market the platform to other companies in need of a solution to comply with COPPA or other regulatory requirements.

 

Our primary strategic objective over the next 12 -18 months is to increase the value of the underlying technical assets of the company by incorporating new essential functionality that will act as a key differentiator in the financial services market. These new technology advances will also augment our current portfolio of patents that give the company its competitive advantage. In addition, the company is redirecting its marketing efforts to increase its user base by entering into affinity marketing agreements with companies targeting specific user communities. This will increase our potential user community while bringing in substantial development and licensing revenue for those sectors. This approach will greatly reduce the expense associated with direct marketing efforts.

The Company's principal office is located in Sunnyvale, California and in 2013 the Company opened an office in London, England to support the sales and marketing efforts in Europe and the development of its mobile applications, which was closed in September 2015.

On December 3, 2015, Finity, Inc. was incorporated as a wholly owned subsidiary of the Company.  On December 11, 2015, Finity, Inc. changed its name to Finitii, Inc.  Finitii, Inc. was established as a not for profit entity for the purpose of teaching children financial literacy.
Basis of Presentation
Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions for Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying unaudited financial statements should be read in conjunction with the financial statements and notes included in the Company's Annual Report on form 10-K for the year ended December 31, 2015 as filed with the SEC. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016.

The accompanying condensed consolidated financial statements of Virtual Piggy, Inc. and its wholly owned subsidiary, Finitii, Inc. (collectively the “Company”), have been prepared in accordance with accounting principles generally accepted in the United States of America.  All intercompany transactions have been eliminated in consolidation.

The Company's activities are subject to significant risks and uncertainties, including failing to secure additional financing to operationalized the Company's current technology before another company develops similar technology to compete with the Company.
Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements

As of March 31, 2016 and for the period then ended, there were no recently adopted accounting pronouncements that had a material effect on the Company's financial statements.
Recently Issued Accounting Pronouncements Not Yet Adopted
Recently Issued Accounting Pronouncements Not Yet Adopted
 
As of March 31, 2016, there are no recently issued accounting standards not yet adopted which would have a material effect on the Company's financial statements through 2017.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND WARRANTS (Tables)
3 Months Ended
Mar. 31, 2016
STOCK OPTIONS AND WARRANTS [Abstract]  
Schedule of Stock Option Activity
Options Outstanding
               
 Weighted -
   
 
 
               
 Average
   
 
 
Remaining
   
Aggregate
 
         
Weighted-
   
Contractual
   
Intrinsic
 
   
Number of
   
Average
   
Term
   
Value
 
   
Shares
   
Exercise Price
   
in years)
   
(in 000's) (1)
 
Balance December 31, 2015
    8,822,500     $ 0.76       2.6        
                               
Cancelled/forfeited
    (535,837 )   $ (0.57 )              
                               
Balance March 31, 2016
    8,286,663     $ 0.77       2.2     $ -  
                                 
Exercisable at March 31, 2016
    5,345,824     $ 0.86       1.3     $ -  
                                 
Exercisable at March 31, 2016 and expected to
                               
vest thereafter
    8,286,663     $ 0.77       2.2     $ -  
 
(1) 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.11 for our common stock on March 31, 2016.
Schedule of Warrant Activity
     
Remaining
   
Aggregate
 
Weighted-
   
Contractual
   
Intrinsic
 
Number of
Average
   
Term
   
Value
 
Shares
Exercise Price
   
in years)
   
(in 000's) (1)
 
Balance December 31, 2015
    26,365,896     $ 1.02       0.4        
                               
Expired
    (1,142,858 )     (0.04 )     -        
Granted
    96,700     $ 0.90       2.0        
                               
Balance March 31, 2016
    25,319,738     $ 1.07       1.1     $ -  
                                 
Exercisable at March 31, 2016
    25,319,738     $ 1.07       1.1     $ -  
                                 
Exercisable at March 31, 2016 and expected to
                               
vest thereafter
    25,319,738     $ 1.07       1.1     $ -  
 
(1) 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.11 for our common stock on March 31, 2016.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
3 Months Ended
Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Minimum period for increase to value of underlying technical assets 12 months
Maximum period for increase to value of underlying technical assets 18 months
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
MANAGEMENT PLANS (Details) - USD ($)
May. 13, 2016
Mar. 31, 2016
Dec. 31, 2015
Mar. 31, 2015
Dec. 31, 2014
Going concern [Line Items]          
Cash position   $ 50,808 $ 16,646 $ 1,455,824 $ 1,652,392
Subsequent event [Member]          
Going concern [Line Items]          
Cash position $ 44,000        
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACCOUNTS PAYABLE - RELATED PARTIES (Details) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Accounts payable - related parties [Line Items]    
Due to related party $ 109,993
Chairman of Board [Member]    
Accounts payable - related parties [Line Items]    
Due to related party 88,658  
Chief Financial Officer [Member]    
Accounts payable - related parties [Line Items]    
Due to related party 13,848  
Chief Financial Officer [Member] | Unpaid health insurance [Member]    
Accounts payable - related parties [Line Items]    
Due to related party 7,335  
Chief Financial Officer [Member] | Unpaid accounting services [Member]    
Accounts payable - related parties [Line Items]    
Due to related party 6,513  
Beneficial owner [Member]    
Accounts payable - related parties [Line Items]    
Due to related party $ 7,487  
Ownership percentage 5.00%  
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONVERTIBLE NOTES PAYABLE (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Convertible Promissory Notes due March 5, 2016 [Member]      
Debt Instrument [Line Items]      
Interest accrued $ 298,751   $ 225,452
Convertible Promissory Notes due March 5, 2016, Issued on March 6, 2015 [Member]      
Debt Instrument [Line Items]      
Note payable included per unit $ 2,000,000    
Interest rate 10.00%    
Interest expense, notes payable $ 73,299 $ 14,247  
Convertible Promissory Notes due March 5, 2016, Issued on May 11, 2015 [Member]      
Debt Instrument [Line Items]      
Note payable included per unit $ 940,000    
Preferred Class B [Member] | Convertible Promissory Notes due March 5, 2016 [Member]      
Debt Instrument [Line Items]      
Conversion price (in dollars per share) $ 90.00    
Number of convertible shares in specific lot size 100    
Conversion price at which preferred stock is convertible into common stock (in dollars per share) $ 0.90    
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
NOTES PAYABLE - STOCKHOLDERS (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2016
Mar. 31, 2016
Feb. 29, 2016
Feb. 28, 2016
Feb. 28, 2016
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Debt Instrument [Line Items]                
Note payable   $ 1,482,221       $ 1,482,221   $ 988,918
January 15 and 19, 2016 Agreement [Member]                
Debt Instrument [Line Items]                
Principal amount $ 62,500              
Warrant Term 2 years              
Warrant to purchase a number of shares of common stock 12,500              
Exercise price of warrants $ 0.90              
Interest rate 10.00%              
January 29 and February 3, 2016 Agreement [Member]                
Debt Instrument [Line Items]                
Principal amount       $ 90,000 $ 90,000      
Warrant Term         2 years      
Warrant to purchase a number of shares of common stock       18,000 18,000      
Exercise price of warrants       $ 0.90 $ 0.90      
Interest rate       10.00% 10.00%      
February 23, 2016 Agreement [Member]                
Debt Instrument [Line Items]                
Principal amount     $ 26,000          
Warrant Term     2 years          
Warrant to purchase a number of shares of common stock     5,200          
Exercise price of warrants     $ 0.90          
Interest rate     10.00%          
Amendment To Promissory Note Agreements [Member]                
Debt Instrument [Line Items]                
Principal amount       $ 475,300 $ 475,300      
Amendment To Promissory Note Agreements [Member] | Minimum [Member]                
Debt Instrument [Line Items]                
Note payable maturity date       Jul. 20, 2016        
Amendment To Promissory Note Agreements [Member] | Maximum [Member]                
Debt Instrument [Line Items]                
Note payable maturity date       Sep. 18, 2016        
March 2, 2016 Agreement [Member]                
Debt Instrument [Line Items]                
Principal amount   $ 5,000       $ 5,000    
Warrant Term   2 years            
Warrant to purchase a number of shares of common stock   1,000       1,000    
Exercise price of warrants   $ 0.90       $ 0.90    
Interest rate   10.00%       10.00%    
March 4, 2016 Agreement [Member]                
Debt Instrument [Line Items]                
Principal amount   $ 100,100       $ 100,100    
Warrant Term   2 years            
Warrant to purchase a number of shares of common stock   20,020       20,020    
Exercise price of warrants   $ 0.90       $ 0.90    
Interest rate   10.00%       10.00%    
Commitment fee, percentage   7.50%            
March 15, 2016 Agreement [Member]                
Debt Instrument [Line Items]                
Principal amount   $ 200,000       $ 200,000    
Warrant Term   2 years            
Warrant to purchase a number of shares of common stock   40,000       40,000    
Exercise price of warrants   $ 0.90       $ 0.90    
Interest rate   10.00%       10.00%    
Commitment fee, percentage   7.50%            
Note Payable [Member]                
Debt Instrument [Line Items]                
Commitment fee, percentage           7.50%    
Commitment fees, amount           $ 76,913   54,405
Note payable   $ 134,601       134,601   $ 81,831
Interest accrued including commitment fee amount           $ 68,932 $ 0  
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
INCOME TAXES (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Jan. 01, 2016
INCOME TAXES [Abstract]      
Income tax expense $ 0 $ 0  
Unrecognized tax benefits    
Change in unrecognized tax benefits    
Accrual for uncertain tax positions    
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONVERTIBLE PREFERRED STOCK (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Class of Stock [Line Items]    
Dividends declared $ 268,280 $ 264,605
Preferred Stock [Member]    
Class of Stock [Line Items]    
Dividend rate 8.00%  
Dividends declared $ 2,072,582  
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY (Details) - USD ($)
1 Months Ended 3 Months Ended
Jan. 25, 2016
Feb. 28, 2015
Mar. 31, 2016
Mar. 31, 2015
Employee Stock Option [Member]        
Equity Issued [Line Items]        
Compensation expense     $ 69,407 $ 305,432
Price exercisable     $ 0.86  
Employee Stock Option [Member] | Executive officers [Member]        
Equity Issued [Line Items]        
Dividend yield      
Risk-free interest rate   0.64%    
Compensation expense   $ 9,692    
Expected volatility   96.40%    
Extension period of options   2 years    
Granted, shares   3,500,000    
Price exercisable   $ 0.04    
Warrant [Member]        
Equity Issued [Line Items]        
Number of shares entitled by warrants   3,877,970    
Compensation expense   $ 219,051    
Warrant extension   1 year    
Warrant [Member] | Minimum [Member]        
Equity Issued [Line Items]        
Exercise price of warrants   $ 0.01    
Warrants/Options expiration date   Feb. 23, 2016    
Warrant [Member] | Maximum [Member]        
Equity Issued [Line Items]        
Exercise price of warrants   $ 1.00    
Warrants/Options expiration date   Dec. 28, 2016    
Extension of Warrants [Member]        
Equity Issued [Line Items]        
Number of shares entitled by warrants 24,372,838      
Dividend yield      
Expected volatility     161.30%  
Risk-free interest rate     0.47%  
Warrant extension 1 year      
Warrant Term     1 year 3 months 7 days  
Fair value of extended warrants     $ 1,305,411  
Extension of Warrants [Member] | Minimum [Member]        
Equity Issued [Line Items]        
Exercise price of warrants $ 0.01      
Warrants/Options expiration date Jan. 26, 2017      
Extension of Warrants [Member] | Maximum [Member]        
Equity Issued [Line Items]        
Exercise price of warrants $ 3.00      
Warrants/Options expiration date Dec. 28, 2017      
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND WARRANTS (Narrative) (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Employee Stock Option [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Compensation expense $ 69,407 $ 305,432
Unrecognized compensation cost related to stock options $ 499,572  
Unrecognized compensation cost related to stock options, period of recognition 2 years 4 months 24 days  
2008 Equity Incentive Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares authorized under plan 25,000,000  
Number of shares of common stock that have been issued and are unexercised under the plan 6,101,664  
Shares available for grant 9,048,336  
2013 Equity Incentive Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares authorized under plan 5,000,000  
Number of shares of common stock that have been issued and are unexercised under the plan 2,105,000  
Shares available for grant 2,895,000  
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND WARRANTS (Schedule of Stock Option Activity) (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Aggregate Intrinsic Value:    
Closing stock price $ 0.11  
Stock Options [Member]    
Number of Shares:    
Balance December 31, 2015 8,822,500  
Cancelled/forfeited (535,837)  
Balance March 31, 2016 8,286,663 8,822,500
Exercisable at March 31, 2016 5,345,824  
Exercisable at March 31, 2016 and expected to vest thereafter 8,286,663  
Weighted Average Exercise Price:    
Balance December 31, 2015 $ 0.76  
Cancelled/forfeited (0.57)  
Balance March 31, 2016 0.77 $ 0.76
Exercisable at March 31, 2016 0.86  
Exercisable at March 31, 2016 and expected to vest thereafter $ 0.77  
Weighted Average Remaining Contractual Term:    
Balance March 31, 2016 2 years 2 months 12 days 2 years 7 months 6 days
Exercisable at March 31, 2016 1 year 3 months 18 days  
Exercisable at March 31, 2016 and expected to vest thereafter 2 years 2 months 12 days  
Aggregate Intrinsic Value:    
Balance March 31, 2016 [1]  
Exercisable at March 31, 2016 [1]  
Exercisable at March 31, 2016 and expected to vest thereafter [1]  
Closing stock price $ 0.11  
[1] The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.11 for our common stock on March 31, 2016.
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCK OPTIONS AND WARRANTS (Schedule of Warrant Activity) (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Number of Shares:    
Balance December 31, 2015 26,365,896  
Expired (1,142,858)  
Granted 96,700  
Balance March 31, 2016 25,319,738 26,365,896
Exercisable at March 31, 2016 25,319,738  
Exercisable at March 31, 2016 and expected to vest thereafter 25,319,738  
Weighted Average Exercise Price:    
Balance December 31, 2015 $ 1.02  
Granted 0.90  
Expired 0.04  
Balance March 31, 2016 1.07 $ 1.02
Exercisable at March 31, 2016 1.07  
Exercisable at March 31, 2016 and expected to vest thereafter $ 1.07  
Weighted- Average Remaining Contractual Term:    
Balance March 31, 2016 1 year 1 month 6 days 4 months 24 days
Expired  
Granted 2 years  
Exercisable at March 31, 2016 1 year 1 month 6 days  
Exercisable at March 31, 2016 and expected to vest thereafter 1 year 1 month 6 days  
Aggregate Intrinsic Value:    
Balance March 31, 2016 [1]  
Exercisable at March 31, 2016 [1]  
Exercisable as of March 31, 2016 and expected to vest thereafter [1]  
Closing stock price $ 0.11  
[1] The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.11 for our common stock on March 31, 2016.
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
OPERATING LEASES (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
OPERATING LEASES [Abstract]    
Total rent expense under leases $ 7,998 $ 156,677
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUBSEQUENT EVENTS (Details) - USD ($)
1 Months Ended
May. 11, 2016
Apr. 14, 2016
Apr. 30, 2016
May. 31, 2016
Mar. 31, 2016
Beneficial owner [Member]          
Subsequent Event [Line Items]          
Ownership percentage         5.00%
Subsequent event [Member] | Chief Executive Officer and Chairman of the Board [Member] | Employment Agreement [Member]          
Subsequent Event [Line Items]          
Officers' Compensation   $ 240,000      
Options to purchase company's common stock   3,000,000      
Exercise price (in dollars per share)   $ 0.90      
Vesting period   3 years      
Options to purchase restricted stock unit   250,000      
Subsequent event [Member] | Beneficial owner [Member]          
Subsequent Event [Line Items]          
Ownership percentage 5.00%        
Monthly payment for consulting services $ 12,500        
Subsequent event [Member] | April 18, 2016 Agreement [Member]          
Subsequent Event [Line Items]          
Principal amount     $ 20,000    
Warrant Term     2 years    
Warrant to purchase a number of shares of common stock     4,000    
Exercise price of warrants     $ 0.90    
Interest rate     10.00%    
Subsequent event [Member] | April 25, 2016 Agreement [Member]          
Subsequent Event [Line Items]          
Principal amount     $ 50,000    
Warrant Term     2 years    
Warrant to purchase a number of shares of common stock     10,000    
Exercise price of warrants     $ 0.90    
Interest rate     10.00%    
Subsequent event [Member] | May 05, 2016 Agreement [Member]          
Subsequent Event [Line Items]          
Principal amount       $ 100,000  
Interest rate       10.00%  
Outstanding debt amount       $ 2,940,000  
EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 97 200 1 true 39 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.virtualpiggy.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.virtualpiggy.com/role/vpig-ccbs Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.virtualpiggy.com/role/vpig-ccbsp Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.virtualpiggy.com/role/vpig-ccsoo Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.virtualpiggy.com/role/vpig-ccsocl Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 006 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Deficit Sheet http://www.virtualpiggy.com/role/vpig-ccsocisd Condensed Consolidated Statement of Changes in Stockholders' Deficit Statements 6 false false R7.htm 007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.virtualpiggy.com/role/vpig-ccsocf Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.virtualpiggy.com/role/vpig-sosap SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 102 - Disclosure - MANAGEMENT PLANS Sheet http://www.virtualpiggy.com/role/vpig-mp MANAGEMENT PLANS Notes 9 false false R10.htm 103 - Disclosure - ACCOUNTS PAYABLE - RELATED PARTIES Sheet http://www.virtualpiggy.com/role/vpig-aprp ACCOUNTS PAYABLE - RELATED PARTIES Notes 10 false false R11.htm 104 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://www.virtualpiggy.com/role/vpig-cnp CONVERTIBLE NOTES PAYABLE Notes 11 false false R12.htm 105 - Disclosure - NOTES PAYABLE - STOCKHOLDERS Notes http://www.virtualpiggy.com/role/vpig-nps NOTES PAYABLE - STOCKHOLDERS Notes 12 false false R13.htm 106 - Disclosure - INCOME TAXES Sheet http://www.virtualpiggy.com/role/vpig-it INCOME TAXES Notes 13 false false R14.htm 107 - Disclosure - CONVERTIBLE PREFERRED STOCK Sheet http://www.virtualpiggy.com/role/vpig-cps CONVERTIBLE PREFERRED STOCK Notes 14 false false R15.htm 108 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.virtualpiggy.com/role/vpig-se1 STOCKHOLDERS' EQUITY Notes 15 false false R16.htm 109 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.virtualpiggy.com/role/vpig-soaw STOCK OPTIONS AND WARRANTS Notes 16 false false R17.htm 110 - Disclosure - OPERATING LEASES Sheet http://www.virtualpiggy.com/role/vpig-ol OPERATING LEASES Notes 17 false false R18.htm 111 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.virtualpiggy.com/role/vpig-se SUBSEQUENT EVENTS Notes 18 false false R19.htm 201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.virtualpiggy.com/role/vpig-sosapp SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 309 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://www.virtualpiggy.com/role/vpig-soawt STOCK OPTIONS AND WARRANTS (Tables) Tables http://www.virtualpiggy.com/role/vpig-soaw 20 false false R21.htm 40101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.virtualpiggy.com/role/vpig-sosapd SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.virtualpiggy.com/role/vpig-sosapp 21 false false R22.htm 40201 - Disclosure - MANAGEMENT PLANS (Details) Sheet http://www.virtualpiggy.com/role/vpig-mpd MANAGEMENT PLANS (Details) Details http://www.virtualpiggy.com/role/vpig-mp 22 false false R23.htm 40301 - Disclosure - ACCOUNTS PAYABLE - RELATED PARTIES (Details) Sheet http://www.virtualpiggy.com/role/Disclosure-ACCOUNTSPAYABLE-RELATEDPARTIESDetails ACCOUNTS PAYABLE - RELATED PARTIES (Details) Details http://www.virtualpiggy.com/role/vpig-aprp 23 false false R24.htm 40401 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details) Notes http://www.virtualpiggy.com/role/vpig-cnpd CONVERTIBLE NOTES PAYABLE (Details) Details http://www.virtualpiggy.com/role/vpig-cnp 24 false false R25.htm 40501 - Disclosure - NOTES PAYABLE - STOCKHOLDERS (Details) Notes http://www.virtualpiggy.com/role/vpig-npsd NOTES PAYABLE - STOCKHOLDERS (Details) Details http://www.virtualpiggy.com/role/vpig-nps 25 false false R26.htm 40601 - Disclosure - INCOME TAXES (Details) Sheet http://www.virtualpiggy.com/role/vpig-itd INCOME TAXES (Details) Details http://www.virtualpiggy.com/role/vpig-it 26 false false R27.htm 40701 - Disclosure - CONVERTIBLE PREFERRED STOCK (Details) Sheet http://www.virtualpiggy.com/role/vpig-cpsd CONVERTIBLE PREFERRED STOCK (Details) Details http://www.virtualpiggy.com/role/vpig-cps 27 false false R28.htm 40801 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.virtualpiggy.com/role/vpig-sed STOCKHOLDERS' EQUITY (Details) Details http://www.virtualpiggy.com/role/vpig-se1 28 false false R29.htm 40901 - Disclosure - STOCK OPTIONS AND WARRANTS (Narrative) (Details) Sheet http://www.virtualpiggy.com/role/vpig-soawnd STOCK OPTIONS AND WARRANTS (Narrative) (Details) Details http://www.virtualpiggy.com/role/vpig-soawt 29 false false R30.htm 40902 - Disclosure - STOCK OPTIONS AND WARRANTS (Schedule of Stock Option Activity) (Details) Sheet http://www.virtualpiggy.com/role/vpig-soawsosoad STOCK OPTIONS AND WARRANTS (Schedule of Stock Option Activity) (Details) Details http://www.virtualpiggy.com/role/vpig-soawt 30 false false R31.htm 40903 - Disclosure - STOCK OPTIONS AND WARRANTS (Schedule of Warrant Activity) (Details) Sheet http://www.virtualpiggy.com/role/vpig-soawsowad STOCK OPTIONS AND WARRANTS (Schedule of Warrant Activity) (Details) Details http://www.virtualpiggy.com/role/vpig-soawt 31 false false R32.htm 41001 - Disclosure - OPERATING LEASES (Details) Sheet http://www.virtualpiggy.com/role/vpig-old OPERATING LEASES (Details) Details http://www.virtualpiggy.com/role/vpig-ol 32 false false R33.htm 41101 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.virtualpiggy.com/role/vpig-sqed SUBSEQUENT EVENTS (Details) Details http://www.virtualpiggy.com/role/vpig-se 33 false false All Reports Book All Reports vpig-20160331.xml vpig-20160331.xsd vpig-20160331_cal.xml vpig-20160331_def.xml vpig-20160331_lab.xml vpig-20160331_pre.xml true true ZIP 53 0001214659-16-011538-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001214659-16-011538-xbrl.zip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

9R>_VL;;MALG/XB8:A@ M-TYJ!;&X O00+9;J[8%HI%,SK=I,"&_%B_!=._+UCJ_#]?!.8C!D1#PT@YN MEQH%0J;Z E57@1YB%@.SO-9>/M'5=ETNRRTDFM"=D-]2^K!=D\OPP9_.HT/0 M0M*) ]CZF7(NGC=!F*B7W4,EH4FG+NF6RET?':>=AL$>'*[I42>>"=DW)5^O MXW6X?#V@+"0 $9S14@2""5W[[>",'@.^PZ:BEET4'+-D=!E'CQ\NPQ>Z(K,T MI1[-CCE%IWW"Z8E//U/.Z>M=;GOV+50,_D EH2FG+NF6LUT?':>5*WI MT:4-DU+7:@]QM93I^E[V?P^L%R9 %Y[P:FV#: MM]08<']<= ^;OD3&\6!>3V1-A+\U%-NG+S0<^YG(9O+Z_G-W3_)[.JN%&Y@[NXU&+!W#*P.FUA:=E% MRY)+B1O/>5N' 9RF7?" .9F+&E!P M&,@9)I X"]8]$DAEL!_V6'JX8YZ037T) 3V0)036N+//!L;(\S/6_Y+$J7%? MIR$$C?>ED%OZ-3QS'/,K6SV85ZC0Q7W>RG,&-B$!YZ (2F .9!WJAT#X76.'0SWQP&4;T(J//QCFA(PC-"S5!M\3L>.@X M/]3M]>#E7HUNH1AK27A3WX>QNV"!)I)20M"B53DT M6J!02& 3IRYH*M:SHMY^RO_P;,&(Z.UT@"Y_A6U4UUIV0>ST/3O)QVW]1B^< M9=MC>.7:' I]Z:,.7' _%&> =)Z+@A3B&0D=>X@!"GPVQ[YUA52/#BOHOA$Q M2@'G9>S:2?#IXKVZ"T@&YUC4VQ_X*X:%(BE2\4@J*CRRPS7'7H MIA$7L- /1+H)S!"C_:')PGC]HDMRN[U/ETG([X$A>^DW U)]5D"'Z<@Y9$7I M,W/N.M=*DX2NN(/GX4NXHM%*6MY"Y3I91"N'1%J@?UAY1&\.PE:=ENF^"=FU M*:F[:^4+1Z$($9#4#%Q=CFKD123U!)? ;/*W ID1?60K>2'Y!&(7 :+\F%2: MIG\GYWG#')RK\DG^CS1+PONM1Q>VN<0H()/@HW3D7+)F8+P.DNSU+@FB-%BR M=ZW<30N2Z>00I0P23P%^8>4.M2D(*54:IN5CPI^36@/?!A)!6! P$0ZA+@<5 MLB+^F2!O=.:EYV&Z7,?I-J&Z0R,M-,!8*=;@DJ,JGYTR5F+8FK]"?7(VIV3? MGGSU[O!(&X1!N0Z *9#Y(DW@.. 'UAV-1YC91P4]JREG9V>+WZ[N;LGU[)^S MT\LY^4!NYI>SN_EY_LG-W<7\]FW"'%!F#@-T'TO/2\TB8J@8+-5=(B\@AGKG M-*E=&BT>UBI1%:.7OBT;!L,#2F 9L("2E(#=Y'(A3=\43&V32P^@^IA&5,L\]!*PY(&Y9$#OD].4 5\NHI!7 M)0J?5AP WC^4=I"%)W)),-6$2!N=8^GI:_V).>44"H C%2(%3CMOQR=C;$.#EB5I@)$,JAT+LN0'/_ M%E0,V*]&ON$(ZIW;/K31W5M:)8#I3>_NWP*C!-P_!MZ^I1.']X6ER!R2HIO@ ME9WLDBX>KN*,IM?%S(.4FNKF'4K*FB-14>T-%@6E5B#4DPA/]T](_$#X,U(^ M](5@FGC9U:$4<6IOCA!:@0](77&@G MH4@-P$Y!,5]SKS#7 V G-8!5^#I:>.G./4& UZCGG=2<:G0=Z+V\.M>+*,J MK@@ZMV1>X9<# DMFQ.HH:,7N9E_WW)NCK4 @4+), QT5S]JB:JZ- #AGFZ@T M)OMAKU$YM -[WB%,]SM'O1DEQ4:A43G1#XK198D**EN1K^5\/=^/!,63&8"$ C5A< M_F9F7!X:O8Z&)&%V46![B-IB,5+N!UH&$9H D4T@.=U_7)[0X]LA6JI7*Z*3%@D"^G1E MA(0! &=(@F1!&-'5/$BB,'I,-0Q1->Y01-P8B2,J3[!((K$!88E0='I.'\)E MF+';*K;/VV*X]7R;Y$U(]D0;J>DV"Q[].XM.^?X%/ +@I4LDD9"(28/CRU$A M)#5E"[1R>^<>8B7LCA%-@+JF#YY&KEZ:+M7>:?E*@8%:+J@)VB)!)P23>^@F MF OMF?--H&9:M2%5(_*]@(P_^$E"!5*TA-2B3$?-K@(]34=$Z"#I0&(6 ZKM M-+$J/GX+P#3.&CC0'#F;O-!H2V_H,GZ,0K8HM.B@Z\]+ \IU'(2=.BW3L@FIM3F$P58H6 2L-<-9E[(:>1%C/8&HHU0"L8J U6(BKX/6 MXTS2GP,7H2\5&I@4KW74,'/[%"3T/DCIZBQ^9I-) M 3_.)TG8;41L?/3T==_DNECW-OLS2%:?@S#Y/5AOZ2Q-M\_\;H^434>Q$?<[ MFCQ_E 0N]P9;H="E010^NO]%<,*U4S_UH<*A^2D7_, E25T[J:EG1PS5VY4F M"+WT! MAYFDAU\89>VBJF-K#DQ(Y0(I?2 [)TC-BV,H>1%B U["0PM4:'G0WB/$!/D6 MHZ9?]7;/[^%E^&05^FF0^[6DY O?F/'IXX3D5=!?WT.:#R'-77%_X$$-[6B3 M,7PW*@?!.RS'^B9^!K:\,BRD2?9>H/D2S=Y+-/D/<["#&U=Q]$+3_%M>;=D: MY\4#;RV;TW=L#7F00FK-B]RC^2W\&&R0.^D^<+,*Q?_5OYI#A^ MBL2% DRKA%L+C-@B0;+UP, MTY.56U>$BW.Z+*-%,3;WTWNT< /68XT6A]R[_)U_H59'^I=<.CL/,KI;-N"H MMVEH';GW";;N12XP_*W\Z)W"G7:?'*"^H/9>?R^[KIW9;FZ8,,NU99_'D7E, M68V>B>S""G9> GJ!GZ>.,JYY.5EMXKLW 8YUGHNF[^%F' 2_T8!ST&M,)<7_ M3;Q>?XX3UG#8&1F!X6$F9QJ&O<@@\%_(CZ(8Y.]H@R5U-X::R"%?F552FO7D M=(0!B3O46(P\: PT*%-S8+#QF4,,6%Y6NT"W?8A]RSQ9Y$E;&F MAD:.*P==V\7D???@\VB%S)J@QZD1#TOX@?E:O2 M3_=Q7V$>M5*MV9F0G:5C&J(%4! ]>X!ICYTSY(;Q<\4!AQHO:TZ-NV/&G&+[ M_>XI6TIPC'M\_ H5S@M,/X+%81:4\W]MP^SU(DJS9,L^3!?9$TWNGH*H_,*S MQ\>$7VK9_+K[Z^YQZTTL?[#*T?[^C)M"L'[/D8M9A*_A,._T]@ZC%"Z<(#4O M"'>#9+D?^T)YYTJ[2B9?*W<.?3 7+8;@)4GDL(:60?OZA9A@WWJD]:N61_DV M'H=RC6H<+N'?8U1@X MOH-.%D?C..C%P!?^+^['F#SJ]QIJD2**NPX6:O.+DW=G:N;!F'W7 M.8A5CM9@.HBG;A9I8CCJ:AWG>\P7?"&_.E1NOMXA!7_MY N/Y+06R=D2#G9Q M:T*#A_S]O(?FPPO- ZV@/_;@?- ]N]UB+.UV U>S2KT=<;5.W\ 1+[*S_2_H M1\_+RO\!5\?"W7*USA^VZ_5X)HOZAP9W:W9MPY2S%;Q@AQRNZ#W^D.EEQ\7R M:_@8.UE'Y"UM[C_LV#;<_H2#BFYOI$

D]@]![ P:6Q0ZWX/738@\B6GE4F(\9K_P[>5;O\@$<1@O[ M$E[%K#=]9.UAA*S!#K;U.V0=_O&W@]RLHC+E9.VFE]P [SWXKP$?$-#P-TEZ6NCA-' MCO/,US&Y/M!:M#'8?ARS0>7?G^/D@88^S Y9.^1JMLC"(2_20/]?U(]*L]?W M&'"PPMP]-[--U4=DY\D;G7^RCR3NADOZ1C=G@R?&CCD<3'E[$=?OY6=V7\?G MT,L*_;,@#T7K-5W]/SNY]P#H7P <;LKKH$/@Y34D]7,8;YSIQM1<#9K)##FN>CJ*;>.]-A'N;);AG MT6>\XMJ3^'.89;/MH66+;99F0;0*HT?L6AK1I;'/$6ZX=)@'7 I^U0,]3;CY M33P\W;+NH ]G"N=E_]ZC \^FF$%E_',UY:$.+>LBN.;!V9K'%8#]&MO'^D)^ M1V+6N3@-UJQ[<5RWC1QM1/3OL&%O8^)A]EG*K^?/V<+_?WM?_QLWCJ3]KQ"+ M V8&<&XGSNW=[AY@P%_)&F]B^VQG@H-Q."C=M"U,6_)):D^\?_TK2NINJ<5O M%*9+&$IXCP>"M'CKXL,-;ZO\$+_>YV+5]4E2'Q5>=% M4>EQIU@3UR1BX'V@I,_=^T[A*)G-YY<-1\5M86<%,YI$69Q^3?(7.HL?8CH_ M2YFBHMA=U7X[PA:WAV%TE3Y T:I$C 8I"GL?K2X=D-9%O6PWL6LV.)X5L2O,:"B-=D#4HW42N@8CVL?;/(2A@."DYCS; 7(>'#T4'4V%ZK#PQ,O 6-@U4T3\_O+H>5[$SRRAG2WR;(K2 MY-OQ6%X7KT%S5&R4W& 5I^%E!R3Q&PLZTZ3*ZGRX2&;I,[V+?K /D28Y/:$) M?8@+PV#->D1A9&8Q(C#S6M\3=,QEHX@)E9J/WV'-37?VKWH 4HY FB'(S\T@ MOXP@<+(W9 D3#D6'F/2,1Y8QW @AYSBRL=/'*?:V8Q8A^C:HN\[2US@OO=$> M;'(;0@XW)-'#&:6?X^A[O*CV.(^+=8DGP]#!;CAAW& Z'#"#V=T- M=,1@K(4)91D.WF&K35_2ZLR26-L?D$8?)5C:K(2U!J% 3%AFP\K8:E2X*KH.:FZB@-Y2][O(6JA42PQC!?DAAG& S)#"GV=\5=+Q@ MI8D)I5D(Z)#:NG][AL.&(-TQ1A [#+!E"9D-1HB8SLR'EE':*''G.)ZP5,@M M %EE&WC8H+%\XN\*FM%'R]E,N!NP>CBH30P]()''&&7V@ M64;GI<;'>4Z+_#B9M\(DXV4(B]$DJQ!&HX%/EBSN!7X-PDP)LQF2R=A;*Q!U MUXJ0ZLXD2N:=^1#^(,+.6J63(7OSE\V$#$:53X1&@R?G:P^FNC@#UO;* P=: M!]UEOA)G-W3!J@VW,ZL6B_0/5@(+X9I#2)09K3B$P!F2..#CLEAF]$N/P@7S:?K\'! GB[IAFZ^ 8OL@UB M'WS8QA(7E;H7]'/\2N<7I?K)8UPJ64=UE;[JX$=S '&$HQP F@0U-0:/5=1R MC5A,-5R7J*K6[ZKF9--^M;A1!QCXH@I=XY(1C)F!2CA$,9"4*$R-/ 077&=I MR5C%VW5I@T4YIV/E?5\8F>DQ@5YW(0^HN@.S@)ZVT!R@E&K" (K!.OA?M3T@ M5>MJE67='BO\-2U* GXCFQ1#7SZ,#/BHK-IQ#*\A',Z\MR/QO8%+7W@P$T<2 MYS8KRM=1J>A=.=G*6>6E-,E/WCI7M!R=Q5A"KV,J\5=)!4K^EW CYR+M(*O)L&19'8*O#? 5J6'\OJ[,MQY)JP%5E!+[$!Z MP%IA/6*(]KO*CSXK;2X(X-C9ZY.WTT64:ZYH"7N(X=;O 8TVD4[@8.,(,L): MKS^G%E7I1JL&:)$FM 9T!1F(\'9=D\IS)2VAJ+?QD$<<@ M.>;5].P1'BR6>4H76L]#&(>!Z]>+JAG@K[P:'D$G]MF @"KN/01]9.')#7]*, M)11=IXMX]E;_J73W)GVW7;M>7QAZ,=$3R&5KBM1@"ZV1CIIF9-WN@-1MR'WS M?WR^ULA\^J1@87T]^.N,P8$Z-N-UXP>U)0-9<>7?&CN^2![2[+F:2>V.M:K= ME4-[#>R&%N68C\?)_$N4_4Z9DDTI,J'O477H.1QQ!R"@JC2"/O24]@."EU F*OV6" M=' E[G]47R3'Y&5UF>1LZ3DG]W43-+&_V@(X,-,UFS[*A#UY, MH:XZX7"YO MD-'547MC=M.V,@TVA[$S#I_#6]JAB:6]TNQ[.M36#@?;VN&?CJXWS,8N')!_ M^==??_WU/7F),O+*JA+^)SD\*']A__5I,%H63VD6_Y/._Y.\_]M?^(W6YMQI M_>M?#_Z];-VTB?-\6?9@$4RZ+/*B_$L5.A=E[Y>B?N4??CT@S&E6K<[HK/GU M??7KOTT4(X>^,'(8/.8Y,8YYI#VX,8^@!R [2'6"C'E$@G0I@=]_Y7Q.QA'S MR"U @#0=L^'CC-M3A+- MN8PYA'+&V1TK9CG9.)6IAGS#+P\/#@_(_8->SDKY+[LD0MB7:/' M+MPL U(I1],2:!4]X_=P[\*Q$8%RIC,>(ACE7*I.)[Y(\B);5D>+KHHGFMT] M14GS$>CC^3QF?XD69W$^6Z3L USY\?>R?30KH*==,-I S="&:A/6+< \R\#S MOL$WX=###-0-PA4UIZ):.I!*"5*46I!&C=)CK14A+4W(_4H7+"O-@6D#SM.! M\AB82QRF%:#WW&5BQ36Q!K@7M S+INO?*#L:51+G<3G)B1XI.?]!LUF<4W*= MQ3/Z]SWQ82(^=\L"$Z&^L&FYSN[Y,DU>R[E457 XBY,\GE5?@_4^NU#HX6U> M(=0#N>-3/#_LD])\:<(YLLR.X"(86R"<*&SZJT)U8%8\9:9SECTK3J MSS;[ZI2E/;DA>&=[>N,]E E."SY5Y4TNDGJ#Q?ML@"_>VR1@6SQR#\9_6MA# M_I[6(=W4EC(> _Q:,HF3:6QGVT+;HWN3DHL_G]95PZ8->\L_X3/XC-5&%F&GXWZB#CH\$]'S05F@R_E:WXJAR3E M*R_G6;-B=4Z*+).XV--3*%/?77J:9F[AU>;0WVJCOMFGOZ'/49R4OY^F2;7S MN8P6[(,MN?=5@ $Z>ELJL-(1N;L;\-RQ+SK8W5I(;VFCL1ID?*X]S2O4R;6^X_DLTCN$D7BX]IQMI#S^9L MY4/-U,SEAW6]ML\K\ S+0FV'GM)8&XB942GT72V5,TGJS(C(/9--&N%C/^IE MC7 XWSF09,"\HJD>@!YOZCR':_I@I3TBPF-A_^6RBO)77S?-QW[R:H0\Y"X^ M'Q$3C3.N-MPNVIID5!?/HH)^C.(LS,DJ2_T")5MJZ(=\R6/?.3&_+3PY M!FIM R9\W,=:M!?G,2;N&4_@ MV54Y+ VQH'-/$]Y,<_)$@3O&S$5WUJSPKFY#M,B[NE[5ZK:-.ITH81J' BOA MQSLX>7*>8E5HW0'J,P=\$.J(ZW! 5 M>:E,].])K'D<>)<;1'>Z3A$[SO/E\^JV7RBK MZ_=;NBB'6<3%VTU4T"_1C_AY^0R]P66M -1VEX4"81>@K9]8X*TP&[T=KDB; MJP.Q3;8Y+D):GI=MS@@SWMF"F_C.\U-N+?X &XS3@+'W%T% L3<*P5& MXX2Z3VP\,?=:;QR^IU$G4,Q=2]\=S[8%\R">C4LU(?Q:K4@8OS92NAMMS-U2 M'Q/OB6/N/3.%M_&=YB:$,;=1?&P4RSHE8A\QX@!>$\=>F-G'E"FL,*V+/Z?F MX]'G#O*/U6'"3IV.M*89$I>44YI6G!#Z8_;$F(H\I!G):?8:SW"?5C8U,TOG MH6MH"$EY4!+WI[J B[_3=%L"W9^E6PO$>IIEZXF@/4>WT3/(\965> ]GZ!I1 MF&D1%(,^#L;P<>_A4$PCV,N1F+%P#:Y5!#UU0Y(.BZSVI.#!'"=-"^.,'<]_ MO,19U9A5.H,.%/FC@Y5\K93+FI5=62"EAM=#5E6"1\[. M C0 %HV4P0V,=;M2(,LU(L8SKIB*HYLW8%>E9"/6JW1+388WH1N@SO= M;:M MD4)UG*&/\LMYG7,)[ ,?#VX^*3=8$:B :H B8;EZ\!,,'*8-T=\A\=NK!1'\ MK2L'R+^]W:T80.Z/O^?59R['_AFZX:P YZ^@& K,L5DK!.@#=X\M<07!PVX# M(VVVO](@X+>Q?]1N$JSF+F ?-:_AG@:H3BFWRNJ&K!5FJ09TM3!C-7 4GK!\ M>D@JAIEK[Z'BA*E2L%7#VL6U=ZYNF"T7P%>T&,9*QNX16!T'-2UV@Q]Q5A"S MN0E\1,F"_=/JDQ +.O_SP^HS$7OJ"OY:]N2%M:Z8J>)ZE<7 "XB[N V$!':X M)S",!.:\GMCX"&PR-<5NXOSWCQFE%TD9;-&\\%Q13$.\R]H&4O'XCOIJ/"V$ M=0WD6GL^W2M3QF5- R:7,,%D)7GR9<1TL.WVV+ ^NX"MMQNJX?C \'3X#==. MH8WR>(B.+12PR^\>&!_%*S[**CZ:;O$PU'SDMX@!2D;"O=NGF$!T/_S^*4MS M\"^@JR4!I^UQ):'(-)$\ QR)=WP%W:>(\.2"IL[5 MH[9Y60D;L+#6B!9XFH M<0R=!,*1")_E,2K2,(LJ7](\+N)7#REH(E6#$ @+%ZL^>5,@I*D/LL<\K E. M#/7^-GDL=#/Z0HRGO%.1GF% ?SB5(^Q8<#YX%P4KSOM[(7AP_L$$YW!?@K+4 M- S2/ZR1?E!_O6D?S0,;W]00_V&,"S6?XX1>%/09?%VF-S#4,DQKX+ $V[O# MP(LL;7T<#@Z%8$)C#O7 @"I$A]0<6V7==7R M@=CUFL4>LQXQZVXMPREJQ[GQ)*X?MJFE 1[K& EU7ZRU(Q1K$47.DT%;M+6K M:Y :BFT5/!1O;8D;.<6;8=-'O48Q)X Y!BWA7JHVCHV+-$-$\+,,PY4.34O- M1V#B;/1KXZ@I(T29UX"D,;4HM%7NX7+Y_)UF_F)1H6CW$2E'-%9?('Q*:*-3 MGL9!G$%?$0^1:J=J62UVLNY'C& ?3DC%'QX<44\%+^YHS.QEF,M5;6>=)V$B M6K[R.*B,1;'Y R;OCW/=OXMN2=XYOP26,FRAIED=6, MWX-N?=HYW@.6PFRAHEM87[&A-? M<22$\V%#.%'.OGVY33O_MJ<=W^:\>[03/)%.67E461,4O!J=JSJ:AA4NV[4G MT=6 U*D0I%TW4593Q\W;=7KLRKA$W[IX7OVN7ZK'\7.S,S*2:FD4@8USE;%-_;%%:6_)(\B*=_5[;PBA?NE8LKW[I MH'%Q/:3#(QD; 4:OO8P%OT39[[08\?O6"J+4[SMX0"*+N%1%W%J;J2$+KENJ M 5UPW5@-'!4Y+9\>DH+KYMI[*,-IJA1LP?5V2L7.%5RWY0+XHI_#6,EX3@ZL MCH.2G[O!CS@+KMOX&3IRGV1]=$1UCCS";5KQL5)T!K%7?'>:Q2O MQ(^DAF?W:8VE1O%::PRE.QMEPM0HKH6/Q,E!8SM 35 NNX#MBQFJ$:(BZ"CY M#=>A:QOE\1"=O$;QGH_"VO?.,A+NH%HU@^C6\@FQ-FZN ?2RN(D&.%9\S)\9 MDL5P(\4]+.\8Z .[!-XOFKP;J]\6:(=?2;*F'/ E)'U-'*P>39GW<"YR&^J/ MB@!9^#VN\J\3XR+W"]HC82/<$;?1;4(O5DN%./T62.B%&>F=8_P"B-NU%;Y( MQ]_]N*0%.S?1^G+F2#R%'9P<5PQVM;+"%>:Z2C!*>L"U.BM6T3=/L%"ON4 > M1Q7RH02RY^]YN(;RJ,.O)I",OB^HB\5.6.G 9NV=!14;?BL<(1X^DJ[YW1= M74"#PI;0J2QI F,:W-G8D0JT#]+4 MXY39+54$:F)KJCH;U]=%-ASW_A#'G7>6?_OGM M$>3E97VCQE,Z_EBU]I/SWI;G,\&]+PY?PVG\6"//W.TIZSF)MR7:9G5^+ M(4S.R+V()N+XTJ74CU7$.ZU@X!=?<5T/78.3"YK;,J;/J-,_IO'R' M2V9&<4)FT6*V7-0\DS[4FSCOYE%!R0/CDE#\( 4Z"N9V_ U<)ET+D22%82 MJQ.A$W0F4KBZ=2L:3.'4O?#D.W8T8R8I_!&K4&L$;,6BV#67O,5T,<7)+#(R M\1NM(J&3<4:PXE(OSI*4A)+ $Y(XDI!LC@F? 99$(YZ"/G:Z^G*!$X@XM0%' M[A T@.5@/TR%8OB=KYY$%[M<(Z(,;-_356@:A#W&5S$/.ZP50"N=!X=Q[(A4(\FA1HGFYZ MZ@\&.#74CS+QN)]W#D^9@'^M=FP4@7*:QM:;5&]K'N=I>ZW[U4%W-CU^C>,%NJ0Q'JQHVT%&;ICBHX$TI+BQ!:SZ- MP*&<6DN'+*T2#A'8-121/M2-EVV;^2DKXL[..XW0SJ8 U"(!?0# MX^867#&@CK+A2&;]7?N<1!UF>-PS@TO+G"PWC#-4E&4-_Y:RLY.+N'CS?3:, M+]G'Z;!MR7B/7O"?$>(38CV% YVZV-+#RRFQCMF MJ>0X6@=MR4&U2-&[?UPKGVWU_*U&;*2Z6>MW2X4:%"%TT4" MGGS'2P1C9BE< :>1U@CHB@6D[/=W#XQ5XA6K9'M6\6JZ.\0KXXQEN\FEF[- M=VD1+$N[EBK@XKT,[ MGUY>"ZP#X)%[(1OPNLKS-Z$.,$]DH(*SLP!3(2Y#58 M'^ 5K0'ZH)@M#GZ>.-:^AMR&^^FDO7:@JV2U&E6TM4X3+PF._;Q5\F:MSC07 MT8:3"/C<%HK7H*>[UGK!SX%WEFI1KM8-NQO$G*NL#E01*&T1Z"O;Z"Z>:$:C MAV(JE<*FQ)'.%P6GP)(3GZ9\H_'C$VOS2K/HD:X65-FW@L/-5724\CYAD2LU M$E>J\V3',G51W L&7RI5,= D9J43:91:9PF02JU=<=-:'!/ 5QMPGW]W+5,N MA,^>/">/=(ZCO"7LY+R?[4R81A',>\9$I*.> 5TMB[PHL1HGCUXV8I3R@.>"8;VL<(Y<*[C]%R#,KH M6:YM0+)A,>])M&"?:YIDX7],Y. \!,5 #[@#QUQT6]4?=Z5^9<#,\I4NHV=Z MECY'<6(;,PX091HN6HGRP^(#GH*G(-%.0P#*MA&L%1KFBMBP^A]A JH%#2:" M,!GDOI:".JL8"&'FK#\?Z M4Q"6 8]]1Y\':3TR\CFXKWGDF& MZB.IID\+QWZ-@=884@UIMNG3XV,K!"D1(6FJU&'W*T].*>QM5".N[0F5,Y$>/\XPF*>>EXS"EP$ MNIVTI2G%LF(PN4Q$\!*=]N0Y33O 31%F@>5+M?YSGLR]9B)YC2)Y4[FXF-X+3FH;/"MVL+_B9>%U=W,T0=^)\NRFF77J=@"?6-;5P MZI^FPVICF*@B.%FNK\VN3&I14Y#/"3!*$L(X69;J.XHIM/(.\!#13DVW<7.1 MQZDY3BZ:R#3^)ETL/J89N^A^ULX1YFZ2WA&&S6UPG@2Z*7A71Z]>H"W:U02; MW#,II!$SEO.!P\#FTEV(P>W0-[2$.G4%8R$3E+E_$E5#L0J;TS9+_NE#?8?:K.::U.Z&Q%N=7%LZB@Z\\T.XH++;4 #AB-M4!!_I;/ M#D>(::Z\>R]AJA-H4/JI.3>Y^;1Q;^NG:D*8#H0I,:529[8\ .[(AA$2M'\S MU ;>\>T$,Z*,EVWN 1U%5D?"FT;OHH;&:%[$SQ$CM@?&8NN/*J>U"/+(ABFO MSI<9FZ$73Y2\3*$>Q,BISGDP/S:R0[,39:JWT8Y4.>[;J/I"PBQ5-49!JYZQ4NOI-MJP@:\]; ."WAV-HF3Z DVJ!&$VJ MX_:N)ZJK EL'=>H@FV?6,U-$3"5]YWQ.T3 3+O9Y_00H#6%9ANEK:1ZS+U)K MNFFAP %65GVXO'J(=>TG\E)9V<]Q0N;I8A%E.0OC2*J-C24$'C=VE&:&K5.GZE\KZZ*R<53;- M4<5H4&:H%?<,-<-^+ %MAA_A(:Y);X+&]L&'L7T('KBVMO^D M 2NG'3=0[;0#!!)'/F1@VAU>%RWM7DT@VDG!P00+W@L4P$'\KOD@:"<="8S? M@UFX/131DV1A(ZV#!@[)L[.1PBG:B%[T9 MVDG8E9\T*^YH]GQ&OQ=5R?T?<2YTHI*V/4?*;0N$!XD>4 Z5+T('"+R>1]7/ M[\KYV#-A%P[JKV###;4Q]-'!Z<-#B([M!,2(XOL\TM8JG !_ M)4>JBR.L&'VKAM]7A!=DWXF1OVDU9C2_UL+MI8&;\-],B1^3^"&>14EQ/)NE MRZ0H_=UUNHAG,LC0GV\*LU" ?.^$S832:6OF@H6Z[V0KY^^7)\ M\]_DZB.YO?AT>?'QXO3X\HX?;V\N[C\1*ZO/E^<7IS?[I(MJV?"3JTY M;,H^FR)_?3F>%?%K7)1JG:9Y4:GX)G)1ZA[;?DG6 P;):IV /)!4D 94)?V/ MJHOOEB]D<_F L :UNWDC]\W_\?D<#9OH@U/;D'IX%/?D@#"D];EQ'@IY@\RP MD#&5EH>B^JQ*W/<4(ORK\*U[F$#?MDWFL(A2*!!F#4 MW1]?"RK;W8[6OY%[]BNI?L9#Q:(7R8.'_*5S,+'5@0L%E8$$L/^KA]NB])=/ MZ6)>DFR]+7[\/2^R:%:H(*'35X02>5]8X.CH"8PEA4@#>$E'.CI-DSE-ZC-M M25[RZKPZK+$!8OI 3I]8EFIU7*T]U$_DC)8Q>%R"=34>-JAJ&9@8O0;V*02T M; P)QHW,.PCL3Z/\Z>,B_2/71[NPBQCDG"[0V!9J!0YIGB0C)/<'4 (XKQ!< M]B-51\Q8%9N'#*(JHY(@L]=5"DBU*0;!X44R2Y_9Q\W9R8*,/I7&$+_2YE=M M:)J,(D:KWBC0 #;1'1S3FL*-8*XUIB;RVR.0SVF.F@&,K%!&"A;F+.$)G=&D MU&&%BP!L4L<93,DT818DR]_0Z2-B"GX?6%Z0Z07, @)1!ICGCK"9#A^0)M]X MTP)7NH>6,8@!JV%#0GCR^DK J&5Z :!WQS[GI\):IY$(7$TC6#1U) /#9S6V M 5[J+NWUHNH7;'#HOB^Q_?/>J]#@J\82"^>__P F?3NC293%J8X7X;45&7BW M+:R=\_0 -OOQ ([3X2/$C-)"#1A&M5H/SVB=("]?1* M;3RR.96NZ4DF4L(AI+,G?<,-@.;3193GS6JMCJ,3M1?AMM\>%JPB?8 1RA%C M ,M>[Z/JEZJ2*_L-IPL4OFHQRA36(836=C\)GI0&Y1-$3(=D_BW*ZOHFU8'0 MLZH46%WII*IF&"CDJ&:) M*)F3U6]-?112C[*NPUD-Q(JF-$.1?D\L+ -DY!PR H5/G[.&#<^CMDD TU%* M&X!2[A'*DN.NRR?\%*TK>)2^_66-PGR-PC_V*#2TIM'@,'!"7ZF,0./ZYX]I M=DNSU](VI8&'Z1B\*$-_##CF,M4;,'XP$*U)1=HC-I&!-!AH+CZD&5GU0\0^ MQO;&IQI+L^6RBNY8 @K!;/WNG+21!L P8.[WHBEEQ!POK7<;F<7G.V_Q>I[4 MD\W#U0$QDNJHBK"Q#M!V?[BW>XV7CL'N@]8UD6A:76NJ]*Z^%RG\L*+M. 8Q MHF )6V;P(42L*\6F(O6^YS!WVJ4)/2199$Z08GF=PYL M!EZ[D'T$U7GEN$ 0]&L*DLGG#U6 M?;4&-%G]50SH?NJA=4<>5H-5>@RR"I300UE/RL*LM5T%M=!ETW M4ROD%$Z'LNAZ1'LQ_E$U:-79'ZH09BTVGXPKGFAF$TEW.II$S$U']R33T=!# M!+R2-Y IZF&T(MJJZ0AHH6LK9O#GV9D1R*L!#,'LUT;]1X\;L1#&NIU)L#J: M.2+'-=A"AX5WUC:*<>FF6G*ZI']45VSV<'I]#79K6GV=KQ/W]'2_ ],6.6S! M=S.2SJY*V;IN@!O, O,Q6M4569_)ZNUZ#+-UVB#&:_AU\*KTTNO !/2N<"!# M9FZH^J7*9F,<2>*JR^Z8[* MAZ%&Z^5(XD::40X:P*&)KF0HF]TZ>-BLI)5_ M:^>7'9!7UFN'['C(DD_*H'WA$+\0H8#5Z-WQX?8%$>*T)Q["%S MM?( U>W*,]N;8.3G.&EBBE_V,-2WI1$!$/E-H'G%B"",G+@Q MR-]W72LZ1+[7 I<#"+'KQYLY/6/NBT_W!K1[B14VTU M6>04]_L9Y'QYR-;LZ^<^UVMP/G%K%)T<+_S9Q!PK,=J '9!+O.EOMNWJU3:] M%Q(%R"/NC,--(YZ^20Y*V[(U2KQ+4O7OUI]940QBLD3%&<1]?"G4W,.2%4_V MP""S/Z36$E9S=30?6U%9G5F,J;)>HTBS-YAAQ(D#!?[WQ_DJ0,-!XYLK(YI< M.0/ L*4R< B$]YY/Z6)>&OEY92Z7:4'/XGRV2/-E1N_HC^*DE/^[S'&:].?Y M3+W^<$1AHB^@I]04J\D*6J,=M9O^1.K&A+4FF^;DGG4@50\T'SPV-2L^)UA8 M)I<,=,81\ !&XW;G +6E UIYM>]S=W7Z__YQ]?GL_.:VM//_^GIQ]]^[9\IZ MGLVQ,2/S9\??\R*+9H6V ]ONH/18FPZ.4+RMD2N?U))C \]U=[[7.2Z*+/Z^ M+%@>#S.OZS(:2@IRO^J&UO7T#$(#H (C4N-QU5$'@-X,SY._Z(@;8H%]CW!V M_O'B].)NBB9F0?HV1H:,UIGS,:9V7B>M"8ESI/$T)UK M#9K!ES6_MSOK!EE"ZPL)0&W0:0/-&;A< \H21$9Q$E80F0#'&"PZ '%F-8:9 MD=42WWFB6SZP+\K&A%B@A[ MM+E JBN$72KG.>5%+',>723559SPZ;]M%7Y$]J$ T+J;$D&^+,K- M@J],F+UI58N]&^.BDS8/I"/<5+. MHN)H0:X>'N(9SF% MZT\!EBU=8&F MKAY.O/]:A#%XFIX'XSGAYN!9=2I]G!!O;I@2*NS=(^ <8[ZG\IVK4"0T M$P6.W7D]OS__IZ?GE'SG\K_[R=GEV9,K259:%B M:E5^C:*Y@J>A7NC!JM#B-\J>/B_2/B^0AS9ZC(DX39=!FU+N' M'0' RTA4*8;I"=4"G-]91NR%A+0EK2EIM$0:$9H;$P:N-)?8AK#4*#]4( M3=G1Q%]?-IA-UXL"U]>?S[^4\YGCS^3LXO;T\]7MUYMS&.W?/5PT4RCU_C^3):?(N+IQNZ MJ#3,G^*7N_0\*1_,FW0"93G*EELS'@6$$RQUAW%SYL+5U& ZYE'[&K/B^BJR M^9JMB?5H89BM;I.#X6A]DAAJ] &I0I+J*FVK@CU@FJM4#T<0UDYQY?<\JGYF MA8,V%U"EM\K?K1IO&JFMW#X:V FTCF)6)I5I1P9<[__,<+37+1 MDHE6GVW$R/O ($='+R $*41I($DZPE%]F43)G'0:D*8%$EQI64(?7P8&U,.9 MK"\';Z'MSLG$3"UQH &R25C=8+J&IIQ%09I:V!E3*>#JX9B5LGVL)G>R,$C6 M=IO4^6UA0"73 XC$!2(TL,/M>53M&9514.M"Q>"7:?(N:OU66DJ2E]-H%B[C MBI.D+[\/+PU;Z8&*UX<#)BW3\@>AKTE&9^EC$O^3SN^B'R]4+RG68[<].%NY;5:E( M?RQM8L!C_#X=DT0#8!0P)W;ZQ&)B$B=D.4IWYM3J;5V?$[L/ZR;S<@)UGA?Q MCK_7W?]:_E#XF7<2S-W+?_!_= M21C!J^S#2?;*>VCI-.; P;UIN"'RO@A3&ZGF$UM6,F9+4#.GD2T$Y;YO]6>[ MI$>SN6VVF&^K#8AU<^7"\-[VT&J3[O8X:OZ)[)0L_TWUS%GV0K=MN=.V;\K. MW[L34NM+,#0 1FG-#_D$;$#):"96$);/:/SX5-#Y\2O-HD=ZN60:73U4WP6Z M6A9Y$27S.'D\B?)X=IS,S^+%LFPM(KY!@VTSI.5@,) :="= G&NK@P8V[88^ M6O4C34=2]V212O.5^U;O U+UK_:IFA&0('Z8F?:I <+L>PQB-2B':L8'(SD?["_'OYW?''\Z)Z=77[Y< M79+;?QS?G-^2JZ]WMW=E^XO+3WLT\6P&)9XV/K[]TCZ7?RM_7/U4_O$]RNG1 M_P=02P,$% @ ^W6M2*+>(7.)> ITP) !4 !V<&EG+3(P,38P,S,Q M7W!R92YX;6SMO>MS[+:U)_K]5MW_P=?S]=K>VTYRXE/)3+5>/IK1EC22'$_N MEQ3%1K<8LXD.R=:6\M=?@&QV\X''PH,$0'75.8ZM!M:+O[7P6ECXR_]XVZ3? MO**\2'#VUV\_?__IVV]0%N-EDJW_^NVN^"XJXB3Y]INBC+)EE.(,_?7;=U1\ M^S_^^__]?_WE__GNN_,<125:?O/\_LTCBGOOF*DE)Y^*;FYOS__>;>_P5 MY?7OUP_7C]^<1_DSSK[[CG8GS7[_3_J/YZA WQ YLJ+ZS[]^^U*6V__\X8>O M7[]^__:,C MZ530^/_<$$&.+?M"?_VI:OKYYY]__J'Z]="T6+(:$IJ??_@_7VX>XQ>TB8Z- M$WGC[UIR%\E_%M4?;W _O"K0D M(E<4ROEN+".M66@72U( ML-GJFZ'J:T4& Q$L>5(1;?6E:+K;DF3YV4P4VM^:+(:BV).D-).DM">)F2!6 MY(@S?2FJOA9DR+:%/CKJSC8L$19:EP7;& MD8 E:5"9YV;B["E8D<=$$ELR&(A@20(3$>S(@%-M$6A7*Q(4.(MQ:N K;1)6 M)#(1Q98,^MBH^EJ001\:=I!A\!DL?85JJ:)OAJ:[G96PR4+8>$\\*>(4%[L< M?;5W#Y,%*J,DU9)5G8<%N^9; M@Z&H[FQ!BFB;ZZ]@Z\XV5DK(8*\66=JG108BP"5HG]K^7+//T)J>RM]$SPC@ M\2Q::9YW2-'SWY_I^>_G/U52=CF8B_J$\@*-+V^;35OH;8X*E)75.=8-^4-' M!O16HFQY/)>B?%1.N2L^#:<4QQWB*3VJQSD$%?^X_->.'KD5Q8X>^"_>DD-L M2JE*=3]!JS(IJ>3<5C^,).D%WD1))I>UVXXO;=.N*V_[&R[RKNQ1?CC1(_\Z M^(#=Q(=]BQ^V44[H?1>_),?1>Y7CC=S.&*[>?4OJ;_[S&P[E;TK,^JFAB/,E MRO_Z+0E;Q @KE.=[SQ0H66F8MCU!Z;NW$VY64?%<$=X5WZVC:$L8?/[C#R@M MB^8O%"%__.[3YWWVR'_;__D?BZ]1OGPB7!A8%K;9&X_3QID^CR\$,F<1G:53X8\:9,O[-,INHPW;;:9@U;/N.*R< M.:\86'A2$_>\GRD:]?UQ19H^?/"&C;?XA6IRM_HMHCJ5!9'V A'-EA?):[(D MP_ 7M'E&.7,L4>W<&6#@G7T:=7J@PH:FD ]&-!')BJ&DCA$MXCXX]^(*.1_V[U@(HR3V*R;*A" MJ@ @T#YMG,C[! 71<6542.GOP?/G_P SV*;)^G35_ST@G=%E"V?7LC2$*&L MT8,/(;6>;2!!>P8 )RTC*(,*RF4/K1_]@-:7Z)TA1CS9!4&WS:I ) HQTS*<-3F^T>KS_Y@=?_O8N(X/E=AK3BH4;W-BZ5 MN@> 17US*.-/B97NTG&BX?IG] H"7A@',AUTFCSV@/GW_ MXR=/!MX+%%>R$='_/Y1CXA?D_^[SY#4JT7T:Q9+!5J-[&V)*W0- FKXYE &G MQ.J .Y]"V56R*E\&+@/'GC:109!3(Q( #DU-HQ?^U!@>8Z%'F.1&\+M5K;_N M,,ON#Q]N^_U# :&>02P/OWU>K6'8DX!(ED5D#82IX,KS.]6^O14NL&\ @-,T MA,X:%LCG"#1_<$8DS'(#>XM=*LNJ\]K!..N@ V:+3 M)-$&G3*) +!G9A9E""JS.R#1DP-7EM3 >*?8E;.O$GRTTS.#R7X*,-9YS+:<5(]>VP! U34)-&C1[ <>/)8Y_ MKZ6[V.5)MKY'>8+W:535CWL_)#/()C7O\@WE52T1%G2L$&P#S)!@"#"T:3-U ML!IR;P+S?_@1F#G:5-YH$<]*] !P!M(+&,TZ%K,&9B#S!LM_]@/+>PD/D^9: M%Q9*Q2W;^..U# %9("W5,<,CVZ3,>;+W>SR-.\>;# M$*&)#U3H9\'&$DEVYKHFR1" :-=NZH@UYM\$.N5YJ&_0KF:.;:;DIX=T(T(3N3W[@>Z]N5I1Y52&['F&H1HVJ3_CR;9ODG=K;C&T$10J, M_04PA1"0:F05=5RJLFNBK">G>MV]M]L=W5B[6_V:)66QV)4O.$_^S5X#*77D M5V;@=@P(:DHVT$:8C,L>6)Z,WFRAF^45<1(J/QQ7G(YR7 TZAHLKL0ULX6K MQ:_[DB24D@496J0I_DK%OL+Y(0MVL2;_N$+LJ9]2Q^Z9':AC$+C2L($&KF!< M/#N\V9>^N%O!X 1HW@:1L'D(T('KJPX8(>T&)I[DGNS#XQ/*-X(]M_;/C(VV M^N<0/CM?'^TMM9I64]Q#^;/:+R'3&0;WB\MJR7B<70VVC>4S%T5"_)D,F% ( M>+)A(].9#IBK7U=5597@[X*943)!:D@[7E:L-#Y6>[M;GES\$J\M='86^'WA MB\!Y["](+6%[*4]!F8W.;AZW<+%E4A_6Y#J\?"KD%-NU.^H@UVB& =R1+:J256!.D.9GR),6DG:FXKV3=# 6R MQ%!.X7 M>P9V]AQ\1K90@J(JIR9^*2\^C#.8[4#S/(V*XC#?O05W.=)W"I7 MN_^U^,Q!JA&M'G U:06"8QN6TH*U)N-F.VCJ)?:(&#],RP^U L^C-$7+L_>^ M_BIH5Z<*P;T*U9 ]0-MZ]GQ!101'-21'=(J[75F44;9,LK4*ZAG=(+#N= L9 MMWS][0&SPZ-!WM3[\W:@=X&>RW._/)DV7VZV*7Y'Z!'EKV32Q%XDW%(S%,0,U=9' M\83+*&W_?HZ+\A:7?T?E XKQ.J/;S$=*=:>[\@7E3R]1MK^HP_$&Y_+T',NA M/('XJ"]?3,O='0K?[ 0IS[H\B1R';:X%,>^FUHKN)M#7&OZ&4V*9E-C^(2IY M^T'J!'J^J4(@$&?2MHD6^E6X-3.U,#D[1^2ZGWVN1+8EO MQ_5_<%"JT+,'3U#/0'"I;@4M0(+8-%,NY?-K3P+G_ABIN,+Y#5I'Z2,JB<6J M/W$P".C1PYZP1R"8@VNMA34A^09C86Z)W.;MK8S/D/5JZD@, _&9R6RN MY6=C2N>JU-U$SQ@+'YG]&YFU'?)9A>YHF87JL\5*+$)RN7'LJN]DUN1ILJ+# MG(MIVZ)_*7VPA?1+=8IWS4Y8=,7>ECLJLY^[JYI]CVG=6%G69G/I@XV<\/VW M+]%;LMGUKRNZ$\"6FVL(,'='-_TFT[JZAK2-LT]]8R <9T\RQ\[>%<"!LS<" MG)Q=_$V\=?9&VL;9I[YLYGKR?J@6=<$_ +5,W=K4NT=][CXHM.;$$^>>*$V. MP&E>7#PDQ>]7.4+-$>'$LV( ^S&'22'[N3NHV?=P/T0*96U5IW%(G53$VG?[,CE.%UNG4H@/WDP^M'7H/" MOX>GPVMO_?F',"^8V(U[DXRLDPRJ\W=*_PYUQ$11_(\1>Z671+,_8/XJM[7<.+$8%&;X5/YO84YSI&_H/(% M+W\M!B7O)N(VY@RXS6WN_JID;??SV[9HC3]^L.,4T<'31?*:+%&V%-PTFXSO M%">E7;X?T5& 9[E[G:IM,*)6]3>1GXC:LS#/;A\2?@$:ZV.137R/JS!+ MD(A>L+]%7ZM?N,DO*GW[<(/U#05Z&I;0@R&,41/J9H7)V@4U0YZE5&Z>IYJI/1!H[-N60U7U7*22+ L*B+:AV M:&M?&K3^UF05:1M7JH-O&U6#!X/X30?O_[":AH,*F+:ZN.!2UZ[ JX^,$0N7 M,Z $;@\I51X0J%3U-@CD A:ZM?%=H^N!;MT(T#3XO8>>UN]!H86GEP$Z6B2U M7[)V#@>4TD> [J.\?'\B("^BN-H<> ML\IW2%U#]I%8IMI\KBU!=Z9QANA;IGR4@OH,MB*$?8+"HHK^!O"3L-%]=-LU MXIZH8>Y6U]F2)NWLHE2 -&';'L(X;8-"%D1? T1QR.L^+CO%JN\";Z(D Z[[ MNHTE*[^FL6. 2-9S@G4?4ULF.M@\1*N^AK;V(>,4V+C+T!=$'^ "PF/07H*0 M5GOO0-+[^ *8\+0&(J5F),)*BX'7<'GZBI7@,F@O@4NK?#4["I3[\,E.-!.-**VG'PX,/( M:H@'X+"JB0?&F!K:^2C\($)V:@%9%TFY20\N^BNDT$:BPZ-\--6EOK',]%EP M>]Z;CL/V]F(.@XEP+(*T;\<@<7OGOB+_)EA=<8ZG<'D=DPJ$/%RE*\.1(QRU M(.TER/%I%#-"CN)8IH4<&ZM$+[(_>YOWPKF^L&T_OK+;VO.0XP-9==KCW8HP MV^"L^DB+;+D?#@NR,,.[]4O_%2V^*UDEW/8Y2X3=.Z<0!GA$,_(\F"70P7LM M">+-0D:HCUVTVX7X!\"U6S##$&QGZ35U%I-P\L]HP-]S@0J*2(@RXE MJV.S*[OQ-I'XP4UDL_XF48=*J)M"[;PVX4J%WU"0D.@\X\(@F9"3BJBRUPCG MRDM"]"\KXYS(OTO+2#0#YK5ISVN';;P""6>J*M$,@(/>['-(T.ZG=F!&:=6# M0OA.:77Q*UN2N79V&VW0\$.H[D]S/LH88K;=6"!>J).L!U24>4++-E5*B1<0 MHK:#(8/9]L,@&6(K1RCFB!;J=&>_,R5$+K--#[&]-A\&J2+;.$)H3R2K%\M< M?$G050.L=H3 ^S0B7IVQC,W#P:S48H&.%YP2\8M:MUMX VDU2$5$%Q!@HLY$;]C/J"(3ZBCS^ VQF])^5(M#NBJ\"79/N'+ MC)A/O!+7I"*[/".CXNX\]0W%NS)Y)=*NDACEXJ058>/^B2JGL7.GU/W$6-$0 M'!]59-\9*3AL=5V6?Z+OPV?AC(4%[L<52D'!WOL=XO/<5$6E36>6]8H)(L4.T1[+F1*U%U$.ZPB]*'' M*J8W&OU^[+)'WWG LH1,/+[U.6'-3(%.'+0G>*C!KPGB@JD3JTG//[I-G"LC MG/* )BO>33.8'P$#M>(X4IMFVRW<#^R\JP/U%E06$V7(TI;*2;C]67!W -*A MU&A;FJ9+J%<5]1_HS=(_]PYP#EKTF,V,K>XNP5%<06E;F*)UQ& M:?MW>I!QB\N_H_(!Q7B=)?\F!JXJ\EWA?/\GVNXS+P7+B1"\8D03"3%3CW;Z M+2>)#%-KN(\P?PYR9!W-6*U+4KQME$EY3Q5-NKQ/0<3:EPL[=G05"_M]7CNK MX\5KE*1TAXP$U&J58GNS%W5+"?O9!".Z\G[]<[C>SB^ML7]>?SH"NLS)/ MLB*)J_U'VQZNP=J6TRNQ/L4!6]_-[]"@I)>KNLD6P\7^,.L^3ZK'/*J_B7Q< MU)[EF.SV<_8F@(6FL7T/]:G>^NG>^NG>^L:B\>YW%O?DN$]3\KWOW[[J1W? M3O?13_?119 ZW4<_W4>WH,!(]]%!06UNUTP\O3OGVP!C;[%_NF'E"_2MFSZT M&U8L)_O1M9,]RW5Z[NMTN RP*(K=ICFPV"*ZZ?2$\@TOW7=\ABRG'(FA>V<= M[PAABF\TW1G$2-JPW'GJRU>.1]NFE *9)^ZJ>'I7OJ#\Z27*]L>859+2X0SS M-T0?1T;+Q2O*HS6J?KP@$]"#L6T/VF/)9VOLMR_?G*.2'Q8.*)? OO*LF/?G M3Y^4\P\\N02E;5G1\'!!2^JB;/E 3&<[H*GRM16HX'Q/ $B*WZ]R MA*XSHALJRJEBAHCOF!&#S?<4+ZQ\L?"B!5LISM'%1XH5?FRV^+&EK-TJ6 M5FHM0UF&E[K5O5Y.L]RZNEE/W0(SM)6Z!6#H+"1.Z@@VDKI4OUXOSDZAKY5T M+X">'_,88F^8O]5EZ;+E(0<.TS^U[,7Y2B-M,AK+8WF[T4">CQF,//CV/L0J M-V;XF,FJ>[O=[:R5EF$8)>Y+6 #E?YQI/6O@226%\9: MDH0]?8PY!TJ;=@I_X6]G<]=QH/0G(IY"GXO0=XIQ-@P2](',J8+:J8(:IX;7 M"/2=YP"=*JB-44'-2J7;N9:;$N4S.JRTYB '[%22[522[522C2E\,X<,^ $5 M.^=^O6EW\_Q,]6[' T[3%_P'"R(OY^?ZTN\1X9$.EO/CS<1 MPEKFO)X0[D<%=PYG)7'?PK>W?;=4VS)V[@WH623\#5T38[5>M'$9P33%L!W# ME,4X13$?OO\\XYBR391K@_U<1[*LRI%;!A_++M^V25YU_#S5KGS3+&:Y8.ZESL1,-CLN"=UP:NI;ETPF(VW,NPPF[-#C?UM0AMQ M.IIH7X3TPM%/+R?II*8<[\+.^^6DL+%MZO'=S*-?X)[3OY[ MHMDH,]H[@JPO-?Z69$O%\=X/W*OVP3/J!@G3HV7/<3E9SY1C<#H% (M?*M@ MP%1-^0Y 8/>9U.]_C10"!)PLAP FIU,(L/BE@@T!3-7F?J41GN![NQ,LC4?C M,UZN?,/GY/S6OE*PKL]0[)2Q+DQO'34:J+*?/ O]%#NF^J;!AA2XOJ=<\/I# MC!I2N'S&.R([!0GK7RG8:,!0[)1E[[G.A6;YI4EBA:)ZJ'@GC<[4-M0GT'UB#TD3S4U,[N'%!#)NOU^_S&S3<]!>&W_G+@;I+]8J(0$R;6R5/!*Q5*^__7;3TY>(1 ]Z?LLC__/G/A_B[/7 M:KM$KX*Y4QD&C_I.*H,_SS(?9#>Z0^N#*#:?:=86Q8/WV5PXDZU;9W8@P'VA M;4+36+NHIFT2UJ#S)^5!Q\*VU2ER0:^&GV+7QXM=LMVR4_0RF#);V74;>_;< MS6,2?Z-1I] Z@HPRCU83Y!2WG']^_V+6] 9A12R;U0)\BE55VK7[2*4@QIAQ M"B3&*4HY_O2SCE$@<[ BE,W*.3Y%J+])/\L4 0HNQ9CQ"2+%*3RY_?"SCDX0 M:[""TUPKD9R><9G),R[.@Y?[#^Y+X')B"5;0FKQ6U\2GNX=2>8L-SLODWQ59 M5BW *8YYP<),<=X+$";@S^O%9_7B<\YUP($[D_5IL^;WGW+PD5K'_O09;A4[ MQR5>S)XODB).<;'+T=VJ;;\'E-+\SG-[L6P/*FDS!F;1N,S-C#.7AW%[\K^X0':6S&$QR=]1D[C\H3.L#( M)V3";RJZJ]F,?A/6U-CSZ\K ZD/W/,^U8,.T \.%"RK1?SVD<&5U5;S*I M3^'CP$U<#. 40'P/($I% N890ARE,_L11/XV7001L;(=1>0!JVYXM\'#8"0Z7%!*$#J] ML3++@#+J5_,G>-A6TXN$.,_F++TLCLIN%R007D5)SGR>>:SIB[(@8\UD% 3Q MY[".?<5F*/L8YW6JO&T>V<%YSV>\4/<46Z=XFE]Z[!$%;!!K!WMP0WAQK M*2;F'?\TK.-%O3H?3W2-PM_T4HQZ$GP*=$J!SMG7]S>Z36D2.Z?/A/XSY@0U M%_"V?IVWA=KZ5_;C/SQ,V9*G#96>'#.ZOJN#_YLD0] *>2^"I%EH+ M%X$ 3BL[JB(P*NRFU&KN@UPEBMK)CPX*<@I9>;!!RDGD/^K0?$?Z" M&,_10YNW4V:%S?WW(Y-G4[&RQ73QKR'E8>P72C=6Z'3^F/37Z/22M/L:[7(G M.KTD;3GBL8'U$5^2;L*9'V]'ZTQO+O^U(['Y.B.SC%UEAKOR!>5/+U&V#^.\ MY=@YSJJ)"0F1H&KC/@EGY7U/^\*% (?6BY'[O2&ZJTE@ZKI?O@=:\\NC$\H&A+]LK+Y$[;36[?)J_9CC3VUX4(* MX2%%[%. #BU G^*Q$V,V%_+F'GZK35_^N9?;>*LIW#0!5EFX4T2=.J*:X>>C MAU!EZS7G0C./F:VAQ)JCZ(/'3RT#ZN[I!Q9".15] M_(B?NL)-,^U4%NX4.:>>=IKAYX.'377K-?F_'^NZHLH.B&:8]5I&6[=5QI'Q M%'3M7XZ< $W>QUY/C=CDO0<9@D^/#)\>&1Y<\SL],BQ!YNF1X8[@TR?C.2X< M)!U(%NMU7CWR<$U&BR0KDGC4 N>VY+%5-LA<'A_*G0_69OS4EJX:W!T;-V+8 M*8)N((;SL._>LT**:8FLG"/U< T'A[;639!5^//4\4F#MNQ8]& M[2GVC!I[Q)_Y0\6:@2G"WYN=\ANU]EY\F1XS1'(]0^Z(=(IM5B[ VX>'CW'/ M#S/9/^.?6V$M3RO1!;W'HW-8<'.J/>>KBU@W?6BUYW1GEL$ZHWSL62X3^B]1 M>MPAEQU3.99FLD-\B30AI,SQ#V8[=?*Q4.Z'",?N-^FE-@6 MV*ZC96:N::^KBRW8PFM+IXBG(-3@S1T_Q#K%/']BGM*S3*>HI[/RMO)" MDYL[N;RW#AR&/G6Y)KR)"Y3K%/Z\^AP?._ZI6,K#4_I1;-*H[6'\TQ)MJEMA M2J*=HJ!O7^1C!T)%8SG**I@\%AZ>\#N/LABEJ?B%C&F#H9YLTT1#5=E.X="[ M3_*QXZ&JM1S=O_*D;(#3*2%8()?E 4[QSH\: *<@IVJBCU*'3Z%HK/L5L+:4 MDRZ&-:0\!4://\Y'CY:Z=MN'T#]_H!#J9<3T,D">XJ$_\? 4_BR8:1_M_B/< M&TT,-#7D\8V<\E6DK'527OZT$4'7^'HQH?*%%@[W5\Z"-/P/865*3_L M!XDEC>ZGR6G71/MS+KJ6F&Y&RF Z_C2TP_1CQA@GG]2' #.5XLIG)3_7T26K M;JP;W SQ-KXT>P,3KG<'+,>/+2V6I\@RT>><>5QIJ:V<6S+[J+)_&&FZF-)C M.'Y$.3 \Q9-)/N7,H\E!:4>7&+R-)%4*3$5FPO4/@^D4R3SCRR M=!17OA8P^YE*ZYLP]W-=L)[TR.]C[^HZ_+PSCSL,]1U6YCC%'P#K0;F%4P2: M5P0:O9Y&,#'(>IV,D.!Z,RAP.'X2G^ZS:./@]&"!"?+RE#6WOP40/#B=UT:> M$H\>*&L_C6=>$!PE4*C4 YT.@"Y4M5^]X 0_P_QCOP&GKIRC9^0MKD-95W7X M#5@KNN"OL,@]98J;(7PH=R]<_!PDUGZ+J 7*+TBP.<%LTT-R)9>;3A+S\,/B3QB]_KWY@_ M=3XR>BM1MCR>^@X^\VN2TY426:JMW[^/\:86X0+'59BGF>A9647^%4IO\KPU^S1Q05 M.$/+ZZ+8#>:+X/8MB$C:AP<5%0.80D;"BP6=SY^GQL[?<+HC.N;O5TE*5CQ< MS'#:#; R:!#%QXK)FPFG+O6TE4@/B?#XAKG[URT,%L-0-)K%2HV1,K:@42/ PL) M/T\-A/O=_A?B#PR<=L/Y0[]= MJ( 0*VQIQM#GP8+$'R:'!-YL@TQ LPD[!(@=N"DLP M$C)DCCH3@JK1Y[AE=T7^PEJP2%HR-L<&+##:<@'2:1LZ1/B*VP5)AP\+)G^:'B;T_%: C/;/###4/X?[_1GJV?KD-6GV M!I?;<^SJX+GX%^GG*LVCG5U ;'J+L^CXER?R;P4Q*$W=$R:":%+II8HH4[%7 M,>YRLTUQG4^QSE'%D*DPK''[4%_0V'DNC.YGPXJ&X.2[*+(_Y.P+V#I*[^.@ MZIS(ODOI=BD 5=+&;50)&@>/*J@A+*-*P-;1JVIV(OQY&A7%W6J?_'67/]!K M*=V\M5XT!_3H16YA#WO^=!>7F'P0JNB>5?&$K[-75! *[!%*N5_;RV#]G#L< MY'MA?5-P_$S ]>!3,&Y6$A%]\:S%6\*K6")M#_&JNKV?F.OH@G4"B@K6*+=V M>JN02Z@8NT#/Y?%:@P!<_(8]5+$:>J+>,*-:J"0C 5ND:KNY<_\1?"ZLK"_' M:X8\VN["I]U:'$_E+/(!_]>L0/&.2')/[)@4!<[?;W&)8*,^K#-GZ)=U]@Q+ M[&L)1A8!X:M[YT"5W_3QF0.YQ39/TLOJZC;*Z,^ I1NT3QM@\C[AX$I1?UTX MR=GX]?QU)>_35R+?^U7RBE3 !.HU@).D5V" 4K&!$:0DC!R59N2 ZDND B9Y MZS:(1*W# 0]89UW0B!@X>F_:SFS\@6Z3"3?Z&2UZ<^Y."V>:?(G>DLUN(]2% MV::G3:^--CXD5=.=Y%YAKQ_T8W+S9*CE_ M2=#J\@W%NY),A^]6JR1&^2);GN$H7]ZM+I(OPT]% M4R6 20@'O>QXW#T7Z%\[8HO+UWT6HF"*(6G=@Q&WM4_:"N<0TO9RC;V94A>;%4*QB\;P;EFCL4';T9RZL6UCUM/U0ZO@G0+!V3J5M#%%XA3 RV+Q;==YT(V;V56]5 //Q;[7XO/G.';B!8D MAU).*P@4V[27!K0-V0=='9>I<_W6R-WJD68ZD2$$%>=1FJ+EV7M??17@JU.% MN( *U?"=0=N&MMU"11#=QQBVN$CH3IUK'^G.JLZ)?N_T<@UK$JS219CCV^\2 M%'05M#? I9A+,PM1?JS-B[#U+5%(G>Z?U,B]0$>=)]58 "'N2OD(0)0E#8U;>- 7B5F!X*1@:)WB]) M5I66:3RT.L,N7I+M4<6S]_OJD_+33U4I#)-3X12"0J^^;0S0J\2T0>_4)U%V MT+O/Z"G:CPYQ8"IJVL,CNVE0P -H:X P-O504VRU'RV]BI*\?H6T*':;^IG( MR[TS(+EC-98A.=^XUC7U.&L217T+OTH0JCZOF4AYA4!QOQ"8\8!RW+KEML()1KPK,5:>3PDQ>]7.4+MK7_; MP[XJ7UOC/9SOO-S<\G=P,<+#13T\R1'F3)Z^.E(]FKF\V.6'!4K]#DGU8R_$ M<>?DVH3ZWJ9!*"SW,;64B3]H\-:]H>C+:-4U2\%YUA[:7'RQJK#VB+V]:XK1 M<\H=405-)9<3ZZ:^.=[P2RB5Q+A\!EOKE!BPFP'A@Z8X;RM+<&1?&@8:F;*3)ZS5YW?49 MTV<]MK"TH+:F:5ET=6<1H=F45UQ+TY0M+-LW;HJY;3<#U7)0BY&[5VK41%)D1MNW-13EM@\$1 M1%=-$'%(ZUX>\,5#Q19KF=;LN3^.T9G&$+5KUX)@M[-7V:)-_R(IXA07NQP]$7.>$3*_RT07=.%I MP>SB]CU5X]ZZJZ2+-MMCH/LG*0_!B_H.4N);&M M;4K6QB.T>1O!PN;CN.-@1L9S0M[43=30K<-!C,_R.^ D5<:#Z70MVBQ7^S', M"U\>%$?T%%Q&JTP(PJ0,Q"]ENZBV$A4O9,9'_X(TB1,DR_Z3=^B-2J(.]OS\EM8*(Y/&LUU!5B-% M4?%Z%SHYL$O;PZ5=G(^U@,^#M?3GC+E\?@<_E_)A>K4?M;5OT=>6ACG.R+_6 MQ<"+6US^'96+)8E.:%GK! &=#8(=2)H1# JP%FUG &%2:+[5>4 MEPE9:U?OLM]'[W3=#8"U6L_.6UW GB$!5H+.E0+';$Z%C$"+) A"Z^!OC"#-T3J%Y05 MR2NZSF*\02IA5K5['[7@[J$!5\\N9M@%\V3!-\R[Y-5I9D9,02U&+\O7E7'I MOW$1*^TQ *F@1W"XA&IO"$4!&Q;ZPIRA7NPE/G^)\C4"CO*P3H,"\.).@<%0 MR09&2)1Q8JZ7PIQZ7D9Y1JQ1W*.\*JX @R.P5P^/TEZ! 5+-"D:(E+)B0C+, M!]T.)6WN5E=)%F7T*?)6";M:=0XPE?KVX GL&QA(=2QB!%4@0Q9@PRSC>X5S ME*RS\QT1.XL[5W/)JK#ZS[0R)7"L-Z;7Q[4^O="P;LER9OC7%X+E$V&^_E:O M))^B-QCD9UL4!2H+,O(D);I) M7IL38"[P@/T&")3V"PZ*:I8PQ*24V5A)9@[ *8H6YEW!/5:D+-3Z@F):M2E9)7 -E^<]=4;TV)G_]59=,#^?J9 +# MN:&=C'"NSIN)\S#/#XA?;U%>OM.$Z9+,Z>FAW[9Z%G*S)8M?^F]<:(-[#M , MZ!D<@%6M88A9 #OFM"/,%XZY^L*F&ZK=H8 -?7JA:9=QH N:3H2Y#?Q [$6^ M(:$$] \.KNC6,H IBQXRR8>;"/! ELQTB MLR"\)HM88C)8> 7W&T!4VB\X@*I9PA">4F9,<(8Y4WU$:^I]#VB+<]5D6*6^ M_3O0L+Z! 57'(D9@!3)D+JW"G+.RWT&IWWH@(\IUE2&4O*+JKJIP$F! "?2L MCH12:- VMI89T'78,^-TF,=ECV64E[]N%S%1D@Q*J*#W-,3PEO<8O%!^+=#=ZK(HDTU4(E[A-W:C'LCZC0+#E5!'(RCU*;/08^$2 MH.L2"LO/IQH*4+5YE]UWM!;.W>H+(JMHNMVSSE%]@O1;4K[\DJQH\;;E?8Y? M$X*:X@E?H&V*R7PP?LEPBM?O=]G3"TKRW]!SD0S=>50>G2OQUGD$$DRFL+#! MQ7GK@OF0FJ_E2\U?Q_ A==IPWU&A/1^?T;;H6+ZB(I /V:Y:/D+?E,G&&6:4 M2<,]1('T?!Q$UYYC^8>"/#XDO@+=H_B5UE$XZG*=T;0U,KV'.("TLPCB@LXA M@QAJ$WLP%7"$;;QG$;\\'>U2[/$EHTG%CC M*GFC_U8(X2?OT*],(.@0*@C!1K"#0Q&[^13(O$%1@5YPNKS>;'/\6N\Q"[$( MZ-$#H[!'J&B$F\$.'(7\1LIY\6DZ><-YD%6](W0R><-[L'72DG;D&\9))+C4 MRVHR*%?7;N*OQPT_%0;IJ>IA-ZP'';OT/X!'_5J@U2Z]25:\S1:%GE"?:O<, M%(?J5K$"3Q#;^4R1N>HVF9[+1N]7;EZM%@THDMDTYH9I@*7&13=;@/G,OQ^B M;(V$\VU&B_ZI2[N%,TV^1&_)9K<1ZL)LT].FU\:Y1['LCV$J<5RC1;'M SU* M\\'XER23(X/5IH^,;AOOD2%021$974KS&>4K?06')H/?69&/=0#B"@V\37U^ M$!KW$,#Q4"-'MI,S]]+]#WXFW73/&Y6KRM MK/_3&7PH7@BV^#U:+$::]#B_O'>ZNP=5F_?.>3T%>D+YY@E?9W%.M\/WQ=!_ M)=\F3\LF\SB)H[0N?MI3T9Q0YS5T/4+.@X%"0KD-6^DGEVMR]^N!Y?VBS@)N M30AU<*M'*"C<6K"5 6[UN,]GM"M/HYTGF^7:E2BU:U"&6X-*V1;CU)V4E4L+ M/SRX3/*;K%)2KNHW>Z%_&$'TMB/II<153GQ 1] NW)MR(!>^L0$..+ MI(A33._ \<*"%5K*!F'2?D*;MSU&V-Q>P#B0OLO8^0F25FV16:WH& T=[K T#U=3J_71;$[ M3K3:XX&D:7M0X#9U#G[9!\!*RG(<@,/D,#APB3=.,'T%" X\CN)%68R:DE"_ M9DE9+';E"\Z3?[/!HM2Q#1U@QV" I&,(35@!6;EZZT 6@>Y17E6T/\>;#8!+*81 MQ@!6PZ@!UM27]#C >HQ2=)_C&*%E\41:%G0/C04E8<,V>#@-@X$+1%%-@'!( M-S,E3V+-;U&>1_2 -V?&%,;/[<_?^3F8C\Y72O-3=P@ZNI?+W?9MB]XD_BSB M."?S]NN,,$4%_7.Z6R;9FL:PI'K,]PHA9L%'NT2[6\C&1(-!H&T#:N+6@ABN MWLSEE6]NGQ.]1.4Y)E9)LJ*2O2#6(:(3A7943!:R=?IWBC@K]0\&KP9FT82F M&L=FGA7F5Q4I!Y9Q*CPX_%_M?BL_CX0X\6^X1$E59(&+5A+GT@:W)W] K) MB&!O]@D?$1D&ZO?ZHC1%R[/WOOHJL%>G"G$ %:K!NX*V"2T[A8H\(<&8'N-$4)->2/Y@RVSZ MGF @03.+#G.,Z-J&L:$E;R@\Q0YGDPNLJ!G*^J0;^(0YG^[MA>S/(B^B$HE" MI*2'$%"]'N$B2Z2Z+8CU> 1=8*:KV9>HI+.3=ZH9"&FL#D*@=3N$BS.!XK9@ MUF7AZ'73,5!V'[TWD1J6XL7J($19MT.X*!,H;@ME71;-N!GFPW-=S:ZBF'UN M!&TNA%B[>;@ XRIM"UYM!H&_0=<_H:J/I!Y(='XL:0'.>Y3'U&1KV- )(2"> MLPD)A(M)!<-8F]$)6>J^"NL);JG^=ZMS(G5"W3%)R9RB4@I8] #);A@0VN:KZP&+2;G9B/H5Z&J8TY)*[3.Y9YH6N. M(5^S1:,\@GKAE]1RQQHLDMIEXL:,G1=68P^>"7]\P7FU?4MEA#T-SN_"?0Z< MU<4+CQ9\0N;SWU+=!5XYY,5^[IO%8QY7\P5/4? ;"GJVF[NA>]P/A=W9Y:K+V@DZS_6P:?M38V?_[E+WREP#H5HV"^_@MJVKV;P MVWJ&"\87QVKZ@J!Q9'.X=,$G/WT%(%X%J-UZ5Y0=(06%H&2-._6@^(W# 0A4 M8UV$".A;?8_$Z)8SVI9-F2L(2B#M.W>>A>W#P8J"WKIP$;/0S;GVY04;L*7A MQ11U#2WDX,_0'F6[*']_^DJ$>[\EB^SRA;YCCY[SZL\O2;ZDG0 ^:T:I,RW0 MI!0.^JS82GM*HRVNDE6)4$84J#0A_ZH&5Z7^#) "^P<'31V[ M& (2R-+1K3E>8:#&;2IO4HF7:CT[Y8& /<,!G98M=.$&9>8HU9BWRB*B+:L4 M57Q/C)P4!<[?Z?$O9%&NW+FS"H-W#@=QNA;17J7!^3E*5>+@[@LQ_LLCBG$& M#6RP'MVGQL0]PH&5DNZZ6)(QT4TB&A% 5WB7ER\J )+V& !(T",P $%U-P*0 M@(EV M&8"*IGAXH@ G0:XDC8*30HP2U@AB8A'U;^EM M--%3].+&@X,Q=F,/5 6< ?*;DZ^+V4@ M?/B V:8'F5X;C[#"CK@0W:00Z097#LE0D5&]WB[$!:-%#Q6=%LXTV1>I%NK" M;-/3IM?&.<99]L6%H.!U:8/AFX;[\$@4$D1 M#%U*09>1J%043 X'O[/B&VL*Z H O D1/U2+/GY_ZM.A8G5<<(F;\Y+(6$]W#O'E8F^&"5@U=T[>:H16$C0%+7V,[LWE8374*P-:\ MD<30O"VRNN>LKM<9704)-\%X+&P[N!'$;!L<FEXX)P_+E_'>?>?;F,6'4).\0MS(K^;F+TFVR7K]_'^/-_CO3\_(X+G"\^M;92RG+?^Z* MJHQ-\80?:%)*G*3H%M%'BO &W>""_/T\*E[N<_R:+&FI=WK'^CJ[VZ*<6"-; M+V*RG*MJP4NN*H_)JO]BRRBL1GB/\BCHW6I?/'R1+9N"XLR\4[6NS'MNZ4QC_.KM\BU_H5L45SA]1_IK$ MB.IQ2<,HK;%_?&Y%Z 'F9#D/E>N3_6">8^T+./4J$RUTEZOC>-S1+%<$%43\ M%4KH)NO=Z@$1[1-:NZB:/;'\2KESVWL4.G\,']&UI@M/4)!5^>#IYQKO&5K3 M@K3CC3&,H5%U^J0Z9_HH4%:PF6^S(]^N 2F-.<:3'^-ISH=#N(95O9^Z^';G MDJI^ERV>HVR)L]I;[\G80 Q%)ED72;'%193>K:Z2-[1<% 5BKP+TJ;2]08?* MQW )8_NZ\ L=H9L-Q*F?E[>]?W=?;N8F3-B;U$ M5=:P7W1>;'!>)O^NC'NW:FH?TE+MQ.R;9,=[SQ#C*$>1B MAGW[K:]@+?_Y2Y2O^>,"I(\$^[T^'Q;W(MMY@OF>B([NGX\!]ZLDBXCQLO4Y M+KB/ED.Z",'>[_)!L2ZTG!=0[TO81/:I:V+9NNQ+A(Z32C?R[RFJ$)8MVSIS M(*_2=7 9&-+UP[B AB4=N0),TL8EPKS-=[EY1DMBFN,U@U^B)*MW!8:_$=MR M_$.;3L]9-.A\&,\QM;$C-](06[T>BZU#,SM>=85SE*RS^H&J^/TIC[*"6(78 MO5']#*U(FZ?HC>-/&A1ZGJ1$XNS%@JB_Q R 99 MRQ&F>;(%77:*V"9'1*<+5/]ORQHW2?1,7QB77ZC2(]*?^"@2\?W^'MGH E5;G]6 +]PK5^D* M\/%A5Y_=G , B8=+S*/NY%TQ9/X]9*^>:NS93C9W2":+8I2\"MZT5^D*GIFU MN\X-OE+SC M?%OL&OO";X+[#]SHK=CG=2']$)3%JM<.C 648&2FL963F!G$E MLXT+=YDH!^@K3,Y\!W\U-!V55-Q48G2$[29U.LX-TA+3C OB(7.=[2+?84ML MN(V2Y>4;W2B'QVAV-RED^]WF!EBA6<:%:Y_U,<;"#SS\ NLM*EFG0(>4TD]T'^7E^SG.7E%>TB2?=H7)GC%,2+0O MP"N3<.[C!I\?6[$;Q_'5Y3I<6U>6)^A75N"&(OJ3N+DC?]O'T&%1'[M$M0,$ MFVC@OC**;:UZCRT)M:\\XC)*7?L3B0K5DFR?[]:DOXFN/$*Z]'/ A%UF@G0% MNXR"8S%_Y>J>?DT VZ/0+L-<14&7N> 4;I=Q<"KD[ZCD MFGV4'C.)[QM%*K^L_PO1';%>AC$ Q_I$!4C7(3I#7S"V[>C>HB.AH_)M]OWI M 6T/ UQ[G4/+K@ \!])=X"/B[C/T!@5[C8Y[L2RAW\%@KM[!J-9 \H= KVO$ M=X\T&9ZPJ]:,,LQS77VB@JE=Q'U"<&.JX6$ C"?>1: (E%MLX:5!0 !F#P+0,^V M:N%&("D@"P L8;._HUX.UJ\B/^U2W+T)2*8R%#^3M^N(W_9TI\E"0&P MSIS4 %GGF3B"EJU& 3Q4D@;8H0ZU SV!)?3 _62 ]K!LWDA8UBN'9QG&W#)W M/X9:YHYC(/5'M/4)P68U"@]@^P-Z[8=Z1GN(7,U/E!_ML2FW_;/78(%A5%!I ME$^N*E&S^6/Q\8XY?DUAS82I/V1?F+ ?I(.;R7Q=KTA4>P0,:UVOZ"96;3N* M[YA*V$P>U4\9?5C7=\9WOG\,VPSAWFXS'_1R-1\+C&V&NCE!GIP WI(Y)+'% M<:&6+0][^]Y]DFTSEWI?%,WS?XMUE&1%V;\Q<(;=#R(J'1KGH%NC?D3\;D6$)Q9BP=X>U3;\;5 -V VL&]6: M.]B0S-'#DO)1X'#9KGK]N%MZ@?GXO&I?3H27] T8R)H&&B-Z2_B[2J'EH/(! MQ6E4%,DJB>OER]WJ?+?9I1%]3:QZ+BFM$7#8"WS"B^6R>A\F2N^):L0?HVU" M%BXLX(Y OHUMJ^0#AO]X9K;F(59%=/5$-B^T,UX9ZVMSU'^0IVM$HQ/JE6D$ MC'E#@]D+_K0X++=?9(C%6LHFH) Q2"ZS@AYHMLQEM]ELM*!BET9$)-W#1]QBN:Q#4 Y>]T+:%ZD"K2N@E:/ MO!6/N^8'J;9('M$2;:K[6 M+#$X?J-!85"^1(%"V+Z@;RR;J%>20KFXL$_P;IWQ\R8XK";]9^ [3<)&H$!= MFQ#KLFEB9)B52A^)2:K'K>Y6-#_X*L5?9>FOD"X#D(FZN-N+(;*0+T[_AVZI MOT8IO6:V*,^C/'\G"*@.BWA;,BI]^SLSL+[.G1'TI;&933B.*6+=V8V!L6P. M])03GK8H3_#R,G-^F79TK/Z#-T)\:+0.K#(I7G]23ANM\4JDR4L_$7M?"=B_ M&:@$7#$)$'IY)&8"8I"%1D$RCW,#:/6IM@_7T2Y7*Q03@S3IW0_$1'<9VP(* M-SQMD>U!WIQL<&Y@V9*&KF$N3>,N%F_3!/ 5C1\Y-/QN.OR;Y(C3EU(JWS?. MEQ+R;[Y4V$4_+'TIXZHNAE\*4IW%8M9:"!]*\U:QZ?>!LVV>Y GS!<['W79; MO^,>I8U%KK,5SCJ.Y M;PFOL#ZGU? =\VXK]TA31 Z&JLP#%XQ?KWY1EX_V-J(GE2^:W$HAG(9-!EAJ M-PD;2%QE;:*HS:19V5F!T%]^&!C]AORA_HWY4^>#H+<299QG^,MRLOW^S0B7M"JDR[!#[C? M\-4N6;\ L*6JO3+2 R"3E%K[J,^H!@EK_3V%MT.K&,Q;Z@#=.F/>,(NGN", M-ZQA+=6%2.NQZHR&0A9!#XJU[O^%4EKQZ#$BFN&2IC;?K9J+T[_D>+>5H$^+ M"',&!B<2$$)-S*.-646F0=\ Z5@#LAJ K +"@]@8".H#1'TFY\.R\92S:@EH M%I-5I0!4R_H+];2BV.7TKM$C*LMZB[0US1!'-*6^@]UH4-]P@*EC#%U@ GD% M77&A6_U2#$1AV^'5+E;;<( &45876!S:NH6UO #2.2V?MZ^M>H$W4<*[;LMO MV!]4&0W=)4B@G&;A="_0?4&;9Y1S] 3TZ"="B'HX]QS!=\,Z6G.<9\BFD]P@ M(A_T#*'6[$P98,(>3(!Q>@0%,(C6!@#CD ]Z"ZCU.ACL7$W>H0>N!OBTV)J=.'[(E^%0]$R+ M=]#3\5Z-2K(LWA=^&UI+X@?TBK*=!'?BQH-R8^S&@>$,I+,1OG@<@CX:;0I2PP*:I'4?6;S6H4$+ MI+49MG@L@M[;!2\^P&N,&2PEQETQ"!8&85:)H(_CUM?YU_01GFK]$Z6PHWFE MOGVDP?J&!CX-BYCA$<;0T8..=B *7Q# 5P%SF/J//-\73?*G?C#7^GBYR.HC MA!><$H4*FN!2OL,WWD'=^6.KI+O3=QZ2ZMTU*N(QKB2#QU45>C!>>.#V\,D# M8=\8Z]A"[I="YOV7';A,YU'GQ>2;@ _++'X2$<_FBX2YBRRSAF;@U R8\X$F MQ"KC )3#6;^4EP]K&N6177DLAX_>@8$2; F+X><8=BV$\]7"594J*;Y+5Z/R[*UO1HI5;M M%O%"%:Q3#S^R3J$ 2DEY/83)6#20"W,%W%*>@R]&"_ZE^W"0PU=+#R8=>@TF MPMP!7L3Q;K.KD@I(>,U1G%2V(/^>5J^0T*R8#<[+Y-_5W[G7O_GI(U;)#U-, M+)%W#F7XS7T\NGDY7B$5L9>X8DDT]0?_?JX=+$-KRO[)A]A[M)):V[P_R_/9A0AMJ !M8%?!JP*=<_,R+$?^&EK*GBZOKS3;' MK_5M.1'LY!WZVS2"#F$"#VP"&\@3,6N@%^9NX9>(?)@,Y>]M$XB@)^_0@YZH M0YC0 YO !O1$S((^,>9:@;^NAG2!UHOR8TVMA3\%,]A H)B=_JOD/JRKN+J) M0B"L$Q2(08=")5.,"L;>:*Q^S] '.![JE-^0D%\5R><>AO :\AY(;#5T#C6! M](."/9J%W@^4A^5ZYOHK@)=E%+KRGU46=/4':A -60!D!649Z@2\F%C<\[ * M0)>VYCIM.\M25J=(9N0^DTXV)8-XJ.[=.GZI3BO/\88H\(*R(GE%]2LQ]/; M%&$7#UDNJU!.@GJ4+*^S\VB;E%'*7PAG^%Q]US$ M>?*,EF>[\M>I6@ %[0< MEG@>M@P,6')MC1#%)*^[SO>D@M8#*J,D0\O+*,^2;%UTLB]729SP]O+@'7M M@W0,#'?*MC""(81;T%6UP#=$P7="O;P%:GK%SB:F!+V_ER\XR62[JFR9-78I57U!ITAC\V*7Z\ MM8(IN1XL]Y3&UY1JVX2?N M*MP!Y'4-![X:IM"%*HQ5T$]!W.O_0O2-Q2I-*EO^ M%N5YE'%GO':(#N^U&!$-">$6S:>/?3,APMZJI.><13VCO\^3F/I[]3?>CJ6L M?7_CDM\^')A"E=9%H("^;J%V3^; ?6^I=;S8Y4FV)DHF>%E-A[K.)@^[MLBR M=MF-R :$:;LFU(:^L1A!EV9N[:>T=:X#PBWZ6OTD] )P9Q;6 9T#0[2J.8QP M"V 6=I)E;86]K]WE#\GZI82\IBSJP3X*8O>P=R"TI[]_L)?YD*VT7?O(AMW. M%V<1VA_#515[!XO+X8"%3=W1"A("BC,@*,Z H#@+'Q1L56V!XFP6[Q@SU1;< M2Y6VA\1'3^ZERG497F ## TJ ./<9&-S"?5*&__NGR ' S+J=AK:BZNMP\/. MO)T?86$]VK%6UL,7YV!]"ZRC-6"FVHNV,O+-W/3[0"/O,5N?"2QI._Z5BT! M!-50"3H"HJ'6CCC O]*8/?L'M>4=.'7;!H(:B*9:R.$0#G7T[:K#7B: V@K1 MX]UR00D].BL%$'KZBX3/WRN?LWB#'_E0!9@&B)N&!A[+8Y9DGA/JP75;J=L= M58I8H-IIO(_J?))%5E<=H FK*2YH&6=)*1M+5(6HU*#J;B<^?D'+78KVV#I[ MKY FK$,F[]'?AFI.ISP=A9NMEGQ=8L+H=94W"S[@]=[T\-9:;%_V HFZH2H).+C+,O MQ.;R!F.V]>,&HU=;YZ>]B?GM380VQM;W'4OZU%_[U7O);CJ@SV!G7=C'WL%3 MG9!SEWTAB'IY3-[X!T[BENV#)EY+][X ^A)816&>4X@X'8Z;>!RT'Y(RSF&5 MHN3],D6O*(/ A-F4C9->TV"!(E+9$E)Z+)KEX?10L55%Z[F\SHHRWT%>G)"T M'M3/XK2VYQC#(AKT(W:V7HY7Y/=)Z]GC%L7)*HEOV(XGNW89QD@&'.AU5J"YEP)#-Z22&[:!3P)@4&\ : MX 9L@KZ&U=6_-8KVU/P,&DH _86#B[!_"- T-8LZ2C4X!GTUH*OG=1;G]#W/ M11SGN^H%>40LR#MZ5.HK!"JW;[@@A9G#%D"YW,(NY]+1\2J*T6)#RSB!\#AL M+H1@NWFXJ.,J;0MH;09!EQ'H^T_M,+120K7!OY06N% G( F!(@+A(E+!,/:" MH8AEX-6(&N4NWV@Q:40UYP!4T+*'1&;+D" G5U4?6TS:05]6IBH 2?@@"Q('>PY.T=RS,^!LSXP^/-((U+>>GJ^L"SJR[A)DHH$K4=5+EAM@T. M51"=#3'%81'JU:)3FIH"NJSEJ8D1-L,G:_M.(TQEDK26Q2YV4I,+? FCD2AL M*>7EL;@((]8HU\E]L*_HABD\ZP=J9]:54R$7^_M&IUS3N>6:QL_%]I1L.M(H M5-?R4;C/".C1'XU$/9P[+RS]%*ZU5A*JD'S0>^O[ND#* !/V8 *,TR,H@$&T M-@ 8AWS0Q9H.X^)@PX2W3./MK(@:6BRDTWX9C=@[3FHP%@4JB_]"Z?(*YX_1 M8$M2JV^GN ZXKW./$7PI;&8)V=SJ9I"E!&<4M!/=[A;'!W'K)^YYQP-:-/IO ZG1\!RJ-BRC!%E-AD'/,/HO/._K#?.FZ>+6 MDB>[#ZT# 1Y,6RV(<4DW8)H)FA:[\@7GR;_AB!KVD*&JW2-49'&UMH.N-GGM MVT>^(>P^RN_R.BVE+HDN?JA!H2X2$/: 53!/+9Z#[JY!L0:Q^[VY5% M&67+)%M#8QVCBRS8=;J$ASF9WG;"78=^$^_"7%IT,PY^S:(-SDL:R)N76$%) ME8)^PEQ*9K] 4*=J 2WH 9@XNM1E!WY729:4Z"9YK5+AHVQ-CZ+JY7MK;;^H MM:Y,Q\&C/J$>0'4(!8)88QMI05B':] W=;K;N(JS2+7.PF* P<\EM6RAA5$H MIZ"O/':5!.S&R#L(\1?DG@Q89PLX8^[,A)FISE),NC<#ZP3 6( [-$JZ6\,: M8Y\FS N'+.7D"V1@+P#B0EPFJVEO#7.LQ?*?@P3=07?AK11F(]XAMB\W3SA2 MLW*)AQB# 8:?-GPSN.=PRDH/*2L=CAW-/'0YA&:4>=ZH=+OH1=_8$:1$,6 !4NR$%X,;$XEPMRI[SI4?.F"QPGQ:E.[REU MVH/,UE/JM"; 3JG3I]3ID0#65-W;;'%&S"*,T<*V/5!QVMK+H6X?E^^>BSA/ MGM&27_$7T+R=*2UL[MPGQ!\"*ZO,\0DFFT-6M)!\T$=KK0/#ISS*BK3^MLM_ M[HJ2SB*%\5>MG3 MQZ*X3T 05%!>&WEB'D&?Z'Z$!YG!8-)\DUD*((O/,GL!FHOF116B,LJ*RA[5 M2H J)<%!H8!I=@*JQG-&Q[\Q?]@5C3G]M+<66 MW8T;UV,!UMB-0T(80%U]7+&)!YUS%UQMA<-JOWC"G&79 WJ-TEWU?>]6 M=UOZO\4B6^Y?VNTK:)MLIR*##;+.W0]2K,&Z_33J.-B0P='.IA3M7(TN$#'' M\B)Y398HHS=ZRCQYWM&&I G._KG+8OH?OR7ERU[+R[?X)F^P8F7C>JE,V4#;[D_+EVS RMZ8:Q==<0*Y[]F2;E/ MR']ZR?%N_7*?D_EHB>[3**ZL"#O!4J"?UBTF#KLS9@WH\S4Y%1F:X T_(!DY>%/WI+63Z(.7 M!S]NS0,YCEO?1:C.'J-*[;N,6<1M!/+]-XNMD0_!$<:SI[I#6)6E&0<\>4S5 MEFY/7_&8;M$B/X9;5.0_DEL,[>G.+2I9&K>8^GS)KEM4U[Y'&RP$U"TX!9/Z MC'U";LW)7((I2N,1GNQ+65+-[C@AH#Z"1\Q]E)!;TYE'=,:(J9.N !YQ> ZC M>_ -'0UE+F&)/,\GC,F'YA1V[6GF%<:R-&ZA7*_0^,'3,1VCB@"C^46'NG6W MV%/_,%[!LJ8CI]B+TOC$U GAHWN$VE1J#%[C>$OHTZP1+>W2DSA3L#],7:1Y M_"G81(ZEL[-EF=F'<:W1=[TL2]8XU]07FZT?$9Z-+")L.;UEOQ#2'V/4F+UG0"SJ;LSH^L;4%_!5?*/R:OK\*,I? MDQ@^5>+TDV)YT"]8C(HM8 E[ R8-IGQ.TZC=00-4O(Y25 T[!@LKB0TLX6K( MI0&6SXFBC3?05Z6( O3VSBTN47$?O=/+V"107V=$'%0P[[]8(@D.<1"2P<)4 MVVZ6 R.$?P-M#Q-YA@YI$=L:-.&1=M;HUK><[?BL@F]/DIDK!>KK:1<[NO=^ MC_($UV]4U7^F&_4/J-BBN'S"CZ@DEJ.V6:QSQ+V]:(]J&^,VJ(: Y M#1$:I'MRJY&C4OO!+(M0UR$+P+H:V8#!;F _:VA7DZ&!NX=I98>1:H2K*2/< M1_D0EU!X/#[K3%H+EILX='?P['30">@4!.U7M-? % M8!%TG66( QW?6^B\PD"G2/M2M0_H7[ND2$JT3PRHMRW)((/76<( KR/N@Z>& M)N+NN3.Y_1I*3CFYJ+HOBAB7+7#MW@^(WI>*R_UUP:IZZ/1N;B2%-7?7E&+V M;F_CZTSL_IHB-RN=J3=FIXL"^XEQ?V*,S(U\266@T;^@QU7UI MQI-AK;G46W3OM'-@*VG=?[R-USH0",*TU0(:EW03'N'YY;9N2=O!TRTJK[,8 M;] -+G@/S3#;]+#3:Q,(8D2::>&D1[!!1ZC1IM[PO]N511EERV'%"&F[_DM$ MPW:!($6FH19:&$0;Q"BG,&VKJ=MEYCRB:&/F'Y_GCYJ!CI9QHWP&5\.&L,M+ MY\"1)KP>[]_PWT33H#%X+DV)1BA0-+",'DC5&.H^$>_+2"G0MKWQ=OF&\C@I MN M-;3H*(.;0F0&0(1:R#F8.TV:A&>9SXB*%>SM)BZ]13GUYA9)REVN%9B!% M!8Q+*0"(8-@.H&XSF_@' M<6_@#Q\ H+_7?G"?>(:WE$%SON.>E2;N9]R:J0_V_CZP.%OY,\).I:V M\@7@"7HO?Z_TW6JHX>*9K)NBN%_+0:OO &&@ON[M\D2KTL@,T&G$TW3?R!\_ M GTV#%17YE0B9ET_ZS+1];'4%\>J5:4)?CBC^4^+MX0__03TX<&+W<>UYD7#8/B1$2;351].0L&XNBG=^RK59R\#M M-EJ#2I])V\@LXE:BX%]^&!B7!-K?Z]^8/W4,C]Y*E"V/1RP#T[\F>;F+TFVR M7K]_'^/-/E>#W@ M<'5 OOW65<#@?[%>I)!^6E%#=_&P>LAIT4U4_H(VS_R] M>!UCYDP9,\(> M3,QP>@2%&8C6!ICAD&=AYD>'F!$NJ'IH@2R^)&W'*("T/R=5>[R"Z1;V";-+ M(1D1=NYD8A@,2R+9,R/''9D",4HC&0G"=%SOZMPQ5+3K '91_P&@[A;?&J#V MI7ACNR[\[KF(\Z1*SKW">77I61G6-NBU@6U&+Q!H6S2:%KC-^+/@_<=/8T=> M[0>KU4*R)3:R6&W,)A"DCV]B:]'=6"R67_S!D[ O',X>T);HDF3K1E'-68R$ M#GC^PJ43,.@5C61_SL+ERX+MGT8/YP>Y#H_2/&'.HS2::%0E#(8GG/ <\*II M1OL A@O"0O1_A!"(9:]X:'J"&EFP'T#)SL$+M$QHWP>@8K \X,]A5JG:#U?" M#7=FF][6::^-_Z"$**>*, Y-YI%+F'!YC%$6$75^S:B7)*L$+86[[]+V_9,: M?GM[@T3W 1!^U!>U:X=Q=COG+B"W/88KRDLEX/$X!%PV;9Y+C/*1G[YBT$<> MM.-\Y%:[,#\R3U$;'[E%FW?Z,,Y')@UAOLQHR?O0[9:!?FJNLE8^=INZS_OR M+9FO\"X'X638D .3=L,P4<)5U09(VL2]V,2SG/QYTT\\YF5]#AKRTCU;#>VY M0'7VL#^/>![4B1 U:<-^T,0]X(67J !ZJ3]0,*#'#'V>O'R[S_O9KTGN\H=D M_5+>[J@_DD4PBG=$\*2Y?.!PXHJ]=);K:''?D$9 MRJ.4:+18;I(LH1K3M[3W^G%0!.S5 Y6T5U 84[.! >2DC((N<4CXXYSH]H!2 M6C99C#MQXQ[<>(V#0AE(8P-P\>@?4O(^A7FT6)6OI08XZG^W1=1QN$\:0;KT M(";N$A30%+0W@)N8BZ.G[2TB;A^KQ5%,T)*%KW[+\& EU-4437WBNB]?>P&B M^QRO4%$D]!U4HOPYSBJEFW+&8ERI=>Y!#=HY*/1I6<0 D%!^86VO<#94QZ](AJ +^F]NS)*LNJ,3P@U4)\>VB1]@@*< MBOX&F).P.4:X,+.MZN>C#WOYDEUG2>L>VKBMG>-,IH=@9Y:C,P=A'$:B#=HC M ]W"IEX B_N$/1-8DM8]8'%;AP0LF,KZN.+25Z\)UGTH[LD'>%U&>4:&_^(> MY=6EWK.H2&+B11=)NN._B CLU2\1*.L5$NS43* //RF?!H9AAK=;5-9&N,%% ML7B-DI0F73SAULWR?6)II3@'CYI4>OA4IA(27LU,I(]?9;X-GL,\5NVH"T$K M!(L!(VT<'!TWTI0?GO<#)3C#S>E'K=5^UBI9-X#[]=$D[Q<4PA3-8( Z.:<& MB6$^E'G7U4X0M00M^X=7K)8AX4NNJCZBF+35WYSV*9H]H"5"FVA0G_"PP!.#5(A.<4^?7Z^0-Z1=F.>S35_WF K.;GL #$5,H$ M)PW!H&_ _H;H75^T7+R2D+M&ATN_=!E]MRN+,LJ6)!##MCS,B/4K?FD2"PF5 M5@RFCV%=]LWR,\SIW"717>&<.'EVOB-B9_%[JVQ.H_<96I$V M3]$;!^8:%'H 5Z(0)K3UC60#U$K<@TX!/#KK15)L<9%4=?]6BZ) )6\^"^K3 MOXTA[A,F2%4,80.6$GY!9]$T1:O%>3.<5H/O1!LZ.Z]5;_3CHDG*R"7NQS;:!ZE*)ZA!(JY* & ML($Y :_F$03SG6^'5]ZS;>'LPOL%>B[I Q0I+G:Y[ !1W+B?'L9I["X7KB/0 M$_EB9ZD@%T[<6JALJ[5S[Y9\,ZRJ,<>AV6PZF7 \\O8&#J?+!K M]:HZ5BOOKN55R:[5W^1P5:'D?O=,!7%;TW*7- M>R1G+7Z+KU%^>!SM;U&ZJQVV*':;ZCW!HJKMPXL@(U%OUW6U2=U]A+*#,SRV MY7F1STC\0Z59FV*S7\D)]-K@T3"WN%I\H&5EH45<)J]$2:$OFA$9/)&B1F1& MGF7%CJ,YD*YTS.+A@3O),7JT;5DE:MS5T4+3<4P)6X3 .:L+D@SBKM>_@Q'%-I)_1XP='RPQJT],G6INY M^/X]B$+!7_7H\5U3E=Z\O=#(NE,ZG*J@[!6=C2)KCO?,3EMF/FZ936SB]M C M#::6J.H:F4=UAH'5KJ5'#Z_&XHXT@7$885>O>)44.-U$Y-_RYZ6S:'L5)3F= M0Z(ZQ6F1+6^2Z#E)J]>SOJ"(?K7E'?E4\2[/Z^)"MSC+F_^D>=:%Z,4EZ_3[ MB9KVZ+M+>+6@PXWDQ<51>(SP+6YX[SPZ"-SVL8NG^2"H)]LW@'3A MQ6UF%W_ +M+(\CQ%X?E1D7BVIQV>/EAZ4&VO1K4:'HXMW<>H>+A5H<$#,HR& M/\B&3158&->PE@S'0F&8B(8)X2UJK[/MKBPJ%7_Z@NCU;!E&^3UXB&3U\ =_ M2BABP5!J$!GH(!(PL2.-;9 ID/99A#0O%O\M M87]41MJ/RDC[<=Y(8QMD"J3]*$+:3[Z<"ZQ>-U]7KR\X7J:[-#F=#9S.!DYG M Z>S@=/9@+?3@]/9P.ELP(^S ]@7R=%66^H[/[J5='RXL',Z7KD7K^AZQ78 M3J?N@6VT\'[7 _>/_MR\.ZN3J!_ZR2'WGY<5?SO7901'2*Z= MK7"^J;X\J!:+):J2J*%,U9_(HKH:M6)'6VM076'F4UGL8 KQ*KQ>=D-]18<6 MST/4:(7K%P8VL^4-:B+,L1[0\0&DEBT6Y<%"BN6[],AQJP&ID@O.&2Q9SM ? M]*48Z7#<]83V-)_U17GP""SJ U _Y""B8@-;(R>;U?P*SFRCTF$B>9(E)8G$ MK]519Y2M:4I&?8IT(\M-5NC:=P]05WM93+^@#.51NLB6B^6&\*:HHR/0_DV4 M?;6C)WQ/_B+19C^ED#(9>9#9O/8$Z5?"[3:I3?)BGN93J$K>*+4 M[CH'D$(M8Q^Q L[SV8X3V.=+]$^AKWVOCLK\+OB&%JJ_LHBVO;77OZ/0PH^8Y>K M+VC(@80P=63W98(-0AQ9?$MS_ 7CY=M!@GGTIFHOCYTH"L8^_Y(* G-S!U] P)BSN\G:+.1\! M+@1NU3$TW"K9B^^<+(S7X6>/=N >CJ/ M)\8CJ[J!; ^I( GF=UJMNR/CZXQ(A)ZB-W#, ?08>)&@A[-X_7?^I+U"@V1:F8P@Z24UWR.R0XJ/J 89W&2)I7-SE]H28;KK+$$:5"/ MVC33JT9)FN*O438H(&2?,&^H,2 <&OBM&]/,/VR(,U*>@^.9WK*,3A,]=R/K M 7&W2#::HP\D0Z%MD97,%ZRP"MYY[!OE@MSFA-CA%M/PMXOK*M=U?*_JS!IXB92FAIL(:,[1 M3Z F'-]1!)(P5X=AWBO4M83RA'L\1I:<:DZ3[=&-[<;]5"?:/\_6)8TU;U M&":=S'E4-Z3#+.W',8ABFH$F%9B7S">9P,Q,HR!?+64@[.KOB<-JSQ\WJXE[ M]4ZL->AN)+=UL)%AQ+N07![S60@U[UJ\7^'\URQ&>1DE&='X'A=)M?>_OZ+, M 9]J]QX:X=U#@Z>F84^W> S"\>V@ UC2, M&8#A3%D _M/, *P,6660S@F6$P%Q3@40?LURLK199\F_JR.7Y@8'!W>2UCW0 M<5N'ACB8VF9PX_*8S[8)1\5[1#2DQ49R%!7H M7_JX9 ,0T8+GDT9H)6D(E& MP3"/\TA;[$XW2TY[)3YH+J^7*.\BU]VG"HFZ6R?:A1!5]T\^3+W#4PAP6:B< M'COAC#Z^0%^78N[=*3[@JTV16\I<@V)H\<6>^HD,R7!TWOWLYJ/2L]_CZM_(+\!K4! _ *U$+URM, MS&;+(11EF%]11YPZF\W>T$T"V5/O[$;](\9>(WTYSM]EU#DSE3.8WT(5IP49U7'JL&#K##W\>&A4272U*PF. MOB19LMEM[J/W#5U_7.R0.*-"CPCWQ ]&)(! 8&07Y:B@RFT^JT6(Y@^(/O%' ME*1O*A5QE/X=1;PK$L;T-*#-H3<3E$.L-0K@.8R9E;(^?0JS A#0\:^SIZ^8 MJB]/TE"DHQ?)VW1F G.1=<:*YVV&\]G; "IOAF0S_,X)M1-AU=:.@P\U.>#N M2;@B.W%W0$D[\K8HS0?% @N-&'U;+#G3BM 7WJ<5]WAQXX%\L_VI'O\1%% ? M<2SH]PG/ZX5:F_IWG_A,MLS@I7CZ9H$V M_TUZ$]H!1(PQK*@<62P),;\=?(='<_1&1%4D<(VR^%T6E<2M^^&)U]KAJ=TZ M2K]$)?WXBVQY%(Z> $M/[A3Z#@(UJ*_[."+YOMC,'+R P>;:/=<#<9MA9'"X MPOA0H:$U_%1@>T0ED;CZ$T=C0(^>UL(>(3D_7'5]EQ?RF,\)W7V.8X26Q17Y M%M=9LIT()F\U6I2CPX:A/JHU2#4%#@-364 :8U6(]W(.=P6(OC M L?N9KU583B:1IZC%Y05AS19^@EO47FWJLHLY'4-X#)/GG=EM0;!]Q40)4.A M9>K]W2M;U-WM\PDT(-$>)>NL3L6(WY^(AQ1$VJ1ZE*[ZK[0.*\M_[HJ2.DVC ML\;',&>F\&U,F#D/K[8AC2?^0)R0;4FMSN[I2.KHG@B^HOP9NY_F&%IZG$@[ M3H3]N.ZJ;G(__!(D=] OOU=E#JLIYO[&7+6),C"&9&*C2:6_Z:Y*Q9G5&%)) M9AN 'CUK"'LX#R2Z7QSKF(03#!1E:#N]D+=VH30?')JH<8Q?'# RV_3@UVLS M!\")U+8/L1XW^WM187Z$<=; ]C^?-3EG42$XWA;.]F3N&[,]ECC^_7:W>::I MZ545\H(8F[X=0[]K]<&.%[MD>126J ZV2 VI.MQN;DLN._.4M!9:Q:=S35LH MP*JFX00L0WFZ6\H<.69U%GHTPG>+\_.[7V^?'N\7?U^H#)*4G=1[ &E9"Q:DH]8MO=W+C"];,/Q,E"?GJ])^FC$EVH (%K] MZ=-/>YWH7_[Q:[:-DN5_H2@M7PY'%E\016Q/'6CSO2;RYL[#!NS#8&75.5%! MR([ZO)R-HZ-0(786<8QWU;'8(\I?DQ@5,OC(>@P1Q.\1)(B !K" (SZGH"]) M<4Q AB-T398*O!4SM!LL&+>Z.3/$_ON26<4[7;>T)$V0Y#4 E:X]@\"Z^NJ: MP\^-C:RBYJ8'[NU9'HQKT(DP7Y*LFJ]>9T0<5)1W7S,BUDNRO4=Y3,VW1F?O MPM,@#0H]W"I1"!*^^C:R@&(EYG,+0T^X!&W7J'KZ"LZ,/UEL#J2&1 M1)\B=O7B YNX5V \Y#/3A] M/5Z ADV5JIO/O&0\$UK<>_!*M+SR7"%"F#?A]>VF./\5WX57$L/JQ-A%:I&1 M]>4;!KRM>E[FD(XX@-V$EACV)Z,S_&R,;86)OU@M@>Y ^U'<2[X;-/%G8PID M)4@Z3,/+MZ6[:_\S.#KEI"-\P5GYDK[O+Y9?X?R7M@^_[U&^6.>H2B9E MY2=HDF@G+"B3J%O2>W+ M ')& T*K(N74 I!8=7<1A:.WY68SZ=@-L=$>TVK6ASM">5O2?G2[J(VWU&E M"IL.P:D&Z15V;6G!4XP%FD]]HE->P2FO8#YY!1R_M#YAC[*2#*V0; #%7HQI MO+"75XCAY+PK:Z]TP 9FX4/,AB\#Z9A#[ZU&&X7Q#W"G*HC4@V"GT!@".V3M@A,FM80U2 M3%:S>@;LE.+B?XJ+#YNPENHF)YN$&*%Y7/I]'[*%> /UZ==0%O<)!',JFFNA M3L)@]OM$11[@\RC)_1!/CE ML;EUN'4Y10)TYNEPQK.J:[XBRNZY0/_:$;4N7\D_9',46?.^LW";NXL? M/9&D\4+67J*R5_% ]O6PNMX\S^>PZO@\G\7D/K[_A?[C.2K0?___ 5!+ 0(4 M Q0 ( /MUK4CREMQF8W$ .)K!@ 1 " 0 !V<&EG M+3(P,38P,S,Q+GAM;%!+ 0(4 Q0 ( /MUK4@L?95C5!D &5! 0 1 M " 9)Q !V<&EG+3(P,38P,S,Q+GAS9%!+ 0(4 Q0 ( /MU MK4BA+QL;/A $[O 5 " 16+ !V<&EG+3(P,38P,S,Q M7V-A;"YX;6Q02P$"% ,4 " #[=:U(*85JKM)5 X108 %0 M @ &&FP =G!I9RTR,#$V,#,S,5]D968N>&UL4$L! A0#% @ ^W6M M2'"-G